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Summary 
Introduction: Bone metastasis is a key event responsible for the progression and 
morbidity in prostate cancer patients. Interactions between prostate cancer cells and 
the bone microenvironment facilitate survival of tumour cells and alter bone turnover, 
a process that enhances growth of metastases in this site. This study aimed to test 
the hypothesis that tumour derived TGFβ signaling regulates the 
differentiation/growth of osteoblastic lineage cells and promotes survival and growth 
of prostate cancer cells in bone. Findings: In initial studies I showed that factors 
produced by prostate cancer (PC3RFP) cells increased the proliferation and 
suppressed the differentiation of osteoblastic cells (SaOS2 cells). I showed that 
interactions between prostate cancer and osteoblastic cells affected the expression 
of TGF-β superfamily genes in the latter. Noggin, a BMP antagonist was expressed 
and secreted by PC3RFP cells but expressed at very low levels by SaOS2 when 
these cells were grown alone. This pattern changed when SaOS2 cells were treated 
with PC3RFP conditioned media, with strong induction of Noggin being 
demonstrated. Silencing Noggin in PC3 cells removed the effects of conditioned 
medium on the growth of SaOS2 cells, while media containing recombinant Noggin 
stimulated growth. Together these studies identify Noggin as an important regulator 
of osteoblast lineage cells that can be either directly secreted by tumour cells or 
induced in the bone cells by factors derived from prostate cancer cells. The latter is 
an important, novel finding of this study. 
Xenograft experiments to test the role of Noggin on tumour colonization were 
inconclusive however; immunohistochemistry showed that in tibiae of tumour bearing 
mice, strong Noggin protein staining was found on the bone surface and in bone 
lining cells in close proximity to tumour foci. 
Conclusion: These studies suggest that tumour derived/induced Noggin may play a 
role in suppression of osteoblast differentiation in prostate cancer bone metastases. 
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1.1 General structure and function of bone 
Bone is considered the major constituent of the skeleton. It is formed through two 
different ossification processes: intramembranous and endochondral. The difference 
between these two processes is that endochondral ossification is thought to be a 
complex multi-step process that requires the presence of a cartilaginous blastema as 
a template for axial and appendicular bone development (Prasanna Bukka et al. 
2004). Intramembranous ossification gives rise to flat bones of the skull and parts of 
clavicle bones directly from mesenchymal cells, which then condense, and 
differentiate into osteoblasts. However, long bones are formed as a result of 
combined action between the two processes endochondral and membranous 
ossification (Taichman 2005) 
Bones of adult human skeleton are composed of 80% cortical bone and 20% 
trabecular bone. This ratio varies according to different bones and skeletal sites 
within the bone itself (Eriksen et al. 1994). Cortical bone surrounds the marrow space 
and is characterized by a dense and solid appearance, a structure that generally 
gives mechanical strength, while trabecular bone is composed of a honeycomb like 
network of trabecular plates and rods scattered in the bone marrow compartment and 
is associated with higher metabolic capabilities (Eriksen et al. 1994).  
Human skeleton aids different functions including providing a structural support and 
permiting body movement. It also protects the vital internal organs of the body. It 
plays an important role in maintaining mineral homeostasis and acid base balance. In 
addition it acts as a reservoir of several growth factors and cytokines and furthermore 
provides the environment for hematopoiesis in the marrow cavity (Taichman 2005).  
1.1.1 Bone cells 
Bone is composed from four types of cells: osteoblasts, osteocytes, bone-lining cells 
and osteoclasts (Marks and Popoff 1988). These cells may be classified according to 
their relationship to cells from which they originate: mesenchymal stem cells are the 
progenitors of osteoblasts, osteocytes and bone lining cells while, osteoclasts 
originate from hemopoietic cells. Another classification has been developed based on 
their function to bone forming (osteoblasts) and bone resorption (osteoclasts) cells. 
Osteoblasts, osteoclasts and osteocytes are located along the surface of the bone, 
whereas osteocytes are located in the interior of the bone ( Marks and Odgren 1996; 
Ducy et al. 2000).  
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1.1.2 Osteoblasts 
Active mature osteoblasts that are capable of synthesizing bone matrix are oval in 
shape with large nuclei located within the center of the cells. These cells contain 
large amounts of rough endoplasmic reticula (RER) and enlarged Golgi structure, as 
well as mitochondria, microtubules, lysosomes, glycogen and lipids. These cells 
secrete type I collagen and other matrix proteins. Osteoblasts cells are responsible 
for the production of the organic matrix of the bone that is composed from proteins 
and polysaccharides (Holtrop 1990). In addition, osteoblasts play a roll in the 
activation of osteoclasts through the release of certain mediators under the influence 
of parathyroid hormone and local cytokines. There are several mediators that 
regulate the differentiation and functions of osteoblasts including Bone 
morphogenetic protein BMP and wingless (Wnt) signaling pathways (Cao and Chen 
2005; Day et al. 2005). BMP signaling controls the expression of Runt-related 
transcription factor 2 (RUNX2) which is essential for osteoblast differentiation via 
recruitment and activation of heterodimer Smad proteins (Ducy et al. 1997). 
Osteoblasts undergo one of three pathways: they either remain as active osteoblasts 
or become surrounded by matrix as osteocytes or they become inactive and form the 
bone-lining cells (Marks and Popoff 1988; Marks and Odgren 1996, Ducy et al. 
2000).   
1.1.3 Bone lining cells   
In the mature skeleton, the bone surfaces are covered with thin, elongated cells 
called bone-lining cells. They are linked to each other or to osteocytes by cytoplasmic 
extensions or gap junctions. Since these cells are considered to be metabolically 
inactive they have fewer organelles and less cytoplasm than osteoblasts (Marks and 
Popoff 1988; Marks and Odgren 1996). These cells may regulate influx and efflux of 
mineral ions into and out of the bone extracellular fluid and thus function as a blood –
bone barrier (Dobnig and Turner 1995). It is also suggested that bone-lining cells 
secrete enzymes that remove the surface of the bone in preparation for the removal 
of bone by osteoclasts cells. However, in the presence of parathyroid hormone they 
may differentiate into osteoblasts (Marks and Popoff 1988; Marks and Odgren 1996).  
1.1.4 Osteocytes 
In the adult skeleton, about 90% of bone cells are thought to be osteocytes. Initially, 
as they begin to be surrounded by bone matrix they are considered to be immature 
osteocytes and resemble osteoblasts in their structure with large amount of RER, 
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Golgi apparatus and mitochondria. As more bone matrix is accumulated over these 
cells, they move deeper into the bone tissue become more mature. Eventually they 
appear to lose cytoplasm around the nucleus, which appears more prominent (Marks 
and Popoff 1988; Holtrop 1990; Marks and POdgren 1996). Osteocytes lack the 
expression of alkaline phosphatase but express osteocalcin together with other 
matrix proteins important in supporting intercellular adhesion and regulate mineral 
exchange between bone fluids and the vascular supply (Plotkin et al. 2002).  
1.1.5 Osteoclasts 
Osteoclasts are much larger than other bone cells and are characterized by their 
multiple nuclei that can be seen as 3 to 20 oval dense shapes located at the center of 
the cell. Osteoclasts are located on the bone surface and are highly motile. They 
contain less RER compared to osteoblasts and large numbers of mitochondria. Their 
main function is bone resorption (Holtrop 1990; Sandberg 1991), which they achieve 
by close adherence to bone surfaces and the creation of a closed space between cell 
and matrix for the concentrated secretion of bone resorbing proteases and other 
factors.  
1.1.6 Bone modeling and Remodeling 
Bone modeling may be defined as the process that bone undergoes in order to 
change overall shape in response to either physiological or mechanical factors. This 
process occurs from birth to adulthood and results in an increase in skeletal mass. 
Bone formation and bone resorption are not usually coupled during this process 
which is less frequent in adult (Kobayashi et al. 2003). However, bone modeling may 
increase as results of some diseases such as hypoparathyroidism and renal 
osteodystrophy or as a result of treatment with certain anabolic agents (Ubara et al. 
2003, Ubara et al. 2005; Lindsay et al. 2006).  
Bone remodeling is the process by which the integrity of the skeleton and mineral 
homeostasis is maintained in equilibrium. This is achieved by continues removal of 
discrete packets of old bone by osteoclasts and replacing them with newly 
synthesized bone by osteoblasts thus preventing the accumulation of damaged bone. 
This process begins before birth and continues until death. This cycle is composed of 
four consequent phases: activation, resorption, reversal and formation Figure 1.1 
(Burr 2002; Parfitt 2002). Activation phase starts by recruitment of mononuclear 
monocyte-macrophage osteoclast precursors via the action of colony stimulating 
factor 1 (CSF-1) and its activation through the release of receptor activator of NF-kB 
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
4!!
ligand (RANKL) and sRANKL from osteoblast and osteoblast precursors and its 
direct binding to membrane bound RANK molecules on osteoclast precursors 
(Roodman 1999; Boyle et al. 2003; Blair and Athanasou 2004). The activation of 
osteoclasts is regulated by another molecule produced from osteoblasts 
osteoprotegerin (OPG), which act as a decoy receptor preventing the binding of 
RANKL and sRANKL to RANK molecules on osteoclast precursor thus the ratio 
between RANKL and OPG controls the activation of osteoclasts (Eriksen 1986; 
Reddy 2004). There are other factors that regulate osteoclast formation, activation 
and resorption such as Interleucin-1 (IL-1), Interleucin-6 (IL-6), parathyroid hormone, 
1,25-dihydroxyvitamin D and calcitonin (Boyle et al. 2003; Blair and Athanasou 
2004). In the resorption phase, osteoclasts mobilize bone mineral by lowering its pH 
by secreting hydrogen ions via H+-ATPase proton pump and chloride channels in 
their cell membranes into the resorbing compartment. Osteoclasts also digest the 
organic matrix of the bone by secreting tartrate-resistant acid phosphatase, cathepsin 
K, matrix metalloproteinase 9 and gelatinase from their cytoplasmic lysosomes. At 
the end of this phase osteoclasts undergo apoptosis (Silver et al. 1988; Delaissé et 
al. 2003). Reversal phase is considered to be transitional phase between bone 
resorption and formation. After the completion of bone resorption, resorption cavities 
have several types of mononuclear cells including monocytes, osteocytes that are 
released form bone matrix and preosteoclasts preparing to begin bone formation. 
There are several proposed coupling signals that link the end of bone resorption with 
the beginning of bone formation, such as bone matrix derived factors, including 
transforming growth factor β (TGF-β), Insulin-like growth factor 1 (IGF-1), Insulin-like 
growth factor 2 (IGF-2), BMP, platelet derived growth factor (PDGF), or fibroblast 
growth factor (Hock et al. 1988; Bonewald and Mundy 1990; Locklin et al. 1999). In 
addition to these factors ephrin B (EphB) receptors and their ligands have been 
implicated in coupling signaling through bidirectional activating signaling: enhancing 
osteoblast differentiation and inhibiting osteoclast function (Matsuo 2010). The 
results of this bidirectional signaling results in switching off bone resorption and 
activating bone formation (Martin et al. 2010). Once bone formation starts it, takes 
around 4 to 6 months to be completed. Osteoblasts start synthesizing new 
collagenous organic matrix and release small membrane-bound matrix vesicles that 
help in concentrating calcium and phosphate in order to regulate matrix 
mineralization. Mineralization is also inhibited enzymatically by the actions of 
pyrophosphate or proteoglycans (Anderson 2003). By the end of bone formation 
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about 50 to 70% of osteoblasts undergo apoptosis, with the balance becoming 
osteocytes or bone lining cells (Dobnig and Turner 1995). Each bone remodeling 
cycle results in the production of a new osteon (Parfitt 1994). The principal 
recognizable function of bone remodeling is the preservation of bone mechanical 
strength by replacing old damaged bone with newer healthier bone and to maintain 
calcium and phosphate homeostasis (Clarke 2008).  
Bone remodeling is controlled by either systemic mechanisms or by mechanical 
regulation. Systemic regulation is achieved by the action of four main hormones 
calcitonin, parathyroid hormone, vitamin D3 and oestrogen (Zaidi et al. 2002). 
Mechanical force plays an important role in bone remolding by influencing bone 
metabolism (Jacobs et al. 2010). Animal studies showed that different bone cells 
such as osteocytes and osteoblasts are able to sense and respond to mechanical 
forces (Bonewald and Johnson 2008).    
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Figure 1.1 The bone remodeling cycle.  
This Figure illustrate the four phases of bone remodeling cycle (a) Micro-damage or mechanical stress  
(b) This induce the recruitment, differentiation and activation of osteoclasts cell in order to resorb the 
damaged bone (c) osteoclast die by apoptosis (d) osteoblast migrate to the area of resorbed bone and 
replace it with un-mineralized osteoid witch then become mineralized. Adapted from (Crockett et al. 
2011).        
1.2 Epidemiology of prostate cancer 
Prostate cancer is the second most common cancer in men. According to the World 
Health Organization (WHO) an estimated 1.1 million men worldwide were diagnosed 
with prostate cancer in 2012, accounting for 15% of the cancers being diagnosed 
(International Agency for Research on Cancer 2015). In the United Kingdom UK, 
prostate cancer accounts for approximately (25%) of the cancer burden in men. The 
incidence trends over the last decade in the UK vary according to the different types 
of cancer being increased in prostate cancer Figure 1.2 (Cancer Research UK 2011).  
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Figure 1.2 Prostate Cancer Incidence 
(A) Represent the most Common Cancers in Males, Percentages of All Cancer Cases (C00-C97 excl. 
C44), UK, 2011. (B) Represent the 20 Most Common Cancers, Percentage Change in European Age-
Standardized Three Year Average Incidence Rates, Males, UK, 2000-2002 and 2009-2011 (Cancer 
Research UK 2011). 
Most patients who die from cancer, do so because of the spread of tumour cells to 
other sites away from the primary tumour (Wingo et al. 1995). About 90% of patients 
with advanced prostate cancer develop bone metastases (Larson et al. 2014). 
1.2.1 Prostate cancer and Bone metastases 
Advanced prostate cancer is most frequently associated with the development of 
bone metastasis (Keller and Brown 2004). Once the tumour reaches the bone it 
becomes incurable with current treatments (Coleman 2001). Bone metastasis is 
associated with several complications such as bone pain, impaired mobility, bone 
fracture, compression of the spinal cord and symptomatic hypercalcemia (Coleman 
1997; Moul and Lipo 1999; Keller and Brown 2004). There are a number of factors 
that govern the special affinity that prostate cancer cells have to attach and survive 
in bone rather than other sites. These include vascular conditions such as elevated 
blood flow in the red marrow (Kahn et al. 1994) as well as the production of 
adhesion molecules by the tumour cells that allow them to bind to the bone marrow 
cells. The presence of the tumour results in an increase in the production of 
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angiogenic and bone resorbing factors that subsequently lead to the enhancement 
of the tumour growth in bone (Van Der Pluijm et al. 2001). Bone is also a repository 
for immobilized growth factors such as transforming growth factor beta (TGFβ), 
Insulin like growth factor I and II (IGF I, IGF II), fibroblast growth factor (FGF), 
platelet-drived growth factor (PDGF), bone morphogenetic proteins (BMP) and 
calcium (Hauschka et al. 1986; Logothetis and Lin 2005). These factors are known 
to stimulate osteoblast function (bone formation) and proliferation (Logothetis and 
Lin 2005).  
Prostate cancer is frequently associated with osteoblastic bone metastases 
(Charhon et al. 1983; Boyde et al. 1986). However, it seems that where prostate 
cancer bone metastases are present, while these lesions are predominantly 
osteoblastic, but there is some evidence that metastatic prostate cancer is also 
osteolytic, since the processes of bone resorption and bone formation are linked 
together (Charhon et al. 1983; Jung et al. 2004).  
1.3 The transforming growth factor beta (TGF-β) superfamily and its signaling 
pathway 
TGF-β family is a large group of structurally related ligands or cytokines that have an 
important role in regulating a variety of cellular processes, such as cell cycle 
progression, cell differentiation, motility, adhesion, bone morphogenesis, immune 
response as well as development in multi- organ systems. More than 30 factors have 
been discovered recently that belong to this superfamily (Chang et al. 2002; Derynck 
and Akhurst 2007). 
The members of this superfamily can be divided into two subfamilies: 
1- The first subfamily consists of TGF-β, activin, inhibin, Nodal, lefty and myostatin. 
2- The second subfamily includes Bone morphogenetic protein (BMP), anti-
mullerian hormone (AMH or MIS) as well as other growth and differentiation factors 
(GDFs) (Derynck and Akhurst 2007; Massagué 2008). 
The TGF-β members are secreted as biologically inactive forms (Gentry et al. 1988). 
Usually, the activity of the mature domain of the TGF-β ligand is veiled by the 
propeptide, Latency associated peptide (LAP) which is cleaved from the mature 
domain by a furin-like endoprotenase during secretion but remains associated with 
the mature domain by means of noncovalent interaction (Dubois et al. 1995). There 
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are several other mechanisms involved in the activation of the TGF-β superfamily 
including activation mediated by the extracellular matrix protein thrombospondin 1 
(TSP-1) (Schultz-Cherry et al. 1994; Schultz-Cherry et al. 1994), integrin αvβ6 
(Munger et al. 1999) and proteolysis (Schultz-Cherry et al. 1994; Munger et al. 1999). 
1.3.1 TGF-β structure  
The general structure of the monomeric TGF-β ligand which involves two pairs of 
antiparallel β-strands forming a flattened surface, projecting away from a long α-helix 
(Schlunegger and Grutter 1992). 
 
Figure 1.3 TGF-β structure. 
The TGF-β monomeric structure involves a cysteine knot motif with two pairs of antiparallel β-strands 
(fingers) that extend from an α-helix. The β-strands are curved to form both a concave and convex 
surface for the interaction with the receptor. This picture is produced from (Lin et al. 2006). 
A “cysteine knot” motif is formed at the core by one of the disulfide bonds that travel 
across a ring, which is formed, by two other disulfide bonds. This monomer has been 
described as a four-digit hand, each β-strand being compared to a finger. Finger 1 
and 2 are antiparallel with finger 2 leading to a general helix ‘wrist’ at the N terminus, 
while finger 3 and 4 being antiparallel at the C terminus Figure 1.3 (Schlunegger and 
Grutter 1992; Lin et al. 2006). 
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There are three isoforms from the TGF-β: TGFβ1, TGFβ2 and TGFβ3 (Kingsley 
1994). The TGF-β is synthesized as inactive precursors that require activation before 
they can binds to their receptors (Li and Flavell 2008). The active form of the TGF-β 
is a dimer which is stabilized by hydrophobic interactions, further strengthened inter-
subunit disulfide bridge (Lin et al. 2006). 
1.3.2 TGF-β function 
Studies showed that mice that are mutant in some isoforms of the TGF-β show 
certain defects. For example more than 50% of mice lacking TGF-β1 die during 
embryogenesis from yolk sac defect while those that survive develop inflammatory 
disorders and die within a month (Shull et al. 1992; Kulkarni et al. 1993; Dickson et 
al. 1995). 
On the other hand, TGF-β2 knockout mice are associated with various craniofacial, 
heart and renal defects. In addition this knockout is also associated with retinal 
hyperplasia, axial and appendicular skeletal abnormalities (Sanford et al. 1997). Both 
TGF-β2 and TGFβ3 knockout mice are involved with perinatal mortality (Kaartinen et 
al. 1995; Proetzel et al. 1995). Studies involving TGF-β3 knockout mice 
demonstrated that these mice have delayed lung development and platelet defect 
(Kaartinen et al. 1995; Proetzel et al. 1995).  
1.3.3 Bone Morphogenetic proteins (BMP) structure 
BMPs are another subfamily that are considered the largest branch of the 
transforming growth factor β superfamily, some of which are referred to as growth 
and differentiation factors (GDF) (Kawabata et al. 1998; Chang et al. 2002). They are 
dimeric proteins composed of two monomers joined together with a disulfide bond 
(Ducy and Karsenty 2000; Sebald et al. 2004). Additionally, the dimer contains a 
‘cysteine knot’ which forms the core monomer consisting of seven highly conserved 
cysteines Figure 1.4 illustrate the structure of BMP7 as an example of BMP family 
(Griffith et al. 1996). 
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Figure 1.4 BMP structure. 
This figure illustrates the structure for BMP7 as an example of the BMPs family: BMP7 exhibits 
extended symmetric arrangements. Monomers are coloured red and blue in the structure and aligned 
by a single monomer (blue). This picture is produced from (Lin et al. 2006). 
In Humans, there are 21 members of the BMP family (BMP2, BMP7, BMP8A/B, 
BMP10, BMP15, GDF1-3, GDF5-7, GDF, myostatin, GDF9-11 and GDF15) 
(Schmierer and Hill 2007) which can be further divided into subgroups according to 
their amino acid sequences (Kawabata et al. 1998; Botchkarev 2003; Ye et al. 2007). 
BMPs exist as both homodimers and heterodimers. Although, the homodimers seem 
to be the major form of BMPs, the heterodimers are the most biologically active 
(Aono et al. 1995; Israel et al. 1996; Zhu et al. 2006). The BMPs are secreted as 
inactive propeptides that are then activated by proprotein convertase, for example 
the serine endoprotase furin (Uzel et al. 2001).  
Even though, BMPs are synthesized mainly by skeletal cells, their synthesis is not 
limited to the bone. They are expressed by a variety of extraskeletal tissues where 
they play a central role in cell development and function (Pereira et al. 2000). BMP-1 
through 6 are expressed by osteoblastic cell lines but the degree of the expression 
depends on the cell line/type studied (Pereira et al. 2000). BMP1 is unrelated to other 
BMPs and does not regulate the growth and differentiation of skeletal cells. It 
functions as a protease that cleaves procollagen fibrils as well as chordin that is a 
peptide that binds and antagonize the action of BMP2, 4 and furin (Uzel et al. 2001). 
1.3.4 BMP function 
BMPs have unique functions (Wozney and Rosen 1998). They initiate bone formation 
by stimulating the differentiation of mesenchymal cells into chondroblasts and 
osteoblasts (Wozney and Rosen 1998). This will lead to new bone formation during 
embryogenesis and bone repair in adult tissues (Reddi 1997; Wozney 2002).   
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Many studies in mouse models have described an association between some 
skeletal defects and mutation in TGF-β superfamily members, their receptors or their 
binding proteins (Wang et al. 1990; Ahrens et al. 1993; Asahina et al. 1993). 
In addition, BMPs also regulate the primal stages of embryogenesis, formation of left-
right asymmetry, neural pattering, tooth and eye development (Luo et al. 1995; 
Hogan 1996; Bei and Maas 1998; Zhao 2003). Many genetic studies indicate the role 
of TGF-β superfamily in heart development (Zhang and Bradley 1996), suggesting 
that BMP-2 is required for the initial formation of cardiac primordium. BMP2 null mice 
have either no heart or develop one that is malformed (Zhang and Bradley 1996).  
There are different BMP antagonists that can bind to it and inhibit the effects of BMPs 
for example follistatin, Noggin and chordin (Iemura et al. 1998). Even though, both 
Noggin and chordin are not structurally related to the BMPs, they are capable of 
binding specifically to BMPs but not to activin or TGF-β. They act by blocking the 
interaction of BMPs with their receptors. Studies done on Noggin null mice showed 
that these mice had excess cartilage and failed to initiate joint formation (Brunet et al. 
1998; McMahon et al. 1998). 
1.3.5 BMP antagonist Noggin structure 
Human Noggin protein is encoded by the NOG gene, that has 205 amino acids and 
is secreted as glycosylated covalently linked homodimer with a molecular mass of 
64KDa (Smith and Harland 1992; Ogawa et al. 2002). Noggin primary structure 
contains of acidic amino-terminal and a cysteine-rich carboxyl-terminal, which 
contains nine cysteine residues. At the center of the Noggin protein structure there is 
a highly basic heparin-binding segment, which maintains the protein at the cell 
surface thus controlling its diffusion (Economides et al. 2000; Paine-Saunders et al. 
2002). Noggin protein was first discovered in Xenopus produced by Spemann’s 
organizer as a neural inducer (Smith and Harland 1992). The main physiological 
function of Noggin is to antagonize BMPs through preventing, their binding to both 
type I and type II serine-threonine kinase receptors and inhibiting their signals 
mediated by Smad1/5/8 (Zimmerman et al. 1996; Brunet et al. 1998; Groppe et al. 
2002).  
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1.3.6 Noggin function 
As the knowledge of BMPs and their role in different tissues has increased with time, 
so the understanding of Noggin’s function has also increased. In Noggin null mice 
increased in BMP activity results in a series developmental abnormalities such as 
defects of the axial skeleton and joint lesions, impaired formation of the neural tube 
and hair follicle retardation (McMahon et al. 1998; Tylzanowski et al. 2006). Noggin 
contributes in somite differentiation (Marcelle et al. 1997; Tonegawa and Takahashi 
1998). In addition, mice lacking Noggin demonstrate excessive cartilage formation, 
shorter extended limbs, and lack joint formation indicating the importance of Noggin 
in the regulation of chondrocyte proliferation and differentiation (Brunet et al. 1998).   
Moreover, a new role of Noggin has been associated in osteolytic prostate cancer 
cell line where re-expression of Noggin in prostate cancer cells results in a reduction 
of their osteosclerotic capacity and balanced bone remodeling (Schwaninger et al. 
2007).   
1.3.7 The TGF-β superfamily signaling pathway 
In general, this superfamily of proteins signals by stimulating the formation of specific 
heteromeric complexes of type I and type II serine/theronine kinase receptors. Type 
II receptors are encoded by five mammalian genes and binding to the ligand 
phosphorylates and activates the type I receptor. Type I receptors are encoded by 
seven mammalian genes (Whitman 1998; Patterson and Padgett 2000).  
Type I receptors may have different names as a result of being cloned by 
independent groups. Such as Activin receptor-like kinase 4 (ALK 4) can also be 
called activin receptor type IB (ActRIB) since it could bind Activin and mediate certain 
Activin responses in cultured cells (Attisano et al. 1993; Yamashita et al. 1995; 
Attisano et al. 1996). These seven members of type I receptor are further divided into 
three groups according to their structure and function similarities (Kawabata et al. 
1998). These three groups are as follows: 
1- The BMPR-1 which include 
BMPR-IA 
BMPR-IB 
2- The ALK-1 
ALK-1 
ALK-2 
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3- The TGFβR-I 
ALK-4/ActR-IB 
ALK-5/ TGFβR-I 
ALK-7 
 
On the other hand, there are three receptors that may serve as type II receptor: one 
of them is specific for the BMPs while the other two are shared by the other TGF-β 
family members including activin and myostatin respectively (BMPR-II, ActR-II and 
ActR-IIB) (Yu et al. 2005).  
The only substrates for type I receptor kinase that is known to have a signalling 
function are Smads (Whitman 1998; Patterson and Padgett 2000). According to their 
function Smads fall into three subfamilies as described in the Figure 1.5: receptor-
activated Smads (R-Smads): this group includes Smad1, Smad2, Smad3, Smad5 
and Smad8, which are phosphorylated by the type I receptors. The second subfamily 
includes the common mediator Smads (Co-Smads) including Smad4 which is then 
oligomerised with the activated R-Smad. The third subfamily includes the inhibitory 
Smads (I-Smads) that includes (Smad6 and Smad7). The inhibitory Smads are 
induced by TGF-β family members and cause a negative feedback effect by 
competing with R-Smad for receptor interaction thus, marking it for degradation 
(Grishin 2001). 
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Figure 1.5 Structure relationships in the Smad family. 
The figure illustrates the Smad proteins with the N-terminal Mad homology 1 (MH1) domains in blue 
and the C terminal Mad homology 2 (MH2) domains in green. Selected domains and sequence motifs 
are indicated as follow: α-helix H2, L3 and H3/4 loops, β-hairpin, the unique exon 3 of Smad2 (ex3), 
Nuclear localization sequence (NLS), Nuclear export signal (NES), the proline-tyrosin (PY) motif, 
Smad4 activating domain (SAD) and the SSXS motif of R-Smads with asterisks indicating the 
phosphorylated serine residues. This picture is adapted from (Moustakas et al. 2001). 
The Smads have two domains, the N-terminal Mad homology 1 (MH1) and C-
terminal Mad homology 2 (MH2) domains, which are joined with each other, by a 
linker region as shown in Figure1. 6 (Grishin 2001).  !  
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Figure 1.6 Smads domains. 
This figure illustrates the three-dimensional structures of the Smad MH1 domain bound to the AGAC 
sequence, and the Smad MH2 domain. The principal interactions of these two domains are listed. The 
structures involved in these interactions are shown in different colors: the β-hairpin (β-hp) that 
mediated DNA binding, the L3 loop and α-helix 1 (αH-1) that specify Smad interactions with type I 
receptors, and the α-helix 2 (αH-2) that specifies Smad2 interaction with SSXS, receptor 
phosphorylation sites. This picture is produced from (Massagué and Chen 2000). 
The MH 1 domain in R-Smads and Co-Smads is highly conserved and plays an 
important role in cytoplasmic anchoring, nuclear import, DNA binding and regulation 
of gene transcription. The MH 2 domain is highly conserved in all Smads (Grishin 
2001; Shi and Massagué 2003). The MH 2 function is to regulate Smad 
oligomerisation reaction by type I receptors and interact with the cytoplasmic 
adaptors and other transcription factors (Shi 2001).  
The first and crucial step in TGF-β signalling pathway is the phosphorylation of the R-
Smads at the C-terminal SSXS motif by activated type I receptor (Abdollah et al. 
1997; Shi and Massagué 2003). The L45 loop in the type I receptors and L3 loop in 
the R-Smad MH 2 domain both determine their binding to their specific substrates. 
Thus the Smad signalling cascade is classified into two groups TGF-β/Activin and 
nodal group which phosphrelayte Smad2 and Smad3 and the BMP group which 
phosphorylate Smad1, Smad5 and Smad8 as illustrated in Figure 1.7 (Chen et al. 
1998).!!
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Figure 1.7 Signaling specificity in the TGF-β superfamily. 
The mammalian Smad signaling cascades are classified into two important pathway Activin-TGF-β 
(red) and BMP (blue) each ligand binds to its specific type I and type II receptors as indicated in the 
diagram. Activin-TGF-β are phosphorylated by Smad2 and Smad3 (R-Smad) while BMP are 
phosphorylated by Smad1, 5 and 8. Both groups share the same Co-Smad. Smad7 acts as an 
inhibitor for Activin-TGF-β group and Smad6 as an inhibitor for the BMP group. Adapted from (ten 
Dijke et al. 2000; Moustakas et al. 2001).  
After the activation, R-Smads form complexes with the Co-Smad (Smad4) which then 
enter the nucleus where they bind to DNA and regulate the transcription of target 
genes along with other different cofactors (Shi and Massagué 2003). This pathway is 
not only regulated with the I-Smads, which regulate the processes by feedback 
inhibition. Furthermore, the TGF-β signaling pathway is highly regulated at different 
levels (Kogawa et al. 1991; Shimonaka et al. 1991). For instance some extracellular 
proteins such as follistatin, Noggin and chordin, antagonize the effect of many TGF-β 
family members and alter their signaling processes (Shimonaka et al. 1991). 
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Follistatin can bind both activin and BMP7 and prevent their binding to their receptors 
(Iemura et al. 1998). On the other hand, Noggin and chordin bind to BMP-4 and 
antagonize its effect (Piccolo et al. 1996; Zimmerman et al. 1996). Additional 
mechanisms are involved in regulating the Smads pathway including, 
nucleocytoplasmic shuttling and ubiquitin-mediated proteasomal degradation (Shi 
and Massagué 2003). The TGF-β pathway can be activated in two ways Smad 
dependent and independent mechanism. The non Smad-mediated signaling pathway 
also has long been known to control other physiological processes (Massagué 2008). 
The nucleocapsid (N) protein can bind to Smad3, which interferes with complex 
formation between Smad3 and Smad4. As a result, a Smad3-p300 complex is 
formed in the nucleus (Zhao et al. 2008). In addition, TIF1γ is found to be selectively 
associated with the phosphorylated Smad2/3 in hematopoietic, mesenchymal and 
epithelial cells in response to TGF-β and transduce the signal independently of 
Smad4 to promote erthrogenesis (He et al. 2006). Moreover, the ubiquitin E3 ligase 
TRAF6 has also been reported to interact with TGFβRI and this coupling is needed 
for TGF-β induced auto-ubiquitination of TRAF6 as well as subsequent activation of 
TAK1-p38 MAPK, leading to apoptosis (Sorrentino et al. 2008; Yamashita et al. 
2008). Figure 1.8 illustrates the TGF-β signaling pathway both Smad dependent and 
independent mechanisms.  
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Figure 1.8 TGF-β signaling pathways. 
After the activation of TGF- β it binds to two types of serine/threonine kinase receptors and transmits 
the signal through R-Smad phosphorylation, R-Smad binds to Co-Smad forming a complex that 
translocate to the nucleus and regulate the transcription of target genes. TGF- β can activate the 
signaling of MAPK in which Smad 7 act as a scaffold protein. TGF- β may activate other pathways 
including MAPK, PI3K, PP2A, Par6 and Rho GTPase independent of Smad signaling. Adapted from 
(Yan et al. 2009). 
In normal physiological condition, TGF-β is known to inhibit the proliferation of cells 
by inducing apoptosis and inhibiting cell growth. As a consequence any deregulation 
of TGF-β expression or signaling has been associated with several diseases 
including cancer where, this inhibitory function is lost (Lindholm et al. 1992; Jennings 
and Pietenpol 1998) as shown in Figure 1.9. 
 
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
20!!
 
Figure 1.9 Possible multiple roles of TGF-β in tumour pathogenesis. 
In non-transformed cells TGF-β can stimulate apoptosis or inhibit proliferation as cells progress to late 
stage they loss the growth inhibitory effect of TGF-β. During late stage of tumour development TGF-β 
are secreted by the tumour cells or stromal cells and contributes to the cell growth, invasion, 
metastases and decrease in the immune response of the host toward cancer cells. Adapted from 
(Kaminska et al. 2005). 
1.4 The role TGF-β plays in different mechanisms  
1.4.1 Apoptosis 
A group of genes regulated by Smads is suggested to facilitate the pro-apoptotic 
effects of TGF-β. These genes include the ones that code for the phospholipid 
phosphatase SHIP, death-associated protein kinase (DAPK) and TGF-β-inducible 
early response gene 1 (TIEG1) (Ten Dijke et al. 2002; Siegel and Massague 2003). 
Moreover, by means of Smad3, TGF-β stimulates the expression and activates Fas 
receptors contributing to caspase-8 activation and apoptosis of gastric carcinoma 
cells (Kim et al. 2004).  
However, as seen in Figure 1.10 there are clear participations of the mitogen-
activated protein kinases MAPKs, such as p38 and Jun N-terminal Kinases (JNK) in 
the apoptotic mechanisms downstream of TGF-β ligands. Interaction between type II 
receptor for TGF-β and the proapoptotic adaptor protein Daxx, results in stimulation 
of JNK and it triggers apoptosis in both epithelial cells and hepatocytes (Perlman et 
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al. 2001). The Daxx-JNK pathway includes homeodomain interacting protein kinase 2 
(HIPK2), that phosphorylates Daxx, regulating the MAPK kinases MKK4 and MKK7 
activity which eventually results in JNK induced apoptosis as described in the Figure 
1.10 below (Hofmann et al. 2003). There is another connection between receptor 
complexes and intracellular kinases. It involves the TGF-β-activated kinase 1 (TAK1), 
which can form a complex with the BMP receptors via its adhering partner TAB1 and 
the inhibitor of apoptotic caspases XIAP, an E3 ubiquitin ligase (Yamaguchi et al. 
1999). 
BMPs may also be responsible for apoptosis of diverse cell types through TAK1, p38, 
Smad6 and Smad7 as shown in Figure 1.10 (Yanagisawa et al. 2001).   
TGF-β might further counteract pro-survival signals. The comparative levels of 
Smad3 and the pro-survival kinase Akt determine whether a cell transition to 
apoptosis in reaction to TGF-β (Conery et al. 2004; Remy et al. 2004). Nevertheless, 
TGF-β stimulates cell death of prostate carcinoma cells by boosting cooperation 
between Smad7 and TAK1-p38 signaling module (Edlund et al. 2003). 
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Figure 1.10 TGF-β stimulating apoptosis. 
(A) illustrates the role of TGF-β in apoptosis through Smads. The expression of the pro-apoptotic 
genes including DAPK, Ship and Tieg is induced by the TGF-β via Smads. In addition Smads may 
promote apoptosis by binding and inactivating the survival kinase Akt. TGF-β stimulate apoptosis by 
mobilizing mitochondrial serpin ARTS to the nucleus, which blocks XIAPs the inhibitors of caspase. 
(B) illustrates the role of TGF-β in apoptosis through TAK1 pathway.  The TGF-β typeI receptor binds 
Smad7 while typeII receptor binds the pro-apoptic protein Daxx. BMP receptors bind XIAP and its 
interacting partners TAB and TAK1. Both TGF-β and BMP receptors simulate the activation of MKK3, 
MKK4 and MKK7 thus leads to apoptosis via either activating JUK or p38. Adapted from (Moustakas 
and Heldin 2005). 
1.4.2 Epithelial-mesenchymal transition and migratory responses 
The TGF-β is crucial in modulating other important cellular responses including the 
cell migration and epithelial/endothelial- mesenchymal transitions (EMTs) which are 
essential at the time of embryogenesis and advanced cancer metastases (Tosh and 
Slack 2002; Condeelis and Segall 2003; Gotzmann et al. 2004).  
Several studies have described the importance of Smads as mediators of actin 
cytoskeleton processing downstream of the TGF-β, since they promote a striking 
change in gene expression in the epithelial cells (Zavadil et al. 2001; Kowanetz et al. 
2004; Vardouli et al. 2005). A work done by Valcourt et al 2005 indicated that Smads 
particularly Smad3 and Smad4 are essential for initiating EMT response which is 
associated with the aggressive carcinoma spread in both in vivo and vitro.  
During EMT TGF-β receptor signaling acts synergistically with EGF signaling in the 
formation of tight junctions regulating the structural protein occludin, and interacting 
with the polarity protein Par6. In TGF-β signaling pathway, the type II receptor 
phosphorylates both the type I receptor and the type-I-receptor-tethered Par6 
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resulting in enlisting of the ubiquitin ligase Smurf1 and consequent ubiquitination and 
the breakdown of RhoA (Ozdamar et al. 2005). This results in local dismantling of the 
actin cytoskeleton and thus breakup of the strong binding, which is one of the 
characteristics of EMT (Thiery 2003). At the same time, stimulation of Smads by the 
type I receptor results in transcriptional initiation of genes that are involved in EMT 
including the ones encoding for Snail (Peinado et al. 2003), which is a transcriptional 
repressor of the gene encoding E-cadherin (Nieto 2002). A couple of reports directly 
connect the cytoplasmic protein kinase Limk1 to the long cytoplasmic tail of the BMP 
type II receptor (BMPR-II) (Foletta et al. 2003; Lee et al. 2004). Limk1, a considerably 
studied kinase that signals downstream of Rho GTPases and modulates structural 
reordering of the actin cytoskeleton (Raftopoulou and Hall 2004), may be involved in 
the mechanism by which BMPs regulate the actin cytoskeleton at neuronal dendrite 
morphogenesis (Foletta et al. 2003; Lee et al. 2004). Conversely, the TGF-β type I 
receptor can stimulate the related Limk2 through Rho and its downstream effector 
ROCK1 in an indirect manner (Vardouli et al. 2005).  
1.4.3 Cell proliferation  
The role that TGF-βs have in apoptosis and morphogenetic responses, also induces 
growth inhibitory pathways via Smads which modulate gene expression and regulate 
transition through the G1 phase of the cell cycle (Massague 2004).  There are 
several cell cycle inhibitors including p15, p21 and p57 that could be induced by 
Smad signaling, while the proto-oncogene product Myc and the inhibitors of 
differentiation (Id1, Id2, and Id3) are inhibited by Smads. The P21 activity is rapidly 
stimulated by all receptor complexes of the TGF-β superfamily (Massague 2004). 
FoxO, p53 and Sp1 together with Smads forms large transcriptional complexes on 
the p21 promoter enhancer. Reports have suggested that Smads themselves may 
inhibit cell growth by binding to protein kinase A (PKA) and activate the enzyme this 
effect is linked to the transcriptional activation of p21 and further inhibition of cell 
growth (Datto et al. 1995; Cordenonsi et al. 2003; Seoane et al. 2004).  
TGF-β may alternatively, control the cell growth by inhibiting p70 s6 kinase through 
dephosphorylation by protein phosphatase PP2A. This leads to cell cycle progression 
and arrest in early G1 phase (Bhowmick et al. 2003; Kamaraju and Roberts 2005).  
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1.4.4 Matrix regulation 
Several important components of the extracellular matrix and its regulatory enzymes 
are encoded by different genes that are stimulated by the TGF-β (Siegel and 
Massague 2003; Schiller et al. 2004), such as plasminogen activator inhibitor 1(PAI-
1), collagenase I and the collagens (Qing et al. 2000; Javelaud et al. 2003). Smads 
work together with transcription factors for instance, Sp1 and TFE3 in order to 
regulate the expression of PAI-1. However, signals from ERK and Rac1 are also 
required (Datta et al. 2000; Kutz et al. 2001).   
In addition, exogenous TGF-β enhances the motion of glioma cells by increasing the 
expression of collagen and subunit of α2,5 β3 integrin and increasingly adjusting the 
activity of matrix metalloproteinases MMP-2,9 at the cell surface of glioma cells (Wick 
et al. 2001). This interaction between the cell surface receptor and its extracellular 
matrix components is important for tumour metastases and angiogenesis (Verrecchia 
and Mauviel 2002). Thus, the TGF-β regulated enzymatic degradation of extracellular 
matrix proteins may lead to an increase tumour spread (Platten et al. 2001).  
1.4.5 Cell differentiation 
Cell differentiation and the regulation of gene expression are linked together by TGF-
β superfamily members (Miyazono et al. 2004). For instance, in order for the 
osteoblasts to differentiate from pluripotent progenitor cells they require BMP inputs 
in addition to the contribution of other factors such as Smad, transcription factors of 
the Runx family and Id proteins (Miyazono et al. 2004). Moreover, the association of 
p38, ERK and JNK pathways are quantifiably evidenced in the process of osteoblast 
differentiation in response to BMP-2, BMP-4 or BMP-7 (Gallea et al. 2001; Lai and 
Cheng 2002; Xiao et al. 2002). In addition, the modulation of Runx2 expression by 
TGF-β and BMP require Smad and p38 stimulation as well (Lee et al. 2002). As with 
cell proliferation, apoptosis and cell migration/cell differentiation induced by TGF-β 
family members largely utilizes the MAPK pathways and infrequently alternative non-
Smad effectors (Moustakas and Heldin 2003). 
1.4.6 Tumour mediated immunosuppression 
TGF-β has been shown to have an essential role in glioma evasion from host 
immunity by system by inhibiting Major histocompatibility complex (MHC) class II 
expression on glioma cells, macrophages and microglia (Zagzag et al. 2005). 
Although, TGF-β wields its immunosuppressive effect on all cells of the immune 
system, its main target of action are T lymphocytes, which can develop into either 
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effector (CD+CTL) or helper (CD+4 TH1 or TH2) cells. The TGF-β has been found to 
be a major inhibitor of the T cells maturation (Gorelik and Flavell 2001; Chen et al. 
2005). 
Some experimental studies have suggested that the inhibition of immunostimulatory 
cytokine expression, such as interferon gamma (IFNγ) and Tumour necrosis factor 
alpha (TNFα), or the reduction of IL-2-mediated proliferative signals, mediate the 
effects of TGF-β1 in immunity (Ranges et al. 1987).  
In addition, TGF-β1 can eliminate T cell stimulation by a negative effect on antigen 
presenting cells, for example dendritic cells. Furthermore, TGF-β1 is also able to 
suppress macrophages by suppression of TNFα, H2O2 and nitric oxide formation. 
More to the point, TGF-β1 might enhance the formation of immunosuppressive IL-10 
by macrophages (Maeda et al. 1995).  
Furthermore, targets of TGF-β1-mediated immunosuppression are natural killer (NK) 
and lymphokine activated killer cells (LAK), as well as neutrophils (Kuppner et al 
1988). Several studies have suggested that blocking the TGF-β1 signaling in the 
immune system cells will enhance the anti-tumour response (Gorelik and Flavell 
2001; Bollard et al. 2002). 
1.5 TGF-β superfamily expression and activities in prostate cancer and 
survival 
The main characteristics of carcinogenesis and tumour cell autonomy are autocrine 
secretion of growth factors and the absence/inactivation of proteins encoded by 
tumour suppressor genes (Goustin et al. 1986; Weinberg 1989). Both human and rat 
prostates produce many peptide growth factors. Moreover, the proliferation of 
prostate cancer in vitro can be altered by the introduction of exogenous growth 
factors (Ware 1993).     
It has been suggested that TGF-β1 has actions in the formation and advancement of 
prostate cancer (Wilding 1991). Even though, TGF-β has been involved in immune 
suppression and angiogenesis, it is a powerful growth inhibitor in most cells specially 
inhibiting epithelial cell proliferation (Wilding 1991; Kulkarni et al. 1993).  
Most prostate cancer cell lines are characterized by increased levels of TGF-β1 
expression in vivo. TGF-β1 stimulates tumourigenicity in many cell types including 
prostate (Chang et al. 1993; Thompson et al. 1993; Eastham et al. 1995). This is 
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interesting with respect to the demonstrated growth inhibitory activity observed 
epithelia in vitro.  
In a study done to evaluate the activity of the TGF-β in cultures of stromal cells 
isolated from benign prostatic hyperplasia tissue, challenge using wide dose range of 
TGF-β1 demonstrated that low dose of TGF-β1 (0.01ng/ml) was associated with the 
increase in the population growth while with higher doses the population growth was 
suppressed. One suggested mechanism by which low doses of the TGF-β could 
increase cell population size is by stimulating production of known growth promoters 
including fibroblast growth factor (FGF2). In addition, it may also result from lower 
apoptosis/differentiation in the treated population. In higher doses, TGF-β decreases 
population sizes by growth inhibition but not by increasing apoptosis (Bretland et al. 
2001).  
Prostate cancer cells and other cell types may develop resistant to the growth 
inhibitory effect of the TGF-β1 by a varied set of mechanisms: 
1- Only few cells can activate the endogenously produced TGF-β from their latent 
form, limiting bioavailability of active forms (Wakefield et al. 1987).   
2- Cells may fail to respond to TGF-β if they have a faulty ligand-binding receptor 
system to cell surfaces. The absence of binding has been associated with the 
expression of little, no TGFβRII mRNA or carry TGFβRII gene mutations (Inagaki et 
al. 1993; Markowitz et al. 1995; Wang et al. 1995). 
3- Finally, since TGFβRI and TGFβRII are heteromeric complex that interact with 
different targets to activate various signaling pathways, it is likely that the expression 
of different type I receptor isoforms or splice variants of type I or type II receptors 
affect these interactions, thus allowing cells to retain sensitivity to some effects of 
TGF-β1, while acquiring resistance to other effects (Xu et al. 1994).  
Moreover, a study by Kim et al 1996, demonstrated reduced levels of expression of 
TGFβRI and TGFβRII in certain human prostate cancer cell lines and showed an 
inverse relationship between the levels of expression of TGFβRI and TGFβRII and 
the grade of prostate cancer. Sensitivity deprivation of TGF-β through the loss of its 
receptors would be likely to induce prostate cancer cells to increase the level of 
expression of TGF-β and this elevated level of TGF-β could then provide survival 
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advantages to prostate cancer cells by stimulating angiogenesis and suppressing the 
immune response (Kim et al. 1996). 
Another paper by Kim et al 1996 showed a correlation between a structural alteration 
in the TGFβRI gene and insensitivity to the effects of TGF-β by comparing three 
different prostate cancer cell lines including PC3 (Kim et al. 1996). 
BMPs may have a role in prostate carcinogenesis similar to TGF-β isoforms. These 
proteins also signal through the interaction with their receptors BMPRI and BMPRII 
as discussed earlier in this thesis (Ide et al. 1997; Autzen et al. 1998). In vitro, most 
members of the BMPs bind to BMPRII which then combines with BMPRIA or 
BMPRIB (Liu et al. 1995). Kim et al 2000, demonstrated that the human prostate 
cancer epithelial cell line have decreased level of expression of BMPRIA, BMPRIB 
and BMPRII as well as an inverse correlation between the levels of BMPR 
expression and tumour grade (Kim et al. 2000). 
1.6 Bone microenvironment in tumour growth: a“vicious cycle”  
Osteoblasts, osteoclasts, the mineralized bone matrix and many other cell types 
make up the bone microenvironment (Kozlow and Guise 2005). A vicious cycle of 
tumour growth and disease is promoted by the negative implication of tumour cells 
and the microenvironment as shown in Figure 1.11 (Yoneda and Hiraga 2005).  
As demonstrated above, tumour cells secrete factors that stimulate osteoclast-
mediated bone destruction and as a result the release of numerous factors which 
were previously immobilized in the bony matrix. These can act on the cancer cells, 
promoting survival, growth, more aggressive phenotypes and potentiating cancer 
spread and further bone destruction (Hall et al. 2006).  
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Figure 1.11 The vicious cycle of bone metastases. 
There are several factors such as MMPs, chemokine receptor 4 CXCR4, vascular endothelial growth 
factor VEGF and connective tissue growth factor CTGF that are secreted from the primary tumour that 
target metastatic tumour cells to bone and enhance their survival within the bone microenvironment. 
Physical factors with the aid of bone derived growth factors including TGF-β and IGFs activate tumour 
cell to express osteoblast stimulatory factors and osteolytic stimulatory factors which in turn stimulate 
bone cells to release factors that promote tumour growth in the bone. Adapted from (Kingsley et al. 
2007). 
Additionally, the bone microenvironment contains physical factors, such as hypoxia, 
acidosis, and extracellular calcium plus growth factors like TGFβ that have been 
implicated in this vicious cycle (Kingsley et al. 2007). 
1.7 Growth factors as mediators of the bone microenvironment 
During the destruction of bone by osteoclasts calcium and many growth factors are 
released from the matrix including IGF, TGF-β, fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF) and bone morphogenetic proteins (Mohan and 
Baylink 1991). All of these factors have the potential to act on metastatic cells directly 
stimulation of cell proliferation or indirectly by promoting angiogenesis and increasing 
tumour production of osteolytic and osteoblastic factors that in turn remodel the 
skeleton to accommodate tumour growth (Derynck and Zhang 2003).  
Although, TGF-β is not the most abundant growth factor in bone, it has an important 
role in osteolytic metastases (Derynck and Zhang 2003). Many studies indicate that 
TGF-β may stimulate bone metastases by inducing the proosteolytic gene expression 
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in association with PTHrP in both breast cancer cell line and prostate cancer cell 
lines such as PC3 (Guise et al. 1996; Yin et al. 1999). TGF-β induced PTHrP in turn 
increases Osteoblastic production of RANK ligand therefore, stimulate osteoclast 
formation and activity this consequent increase in bone resorption releasing more 
bone matrix factors to act on cancer cells thus sustaining a vicious cycle (Pollock et 
al. 1996; Kitazawa and Kitazawa 2002). 
1.8 The role of TGF-β in the initiation of bone metastases 
From the previous sections it is clear that the activity of the TGFβ family in the 
context of tumour growth and metastasis is complex. On the one hand, these factors 
are potential growth inhibitors for the tumour population but on the other, they provide 
modification of the tumour phenotype and associated environment in bone that 
favours metastasis. As stated earlier, osteoblastic lesions are frequently produced by 
prostate cancer that metastasizes to the bone. The mechanism by which prostate 
cancer promote bone remodeling/mineralization is not well understood: prostate 
cancer cells produce different factors with, osteogenic properties (Boyce et al. 1999; 
Deftos 2000). These factors could be grouped into those that have direct effects on 
osteoblast function; BMPs, TGFβ1, TGFβ2, IGF1, IGF2, FGF, PDGF, WNT (Mundy 
2002) and endothilin-1 (ET-1) (Kimura et al. 1992). ET-1 also has indirect effects: it 
stimulates the WNT signaling pathway by causing a reduction in the production of the 
WNT antagonist dickkopf homologue 1 (DKK-1) (Clines and Guise 2008). WNT 
signaling is a major osteoblast regulatory pathway, controlling normal osteoblast 
differentiation and function (Hall et al. 2005). A second category includes factors that 
have entirely indirect effects on osteoblast function such as vascular endothelial 
growth factor (VEGF) (Ducy et al. 1997) by modifying the bone microenvironment,  
Several other proteins also work indirectly to stimulate bone formation, for example 
the serine proteases, prostate specific antigen (PSA), and urinary plasminogen 
activator urokinase (uPA). These proteases could enhance the activation of growth 
factors such as TGFβ (Killian et al. 1993) and parathyroid hormone-related protein 
(PTHrP). How PSA facilitates the tumour growth has not been established but there 
is a possibility that it may also activate osteoblast stimulating factors such as TGFβ 
and IGF by cleaving them from their inactivating peptides (Cramer et al. 1996; 
Iwamura et al. 1996). Figure 1.12 describes the bone formation in prostate cancer 
osteoblastic metastases. 
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Figure 1.12 Bone metastases in prostate cancer. 
Prostate cancer cells stimulate osteoblast proliferation and new bone formation via the secretion of 
many factors into the bone microenvironment such as endothelin-1ET-1, FGFs, BMPs and PDGF. ET-
1 decreases the secretion of DKK-1, which is Wnt pathway inhibitor that in turn results in the 
stimulation of osteoblast activity. Proteases mostly prostate-specific antigen produced from the tumour 
cell cleaves PTHrP, TGF-β and IGF from its binding protein which results in the production of 
fragments of PTHrP and active TGF-β thus stimulate osteoblast activity. Adapted from (Clines and 
Guise 2008). 
In breast cancer, metastases have been shown to stimulate osteoclastic activity in 
the bone marrow and cause release of the TGF-β from the bone matrix, which acts 
on cancer cells to stimulate the formation of PTHrP and Interleukin- 11. These two 
factors act on osteoblasts and cause the release of the RANK ligand and other 
factors involved in osteoclast mobilization and feed-forward into the osteolytic 
metastases cycle happen again as seen in Figure 1.13 (Kingsley et al. 2007). 
Metastatic breast cancer cells in the bone microenvironment use Smad dependent 
transcription as revealed by a noninvasive imaging reporter in mice (Kang et al. 
2005). PTHrP is a mediator of TGFβ osteolytic action(Kingsley et al. 2007). 
Apparently, TGFβ stimulates PTHrP secretion without increasing PTHrP mRNA 
levels (Käkönen et al. 2002). In addition, PTHrP promotes the production of RANK 
ligand in osteoblasts which results in promoting the differentiation of osteoclast 
precursors and bone resorption (Käkönen et al. 2002).  
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Figure 1.13 Role of TGFβ in breast cancer metastasis 
TGF-β derived from either infiltrating mesenchymal or myeloid precursor cells (green) or from the 
cancer cells themselves (brown) stimulates the expression of Angiopoietin-like 4 (ANGPTL4). 
Disseminated cancer cells then enter the circulation with increased ANGPTL4 have the advantage of 
seeding the lung this cytokines have the ability to disrupt vascular endothelial junctions. In the lung 
breast cancer cells respond to the local TGF-β thus results in an inhibition of differentiation/DNA 
binding1 (ID1). In addition circulating tumour cells enter the bone marrow where TGF-β being released 
from osteoblasts (blue) acts on the growing cancer cells and stimulate the production of parathyroid 
hormone-related protein (PTHrP) and interleukin-11. However these factors act on osteoblast cells 
and enhance the release of RANK ligand (RANKL) and other mediators of osteoclast mobilization 
initiating osteolytic metastases cycle. Adapted from (Massagué 2008). 
Other mediators that modulate bone metastasis include interleukin-11 (IL-11) and 
connective tissue growth factor (CTGF), which are TGFβ target genes (Kang et al. 
2003; Kang et al. 2005). The induction of both IL-11 and CTGF expression by TGFβ 
is mediated by Smad signaling (Kang et al. 2005).  
In addition, Smad molecules can activate the transcription of downstream targets 
such as plasminogen activator inhibitor type I (PAI-1) (Tu et al. 2003). Reduction in 
the level of PAI-1 is associated with disruption of the TGF-β activity in prostate 
cancer, which in turn leads to inhibition of urokinase type plasminogen activator 
(uPA) mediated extracellular matrix proteolysis. This is suggested as another 
possible mechanism for modulating metastasis (Lyon et al. 1995; Soff et al. 1995). 
Blocking the effects of TGF-β may be essential to allow tumour growth but 
consequent restoration of the TGF-β pathway at the right time contributes to tumour 
cell motility, epithelial-to-mesenchymal transition and eventually metastasis (Derynck 
et al. 2001). 
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In addition to the above, TGF-β1 was found to stimulate collagenase production and 
enhance tumour cell invasion and metastatic potential (Welch et al. 1990). Therefore 
autocrine production of TGF-β1 may affect tumour cells directly by decreasing cell 
adhesion or enhancing degradation of extracellular matrix components (Morton and 
Barrack 1995). 
Additionally, loss of BMPs is linked to advanced prostate cancer and bone 
metastasis (Soda et al. 1998). Prostate cancers maintaining high levels of BMP 
signaling may be unable to proliferate in such a microenvironment. However, 
prostate cancer cells that lack expression of BMPRs could be released from the 
growth inhibitory effect of BMPs and enabled to proliferate in the bone (Kim et al. 
2000).  
A work done by Hamdy et al 1997 of the relation between the expression of BMP-6 in 
prostatic cancer tissue and skeletal metastases, suggested that BMP-6 might be 
partially the cause for the osteoblastic changes in metastatic lesions that occur in 
prostate cancer (Hamdy et al. 1997).  
However, BMP-7 was found in another study done by Buijs et al to provoke TGF-β 
signaling effect in human prostate cancer cells that are known to be metastatic to 
bone. This study suggested that BMP-7 may govern the epithelial homeostasis in 
human prostate gland by maintaining the epithelial phenotype. It has been suggested 
that BMP-7 could be used as a new therapeutic molecule for repressing the progress 
of prostate cancer (Buijs et al. 2007).  
1.9 Modulation of the TGF-β signaling as a strategy to suppress the formation 
of the bone metastases 
The accumulation of evidence of the various roles TGF-β in immunosuppression, 
regulation of tumour growth and metastasis, has given rise to an increased interest in 
TGF-β as a therapeutic target (Arteaga 2006; Bierie and Moses 2006; Wrzesinski et 
al. 2007).  
A study done by (Muraoka et al. 2002) revealed that cutting off the action of TGF-β 
resulted in inhibiting mammary tumour cells viability, migration and metastases. 
Introduction of dominant negative TGF-β Type II receptors (TβRII) into mammary 
cells resulted in retarding the primary tumour and metastases formation and 
prevention of epithelial-to-mesenchymal transition (EMT) (Oft et al. 1998). 
Furthermore, in osteolytic bone metastases inhibiting TGF-β might result in 
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interruption in the osteoclastogenic cycle and the progression of tumour growth 
(Loeys  et al. 2006). 
In another study done by (Shah et al. 2002) retrovirus-mediated introduction of a 
dominant negative TGFRII to bone marrow  cells resulted in production of leukocytes 
capable of potent anti-tumour response and suppression of metastasis in both 
melanoma and prostate cancer models. These mechanisms were based on the 
interaction between the cytokine and its receptors. Recently another effective therapy 
was introduced based on siRNA in order to repress TGF-β activity in malignant cells 
(Friese et al. 2004; Bhola et al. 2013). Blocking the cytokine expression by using 
siRNA against TGF-β was found to inhibit tumour cell migration, tumour invasion, and 
restore anti-tumour immune response in mouse model (Friese et al. 2004). Inhibitors 
target phosphorylation of Smad proteins have been used and result in the 
suppression of Smad nuclear translocation (DaCosta et al. 2004; Scott et al. 2004) 
and might be used to inhibit TGF-β action.  
Aiming at the osteoblastic response to prostate cancer could also be promising. An 
endothelin A receptor (ETAR) antagonist is found to reduce the advancement of 
prostate cancer bone metastases (Clines and Guise 2008).  
A new class of possible beneficial agents is recognized against a wide range of 
diseases this class includes Si/shRNA. On the other hand, the benefits of this 
approach depends mainly on the effective delivery of shRNAs to tumour cells. 
Transfection of shRNA with lentiviruses into cultured mammalian cells may be an 
encouraging method in specific, efficient and stable knockdown of various genes (An 
et al. 2003; Grimm et al. 2005).  
However, these examples show the enormous potential of the pathway as a 
therapeutic target although there may be negative consequences: the inhibition of 
TGF-β might result in chronic inflammatory and autoimmune reactions. In addition, 
Inhibition of TGF-β receptor function could further result in the development of 
compensatory resistance mechanisms by other activators of the Smad pathway 
similar to those that occur in individuals with inactivating mutations in TGFβRI and 
TGFβRII (Loeys et al. 2006). 
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1.10 Aim of the study 
Prostate cancer represents one of the most common cancers and the second most 
common cause of cancer deaths in men worldwide. More than 80% of patients with 
advanced prostate cancer develop bone metastases (Mundy 2002; Jemal et al. 
2007). The human prostate cancer cell line PC3 preferentially colonizes vertebrae 
and the long bones of the hind limbs when injected into the circulation of 
immunosuppressed mice. The factors that regulate colonization of the skeleton and 
tumour growth in this model are not well understood. What is clear is that these cells 
produce lesions that are eventually osteolytic in appearance and that this is a result 
of tumour cells modifying the bone microenvironment during the formation of 
metastases. It is also apparent that PC3 cells produce significant levels of a number 
of cytokines that are osteoinductive such members of the TGFβ family including 
TGFβ1, BMPs 2 and 3 and an antagonist in this system, Noggin. The relative 
contribution of these signaling molecules to the events of attachment of tumour cells 
to bone cells and early colony initiation is unknown, what is clear is that the effects of 
these cytokines are unlikely to be simply autocrine but also paracrine acting on 
tumour associated cell populations.  
The aim of this study is to investigate the interaction between prostate cancer cells 
(PC3-RFP) and bone cells (SaOS-2 and MG63) and to determine which members of 
the TGFβ superfamily contribute these interactions and potentially to the colonization 
of tumour cells to the skeleton. This study will test the hypothesis that tumour derived 
TGFβ signaling regulates the growth and differentiation of osteoblastic lineage cells 
and contributes to the survival and growth of prostate cancer cells in vivo.  
The hypothesis of my study was addressed through four objectives. 
1- Determine the effect of Prostate cancer cells on the growth of osteoblastic cell 
lines and their differentiation (chapter 3). 
2- Determine the expression of TGF−β superfamily genes in human prostate cancer 
cells grown alone and in direct contact with osteoblastic cells or when 
osteoblasts were exposed to products of prostate cancer cells present in 
conditioned medium. Levels of expression of these genes in these populations 
will be compared and important differences investigated further (chapter 4). 
3- Determine the effect of Noggin on the growth of osteoblast SaOS2 cells. This will 
be achieved by evaluating the effect of conditioned media collected from PC3 
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knock down Noggin (PC3-KD) cells on the proliferation of osteoblast (SaOS2) 
cells compared to conditioned media collected from control PC3RFP-mock cells. 
In addition I will determine the effect of exogenous recombinant Noggin on the 
growth rate of osteoblast cells (chapter 5).  
4- Determine whether tumour frequency and growth of PC3 prostate cancer cells  
(Noggin knockdown/ mock control) is affected by Noggin expression in the 
BALB/c nude mice (chapter 6) 
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2 Chapter 2: Material and Method 
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2.1 Tissue culture Materials and Disposable Equipment: 
Item Supplier 
Disposable pipettes (2,5,10 and 25ml) Sterilin 
Disposable Tips (200 and 1000µl) Corning Incorporated 
Centrifuge Tubes (15 and 50ml) Sterilin 
Flasks (T25 and T75) IWAKI 
Multi well plates (24 and 96 wells) IWAKI 
Cryovials 2ml Corning Incorporated 
NalgeneTM Cryo 1ºC freezing container NALGENE 
Cell culture Materials  
DMEM without pyruvate Gibco 
Penicillin/streptomycin Sigma 
Sodium bicarbonate sigma 
Fetal Bovine Serum (FBS) PAA-The cell culture Company 
Trypsin/EDTA Sigma 
DMSO Sigma 
Ethanol Sigma 
Vi-CELL™ XR Quad Pak Reagent Kit Beckman Coulter 
Vi-Cell XR Cell Viability Analyzer Beckman Coulter 
 
2.2 Tissue culture techniques 
2.2.1 Cell Lines 
PC3 cell line was obtained from the American Type Cell Collection (ATCC), and was 
transfected with pDSRed-monomer-Hyg-C1 plasmid to become stable hygromycin 
resistance and to stably express RFP by Dr. Colby Eaton's group at Sheffield 
University.  
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Figure 2.1 Plasmid map for the pDSRed-monomer-hyg-C1 used to produce PC3 RFP cells. 
Illustrate that transfected cells acquire red fluorescent and hygromycin resistance. 
 
The SaOS-2 cells are osteoblasts-like human cell lines derived from patient 
osteosarcoma (Rodan et al. 1987). They were acquired from the ATCC. 
The MG63 cells were obtained from ATCC. They are human undifferentiated 
osteosarcoma cell line, which has both mature and immature osteoblastic 
characterization (Pautke et al. 2004).  
All cell lines (PC3-RFP, SaOS-2 and MG63 cells) that have been used in these 
experiments were thankfully given by Dr. Colby Eaton at Sheffield University. 
2.2.2 Maintaining and sub-culturing of cell lines 
All cell lines were routinely maintained in sterile T75 flasks in humidified incubator at 
37ºC and 5% CO2. PC3-RFP, MG63 and SaOS-2 cells were grown in a high glucose 
without Pyruvate formulation of Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin/streptomycin 
(p/s). The confluence of the cultures was checked under an inverted microscope. 
When the cells were around 90% confluent the cells were harvested by trypsinisation 
and passaged in new T75 flasks and some of them were freeze down and stored in 
liquid nitrogen as a stock. 
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2.2.3 Cell harvesting by trypsinisation 
Trypsinisation is a method that is used for harvesting the adherent cells to generate a 
cell suspension for either the purpose of sub-culture or for counting in order to re 
seed for a specific experiment.  
For a T75 flask, the medium was removed, and the cells were washed with 10ml 
Dulbecco's phosphate buffer saline (PBS). 5ml of Trypsin-EDTA was added in order 
to detach the cells. The flasks were incubated in trypsin-EDTA at 37ºC   until all the 
cells detached. This was detected by using the inverted microscope. After cell 
dissociation, trypsin-EDTA was neutralized by adding 10ml of the standard medium 
with the correct percent of FBS designed for the experiment. The time for cells to 
dissociate differs according to the type of cell (5-10min for the PC3-RFP and MG63, 
10-15min for the SaOS-2 cells) and the time it had been cultured.  
2.2.4 Thawing and freezing of the Cells 
Cell lines were regularly frozen for long-term storage. All experiments were done 
within 5 passages for PC3RFP and up to 20 passages for SaOS2 and MG63 cells. 
 Freezing cells 2.2.4.1
Cell lines were harvested near the confluent phase by trypsinisation. Cells were 
pelleted by centrifugation and re-suspended in 1ml of freezing medium (standard 
medium with 7.5% DMSO). The cell suspension was put in aliquots of 1ml in cryo-
vials, placed in a Nalgene Cryo 1ºC freezing container to allow slow freezing (-
1ºC/min) and frozen at -80ºC overnight. After 24h, the cryo-vials were transferred to a 
liquid nitrogen storage tank for long term storage.  
 Thawing cells 2.2.4.2
The vials from liquid nitrogen were defrosted by partial immersion in water bath at 
37ºC. Then the cells were centrifuged (500xg, 5min). The pellets were re-suspended 
in standard medium and seeded in sterile flask.    
2.2.5 Cell counting using Beckman Coulter Vi-cell XR Cell Viability Analyzer  
The Vi-cell Cell viability analyzer uses the same widely accepted trypan blue dye 
exclusion method to determine cellular viability.  
In the Vi-CELL system a proprietary algorithm is utilized to determine which cells 
have absorbed the trypan blue dye and which have not. 
In order to count the cells by using the Beckman coulter vi-cell cell viability analyzer 
the cells were harvested by trypsinisation method as described in 2.2.3. The cells 
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were centrifuged at (5000xg, 5min). The supernatant was removed and 10ml of the 
standard medium was added to the pellet. The cells were mixed well using 10ml 
syringe. 1ml from the solution was transferred to an empty cup designed for the 
Beckman coulter vi-cell cell viability analyzer. The results obtained will be in the form 
of Total cell/ml and viable cell/ml.  
2.3 Molecular Techniques 
2.3.1 Materials and Disposable Equipment used for RNA Extraction  
ITEM SUPPLIER 
QIAGEN® RNAeasy Mini Kit QIAGEN® 
QIAGEN® DNase treatment  QIAGEN 
Ethanol( for molecular biology) Sigma-Aldrich 
Nuclease Free PCR tubes 1.5ml Fisher scientific 
10cc Syringe Hwajin medical company 
NanoDrop-1000 spectrophotometer  Thermo-Fisher 
RNA 6000 Nano Kit Agilent 
Agilent 2100 Bioanalyzer Agilent 
Chip Priming Station Agilent 
IKA vortex mixer IKA 
RNaseZAP Ambion 
RNase free Water Ambion 
Microcentrifuge  Agilent 
Heating Block  Agilent 
Reverse Transcription 
dNTP Bioline 
Oligo dt Promega 
Random (N)6 primer Promega 
DEPC- treated water Ambion 
Buffer Invitrogen 
0.1 dtt Invitrogen 
RNase inhibitor Promega 
Superscript III reverse transcriptase  Invitrogen 
Quantitative real time PCR 
TaqMan Universal master Mix  Applied Biosystem 
Human GAPDH(20X) Applied Biosystem 
COL1A Applied Biosystem 
TaqMan gene expression assay Noggin Applied Biosystem 
Runx2 Applied Biosystem 
Osterix Applied Biosystem 
MicroAmp optical 96-wellreaction plate (0.1ml) Applied Biosystem 
StepOne Plus Real time PCR Applied Biosystem 
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2.3.2 RNA Extraction from cells using Qiagen RNAeasy Mini Kit 
Preparation of the RNeasy Lysis (RLT) Buffer: 
Six microliter of β-mercaptoethanol was added to each 600µl of the RLT Buffer.  
The amount of RLT buffer added to different sizes of Tissue culture flasks: 
Tissue culture Flask 
Amount of RLT buffer 
added 
Amount of β-
Mercaptoethanol 
T25 flask 600 µl 6 µl 
T75 flask 1200 µl 12 µl 
 
First Step: 
After preparing the RLT buffer, the medium was removed from the flask and cell were 
washed with 3ml could PBS. RTL buffer was added to the flask and cells were 
removed completely from the flask in to RNase free PCR tube by using 10ml Syringe. 
The cells were mixed by vortex; at this point cells were stored at -80ºC.  
Second Step: 
Samples were thawed out completely, and an equal amount of 70% ethanol was 
added to each sample (i.e. 1200µl Ethanol). The samples were mixed thoroughly by 
vortex for 1 min.  
700µl of each sample were transferred to an RNAeasy Mini spin column placed in a 
2ml collecting tube. The lid was closed carefully and centrifuged for 30 s at maximum 
speed (8000xg). The flow through was discarded and another 700µl of each of the 
samples were transferred to the same RNAeasy Mini spin column and steps were 
repeated again until all the samples were finished. 350µl of RW1 (washing Buffer 
lysate/ethanol) were added to each column of samples and centrifuged for 30 s at the 
maximum speed (8000xg) and again the flow was discarded.  
DNA digestion step:  
Preparation of the RNase-free DNase I Enzyme for the first time: 
560µl RNase free water was injected into the enzyme vial and was gently mixed by 
inverting the vial. The enzyme should be divided into single use aliquots and store at 
-20ºC.   
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70µl of RDD buffer were added to each 10µl of Enzyme for each sample. 80µl of the 
above mixture (enzyme+ buffer) were added to each sample and were kept at room 
temperature for 15min. 350µl of the RW1 were added to all samples and centrifuged 
at the maximum speed for 30 s. The flow was discarded and 500µl of the second 
washing buffer RW2 was added on all samples. The samples were centrifuged again 
for 30 s and the flow was discarded. Another 500µl of the RW2 were added and 
same previous step was repeated. The collecting tubes were changed and the 
samples were centrifuged for 1 min. The spin columns were placed on a new 1.5 
collecting tube and a 30µl of RNase free water were added directly to the membrane 
of the column in order to dissolve the RNA. The lids were closed and the samples 
were centrifuged for 1 min, this is called the first elution. The spin columns were 
placed on another new 1.5 collecting tube and a 30µl of RNase free water were 
added directly to the membrane of the column in order to dissolve the RNA. The lids 
were closed and the samples were centrifuged for 1 min and this is called the second 
elution. 
2.3.3 Quantification of RNA  
The quality and the quantity of the RNA produced were assessed by using the 
Nandrop spectrophotometer. One microliter of each sample was loaded on the 
Nandrop spectrophotometer. The concentration of the RNA was measured at a 
wavelength of 260nm while the ratio between the two wavelengths A260 and A280 
indicate its purity. In all experiments the concentration of the RNA extracted from 
cells ranges between 50-1000ng/µL. the A260/A280 ratio in all experiments were above 
1.8 which indicate that the RNA obtained were free from protein contamination. 
2.3.4 Analyzing the RNA integrity by using the RNA 6000 Nano Bioanalyzer Kit 
The integrity of the RNA was assessed by using RNA 6000 Nano Bioanalyzed kit, 
which resemble RNA agarose gel electrophoresis. A good quality undegraded RNA 
characteristic was indicated by the presence of 2 horizontal bands representing the 
28S and the 18S ribosomal RNA as shown in Figure (2.2).  
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Figure 2.2 RNA integrity using RNA 6000 Nano Bioanalyzed kit. 
clear 28S and 18S bands represent an intact RNA (A) illustrate RNA integrity in PC3RFP (B) illustrate 
RNA integrity in SaOS2 (C) illustrate RNA integrity in MG63 
Preparing the RNA ladder: 
The ladder was transferred to an RNase free vial and denatured for 2 min at 70ºC 
then; the vial was immediately cooled down on ice. Aliquots were prepared in RNase 
free vials and stored at -80 ºC. The ladder aliquot that will be used was thawed and 
was kept on ice.  
Preparing the Gel: 
All reagents were allowed to equilibrate to room temperature for 30 min. Five 
hundred fifty microliter of Agilent RNA 6000 Nano gel matrix (red) were added into 
the top receptacle of a spin filter. The spin filter was placed in a microcentrifuge and 
centrifuged for 10 min at 1500xg. The filtered gel was divided into aliquots containing 
65µl in each 0.5ml RNase free microfuge tubes. 
Preparing the Gel-Dye Mix:  
All reagents were allowed to equilibrate to room temperature for 30 min. Note: the 
dye concentrate should be protected from light while keeping at room temperature.  
The RNA 6000 Nano dye concentrate was mixed buy vortex for 10 s and spun down. 
One microliter of the RNA 6000 Nano day concentrate was added to the 65µl aliquot 
of filtered gel was prepared previously. The tube was closed and mixed thoroughly. 
The tube was spun down for 10 min at room temperature at 13000xg.  
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Loading the gel-Dye mix: 
The gel dye mix was allowed to equilibrate to room temperature for 30 min. A new 
RNA Nano chip was taken out of its sealed bag. The chip was placed on the chip 
priming station. 9µl of the gel dye mix was pipetted at the bottom of the well-marked 
G. 9The timer was set to 30 s and the plunger was positioned at 1ml. Then the chip 
priming station was closed. The plunger of the syringe was pressed down until it was 
held by the clip. The syringe was released after 30 s. The plunger was pulled back 
slowly to the position 1ml again. The chip priming station was opened.  9µl of the gel 
dye mix was pipetted to each of the wells. 1 gel-d 
Loading the RNA 6000 Nano Marker: 
Five microliters of the RNA 6000 Nano marker were pipetted into each of the 12 
sample wells and the ladder well.5 µl marker 
Loading the ladder and the samples: 
The ladder aliquots were thawed and kept on ice. The samples were heat denatured 
at 70ºC for 2 min in order to minimize secondary structure before loading the 
samples. One microliter of the RNA ladder was pipetted into the well-marked with the 
ladder symbol on the top of the chip. One microliter of each sample was pipetted into 
each of the sample wells. The chip was placed horizontally in the adapter of the IKA 
vortex mixer and was mixed by vortex for 60 s. The chip was inserted into the Agilent 
2100 bioanalyzer and the run was started.   
2.3.5 Reverse Transcription and cDNA production 
The RNA samples were diluted to be about 500ng/µl. one microlitter of the samples 
were added to 1 µl of dNTP, 0.5 µl of oligo dT, 0.5 µl random (N)6 primer and DEPC-
trated water to a total of 10 µl of volume. The solution was incubated at 65ºC for 5 min, 
and chilled in ice for 1 min. Four microliter of the buffer, 1 µl of dtt and 1 µl of RNase 
inhibitor were added to the negative sample only. Four microliter of the buffer, 1 µl of 
dtt, 1 µl of RNase inhibitor and 1 µl of Superscript III reverse transcriptase were added 
to the positive sample and the No RNA tube. Samples were incubated for 2h at 50ºC, 
and the reaction was terminated by increasing the temperature to 70ºC for 15 min. The 
cDNA produced from the reaction was stored at -20ºC.  
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2.3.6 Quantitative real time PCR 
Reverse transcription RT/PCR is the most sensitive technique to determine the 
expression of specific transcript in an mRNA population. QRT/PCR was performed on 
cDNA samples either to test the quality of the cDNA produced by checking the 
expression of the housekeeping gene Glyceraldehide-3-phosphate dehydrogenase 
(GAPDH) or to determine the expression of specific genes in the study. Taqman 
universal master mix was used with primer of interest. Each 20µL of cDNA sample was 
diluted with 20µL of DNase/RNase free water. 2µL of each sample was loaded in fast 
optical 96 well reaction plate (0.1ml). The volume of reagents added per reaction is 
listed in Table below. 
Reagent Volume (µL) 
Taqman universal master mix 5µL 
Primer of interest 0.5µL 
DNase/RNase free water 2.5µL 
  
Quantitative RT/PCR was performed using StepOne plus PCR with denaturation 
temperature of 95ºC, annealing temperature 55-65ºC and elongation temperature of 
72ºC these three steps makes one cycle which is repeated for 40 times (40 cycles). 
Runx2, COL1A, Ostrix, Noggin and GAPDH assays were used. Expression was then 
normalised with housekeeping gene GAPDH.   
2.4 Western blot  
Western blot is a technique used to detect the presence of specific proteins 
according to their capability to bind to precise antibodies against these proteins. 
Polyacrylamide gel electrophoresis (PAGE) is used to separate proteins within 
samples. Samples must be treated with strong reducing agent to remove secondary 
and tertiary structure of protein allowing the separation to occur according to the 
molecular weight of the protein. Sodium dodecyl sulfate (SDS) was added to both the 
polyacrylamide gel and to the running buffer in order to maintain the polypeptides in 
the denatured form and to impart a uniform negative charge to linearized proteins. ! !
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Materials, disposable equipment and chemicals used in western blot technique 
 
  
Item Supplier 
Protein extraction and measurement 
RIPA buffer Sigma-Aldrich 
Protease inhibitor cocktails Sigma-Aldrich 
Bicinchoninic (BCA) Sigma-Aldrich 
Copper (II) sulphate solution Sigma-Aldrich 
Bovine serum albumin (BSA) Sigma-Aldrich 
Western blot 
Mini protein electrophoresis apparatus with mini trans blot 
electrophoritc transfer cell Biorad 
0.25M TRIS Sigma-Aldrich 
Glysine Sigma-Aldrich 
SDS Sigma-Aldrich 
Methanol Sigma-Aldrich 
Phosphate buffer saline Tablet Oxoid 
Tween 20 VWR international 
1.5M Tris-HCl pH8.8 Sigma-Aldrich 
0.5M Tris-HCl pH6.8 Sigma-Aldrich 
30% Acrylamide Geneflow 
ammonium persulphate (APS) Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
BIO-RAD molecular weight marker Biorad 
β- Mercapto Ehanol Sigma-Aldrich 
Glycerol Fisher scientific 
Bromophenol blue Sigma-Aldrich 
Anti-Noggin antibody abcam 
Anti-GAPDH abcam 
Anti-β- actin abcam 
anti-rabbit IgG, horseradish peroxidase-linked species-
specific secondary antibody GE Healthcare 
Polyvinylidene fluoride (PVDF) Immubilon transfer membranes, milipore 
Filter paper Sigma-Aldrich 
Supersignal west dura chemiluminescent substrate Thermo-scientific 
Kodax biomax MS film Sigma-Aldrich 
Skimmed milk powder Marvel 
Developer AGFA 
Rapid Fixer AGFA 
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2.4.1 Protein extraction using Radio-Immunoprecipitation Assay (RIPA) buffer  
RIPA buffer and protease inhibitor cocktail in ratio of (1:100) was used to extract 
proteins from cells. 500µL of RIPA buffer and 5µL of protease inhibitor cocktail were 
added to confluent T75 flask of either osteoblast or PC3RFP cells. Protease inhibitor 
cocktail was added in order to stop protein degradation.  
2.4.2 Bicinchoninic acid (BCA) protein assay  
Total protein concentration was determined by BCA protein assay method (Smith et 
al., 1985). The copper sulphate(II) in the reagent is reduced to copper sulphate(I) by 
the presence of  peptide bonds in the proteins. The amount of proteins in the sample 
is relative to the amount of copper sulphate(II) that being  reduced. Standard curve 
was conducted using the following BSA concentration, 1000 µg/ml, 800µg/ml, 
600µg/ml, 400µg/ml, 200µg/ml, 100µg/ml and 0µg/ml. 10µl of each standard protein 
concentration and samples were added in duplicate into 96 well plates. BCA working 
reagent was prepared by adding 50 part of BCA reagent to 1 part of copper sulfate 
(II). 200µl of BCA working reagent was added into each well of standard and 
samples. Plates were incubated for 30mintes at 37ºC and read on a plate reader 
(DYNEX technologies, MRX II) at 562nm. 
 
Figure 2.3 Example of Protein assay standard curve. 
10µL of protein standards dilutions (BSA 1mg/ml) and of protein samples in duplicate were incubated 
with 200µL of BCA/copper sulfate solution for 30 min. It was measured using microplate reader at 
absorbance of 560nm. The concentration of the unknown protein samples was calculated from this 
protein standard curve.  
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Preparation of buffers used in Western Blot 
10X Tris/Glysin (1L) 1X Transfer Buffer (2L) 
5X Sample (Laemmli) 
buffer 
Tris 250mM 
MW 
121.14g/mol 
30.3g 10X Tris/Glysin 200ml 
0.5M Tris-HCl pH 
6.8 
1.75ml 
Glysin 1.92M 
MW 75.07 
144.1g Methanol 20% 400ml Glyserol 4.5ml 
1X Running Buffer (2L) Washing Buffer 
(2L) 
Washing 
Buffer (2L) 
SDS 0.5g 
10X Tris/Glysin 200ml PBS 20 Tablet 
Bromophenol blue 
0.2% 
0.5ml 
SDS 10% 20ml Tween 20 1ml 
β- 
Mercaptoethanol 
1.2ml 
Stripping Buffer (1L) 1X TBST 
Glycine 15g 10XTBS 100ml 
SDS 1g Tween 20 1ml 
Tween 20 10ml Complete the volume to 1L 
with ultra-pure water Adjust pH to 2.2 bring volume to 1L with ultra-pure water 
 
2.4.3 Sample preparation 
All samples, whether the recombinant Noggin or cell lysate, were mixed with Laemmli 
Buffer X5, one part buffer with four parts sample. Protein sample and buffer solutions 
were mixed by inversion and denatured for 5 min at 95⁰C. Boiled samples were 
mixed by inversion and kept on ice until gel loading.  
2.4.4 Sodium-Dodecyl-Sulphate Poly-Acrylamide Gel Electrophoresis (SDS-
PAGE)  
For each experiment two SDS 12%(w/v) resolving gel was prepared by a mixture of 8 
ml of Acrylamide 30%, 5 ml of resolving gel buffer 1.5M Tris (pH8.8), 6.6 ml of water, 
200 µl of 10% SDS, 200µl of 10% ammonium persulphate (APS) and 8µl of 
Tetramethylethylenediamine (TEMED). This was loaded between the spacer plates 
1.5 mm apart and kept for 30 – 40 min to polymerise. To maintain an even gel level 
and stop gel dehydration, butan-2-ol was added covering approximately 0.5 cm of the 
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top of the gel. Once the separating gel had set, all traces of butan-2-ol was washed 
form the gel three times, using distilled water.! 5%(w/v) stacking gel was prepared by 
mixing of 1.34ml of Acrylamide 30% (Total), 1ml of stacking gel buffer 0.5 M Tris, 5.4 
ml of water, 80µl of 10% SDS, 80µl of 10% APS and 8µl of TEMED. These were 
loaded onto the resolving gel after it had polymerised. 10 or 15 plastic toothcombs 
were placed between the glasses in the separating gel to form wells for the samples. 
When the gel had set, the comb was removed and the glass plates were placed into 
an electrophoresis tank. The tank was filled with 1X running buffer. Horse Radish 
peroxidase (HRP) conjugated molecular marker (BIO-RAD) was added to the first 
lane of each gel and 40µg of protein in 30µl were then loaded into the gel slots for 
electrophoresis and run at 60 volts (constant voltage) for 40 min. Afterword, the volt 
was increased to 150 volts for another 40 min or until the sample buffer disappears 
from the gel.  
2.4.5 Protein transfer  
Following protein migration, the stacking gel was cut off from the remainder of the gel 
and discarded. The separating gel was dislodged from the glass pane. Polyvinylidene 
fluoride (PVDF) membrane was soaked in methanol prior to use. Within an open 
transfer cassette a sponge and one of the filter paper were placed followed by PVDF 
membrane then, the gel was placed on the PVDF membrane (marker facing top left 
of membrane) and sandwiched with another pieces of cellulose blotting paper and a 
sponge were made. The cassette was then closed and placed into an electrophoresis 
tank. The tank was filled with 1X transfer buffer, and ice pack and a magnetic stirrer 
to maintain temperature.  Membranes were blotted at 70V for 55- 60 min at 4ºC.  
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Figure 2.4 Diagram illustrating the transfer apparatus for western blotting 
proteins, which are negative, charged with SDS travel to positive pole, when electric field is applied to 
the apparatus. The protein then was captured by PVDF membrane. Mini trans-blot electrophoritec 
transfer cell, Biorad is gathered in this order: cassette (red/anode, sponge, filter paper, PVDF, SDS-
PAGE, filter paper, sponge and black/cathode side of the cassette).   
2.4.6 Immuno-detection of Noggin on western blots  
After the transfer, the membrane was blocked using 3% BSA in PBS /Tween for 1h at 
room temperature. After the blocking, the membrane was incubated on a rotary 
shaker overnight at 4˚C with 10µL of anti-Noggin antibody (1:500 dilution) in 5ml 3% 
BSA. Membranes were washed 3 times for 10 min in PBS tween on a rotary shaker 
and incubated with 2µL anti-rabbit IgG, horseradish peroxidase-linked species-
specific at a (1:15000 dilution) in 30ml 5% milk solution for 1h on a rotary shaker at 
room temperature. Membranes were washed 3 times for 20 min in PBS tween on a 
rotary shaker. Membranes were dipped in enhanced chemiluminescent substrate for 
5min for detecting horseradish peroxidase, in which horseradish peroxidase cleave 
the chemiluminescent and produces luminescence in proportion to amount of protein. 
Films (Hyperfilm™, Amersham) were developed using AGFA Curix 60 in the dark 
room. 
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2.4.7 Antibody stripping and membrane re-probing 
After membranes were analyzed with Noggin antibody the membrane was ‘stripped 
off’ and re-probed with housekeeping antibody (GAPDH or β-actin). In order to strip 
the membrane of bound antibodies, the membrane was washed twice with TBS/T for 
5min on shaker at room temperature. Then it was washed twice with PBS/T for 5min. 
The membrane was blocked using BSA 3% for 1h at room temperature. Primary 
antibody of the housekeeping protein (GAPDH or β-actin) was added in 1:10,000 
dilution and was incubated for 1h at room temperature on shaker. Same secondary 
antibody was used as described previously and washed with PBS/T. Then the 
membrane was visualized using chemiluminescent substrate for 5min. Films 
(kodak™, Amersham) were developed using AGFA Curix 60 in the dark room. 
2.5   Cell Sorting using Flow cytometry BD FACS Aria 
Flow cytometry was used to separate different cell populations from each other to 
form highly purified cells for further specific characterization. PC3RFP were seeded 
with either SaOS2 or MG63 in co-culture experiments until cells reached specific cell 
densities when cells were separated and sorted using BD FACS Aria. The separation 
was based on the presence of the red fluorescent dye for which PC3RFP cells were 
considered to be positive cells and osteoblasts (SaOS2, MG63) were considered to 
be negative. The purity of all cells that were used in further experiments after sorting 
was above 92%. 
2.6 Statistical analysis  
All data were analysed using an ANOVA test (1-way analysis of variance) for more 
than two group comparisons or with t test for two group comparisons data was first 
tested for normality distribution if the data was normally distributed ANOVA test was 
used and Bonferroni test was used as post-hoc analysis. When data not normally 
distributed, ANOVA test (non-parametric Kruskal-Wallis test) was used for more than 
two group comparisons or non-parametric Mann–Whitney test was used for two 
group comparisons. Dunns test was used as post-hoc analysis when ANOVA test 
was used in not normally distributed data. Data were considered statistically 
significant when a p-value was equal to or less than 0.05. Results are expressed as 
mean ± values of standard error (SME). 
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3 Chapter 3: General characterization of cell lines and assessment of the 
effects of prostate cancer cells on osteoblastic cell proliferation and 
differentiation 
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3.1 Introduction 
Ninety percent of patients with advanced prostate cancer develop bone metastases 
(Bubendorf et al. 2000). Bone metastases associated with prostate cancer differ from 
those derived from other types of cancer in that they are characterized by an 
osteoblastic appearance. This is due to an imbalance between bone resorption and 
bone formation where the latter is favoured in prostate cancer metastases 
(Weilbaecher et al. 2011; Theriault and Theriault 2012). Bone is the most frequent 
single site for prostatic cancer metastasis, which suggests that prostate cancer cells 
have a specific affinity for bone both in terms of attachment and as a site for 
survival/growth outside the prostate. This interaction between cancer cells and bone 
microenvironment is thought to be mediated by survival/growth factors secreted by 
bone and cancer cells, as well as angiogenic factors and bone resorption regulators 
that promote the growth of cancer cells themselves inside a modified bone 
microenvironment (Mundy 2002; Roodman 2004). In addition, bone cells secret other 
growth factors such as TGF-β and BMPs which enhance the survival of prostate 
cancer cells in the bone (Miyazono et al. 2010). A so called ‘vicious cycle’ of tumour 
growth leading to disrupted bone turnover and release of more tumour promoting 
factors has been suggested (Yoneda and Hiraga 2005). 
The exact mechanisms by which prostate cancer stimulate bone growth are still 
unknown. For this reason many studies have focused on soluble protein that is 
secreted from the tumour cells which stimulate bone growth within the bone tumour 
microenvironment (Larson et al. 2014). Several studies have shown that condition 
media collected over the human prostate cancer cell line PC3 stimulated proliferation 
of osteoblast-like cells (Martínez et al. 1996; Larson et al. 2014). Nishimori et al 2012 
showed in his study that prostate cancer cells facilitate the differentiation of 
osteoblastic cells when co-culturing prostate cancer cell line LNCaP with mouse 
osteoblast MC3T3 (Nishimori et al. 2012).   
Cell lines that were used in my study were a strain of human prostate cancer cell line 
PC3 (PC3RFP) and human osteosarcoma cell lines SaOS2 and MG63. Growth 
curves were conducted to all of these cell lines to determine their rate of growth 
during the log phase and exponential phase. Serum titration curve was established to 
determine the maximum and 1/2 maximal growth rates during the log phase which 
will be used in further experiments.  
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Aim  
The aim of this study is to determine the effect of prostate cancer cells on the 
proliferation and differentiation of osteoblastic cells (SaOS2 and MG63).   
Hypotheses  
Prostate cancer cells stimulate the growth of osteoblastic cell lines and decrease 
their differentiation. 
Objectives 
1- To determine basic cell growth and differentiation characteristics of prostate 
cancer and osteoblast cell lines. 
2- To evaluate the effect of prostatic cancer cell (PC3RFP) conditioned media (CM) 
on the growth of both SaOS2 and MG63. 
3- To determine the effect of PC3RFP-CM and co-culture on the differentiation of 
osteoblastic cell lines by measuring ALP activity, Alizarin red and the expression 
of some of the structural protein genes associated with osteoblast differentiation 
such as Runx2, Col1A and Ostrix (SP7).  
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3.2 Materials and Methods 
3.2.1 Materials and Disposable Equipment   
Item Supplier 
Triton Sigma-Aldrich 
Fast p-nitrophenyl phosphate Tablets to prepare 20ml contains 
1mg/mlPNPP and 0.2M tris buffer. 
Sigma-Aldrich 
Quant-iT PicoGreen dsDNA assay kit, 10×100µL enough for 2000 
assays. 
Invitrogen 
Alizarin Red S Sigma-Aldrich 
DNase and RNase free water Invitrogen 
COL1A Taqman assay Applied Biosystem 
Runx2 Taqman assay Applied Biosystem 
Osterix Taqman assay Applied Biosystem 
Human GAPDH Taqman assay Applied Biosystem 
TaqMan Universal master Mix  Applied Biosystem 
 
3.2.2 Generating Growth Curves 
The cells were harvested by trypsinisation and counted by using the Beckman 
Coulter Vi-Cell counter as described in chapter 2 section (2.2.3 and 2.2.5). The PC3-
RFP cells were seeded at a density of 5000cell/well in a 24 well plate for growth 
curve experiments. For the SaOS-2 and MG63 growth curves, the cells were seeded 
at a density of 15,000cell/well in a 24 well plate.  
Cells were counted every 48h 12 days and each 48h time point was done in 
quadruplicate. The average (mean) cell numbers present were calculated for each 
day. The media was changed every 4 days during the growth curve and finally, a 
growth curve was generated for the number of cells present on each day in culture. 
In initial experiments, growth curves were done in medium containing 10% FBS to 
establish the start and duration of exponential growth and this information used in 
subsequent experiments to ensure cells were challenged during this growth phase. 
3.2.3 Generating Serum titration curves 
The cells were harvested by trypsinisation and counted by using the Beckman coulter 
counter and seeded in the same density as used in the growth curve experiments for 
both PC3-RFP and SaOS-2 cell lines using the standard medium of 10% FBS. 
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After 48h, cells were first washed with serum free media and then challenged with 
different FBS concentration starting from (0%, 1%, 2%, 4%, 5%, 6%, 8%, 10%, 12%, 
14%, 15%, and 20%).  
All cells were harvested and counted on day 6, which was estimated as mid 
exponential growth from 3.2.2.  
3.2.4 Generating Condition media from PC3RFP cells 
Ten T75 flasks were made with a density equivalent to the density that was used in 
the growth curves. Seven flasks were for the collection of conditioned medium (CM) 
and an additional three flasks were made for counting to monitor the growth of the 
cells. The cells were seeded in standard medium with 10% FBS. 
After 48h the cells were washed with PBS and transferred to DMEM containing either 
2% or 4% FBS. One flask was counted on the same day. Another two flasks were 
counted on day 4 and day 6. On day 6, the cells were found to be at the beginning of 
the confluent phase so the medium was changed in all flasks. On day 7, the medium 
was collected from the remaining flasks, transferred to a 50ml tube and centrifuged at 
room temperature at 1000xg for 10 min to pellet all cell debris and dead cells. The 
medium was filtered through 0.22 micrometre filter. Medium was divided into aliquots 
of 5ml each and stored in -80ºC. The cells in each of the seven flasks were counted 
in order to know the exact number of cells present in each flask. 
3.2.5 Challenging the SaOS-2 cell with the conditioned medium (CM) 
The SaOS-2 cells were seeded in 24 well plates in the same density used for the 
growth curve using standard medium of DMEM with10% FBS. After 48h, the cells 
were washed with PBS and the conditioned medium was added at different 
concentrations to quadruplicate cultures for each specific concentration (2%, 5%, 
10%, 25%, 50%, 100% conditioned medium). The cells were counted on day 6 in the 
middle of the exponential growth and on day 10 at the end of the exponential growth.  
The same experiment was repeated but by using the concentration that was 
associated with the maximum observed growth.  
3.2.6 Analysis of the effect of condition media (CM) on the proliferation of 
Osteoblastic cell lines 
The cells were harvested by trypsinisation and counted as described in chapter 2 
sections (2.2.3 and 2.2.5). The same seeding density was used in SaOS2 and MG63 
that were used in growth curves in the 24 well plate using 50%CM containing either 
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2% (Saos2) or 4% (MG63) FBS. This was compared to controls for each type of cells 
grown in half maximum FBS concentration in standard DMEM media, which were 
2%FBS for the SaOS2 cells and 4% with MG63 cells.   
Cells were counted every 48h until day 12 and each 48h was done in quadruplicate 
and the mean cell numbers calculated for each day. The media was changed every 4 
days during the growth curve in all groups.   
3.2.7 Differentiating MG63 by using differentiation media 
MG63 are considered to be an undifferentiated osteoblast cell line. These cells were 
differentiated by differentiation media. Differentiation media was prepared by adding 
10mM β- glycerophosphate and 50µg/ml of Ascorbic acid in the standard DMEM 
with4% FBS. The differentiation of MG63 was detected by measuring alkaline 
phosphatase (ALP) and alizarin red over 4 weeks. MG63 was seeded in nine 96 well 
plates (3000cells/well) for measuring ALP activity and in nine 24 well plates (15,000 
cells/well) for measuring alizarin red in standard DMEM with 4%FBS. After 24 hours 
ALP activity and alizarin red were measured in the first 96 well plate and 24 well plate 
respectively. The media was changed to the differentiation media in the rest plates 
and ALP activity and alizarin red was measured on the days 2, 4, 7, 10, 14, 21 and 
28. Media was changed regularly every 4 days. 
3.2.8 Analysing the effects of condition media on the proliferation of 
differentiated MG63 
After differentiation, MG63 cells were used to generate growth curves using 50% CM 
and DMEM 4% FBS as control. The same seeding density was used in previous 
growth curves in the 24 well plate.  
Cells were counted in quadruplicate cultures every 48h until day 12 and the mean 
cell number was calculated for each day. The media was changed every 4 days 
during the growth curve in all groups.   
3.2.9 Analysis of the effects of condition media and co-culture on the 
differentiation of Osteoblastic cell lines 
The effects of challenging osteoblast cell lines with condition media collected over 
PC3RFP cells and of growing PC3RFP together with the osteoblasts in co-culture, on 
the differentiation of osteoblastic cell lines SaOS2 and MG63 were determined by 
measuring alkaline phosphatase (ALP) activity, alizarin red and the expression of 
differentiation genes such as COL1A, Osterix and Runx2. These assays were first 
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done 24h after seeding the cells as base line and then after every 48h until day 12. 
For both SaOS2 and MG63, ~ 3000cells/well were seeded in 96 well plates for ALP 
activity assay. ~ 15,000 cells/well in the 24 well plates and ~ 66,000 cells/75cm2 in 
the T75 flasks for molecular biology assays. For the PC3RFP cells, which were used 
in the co-culture experiments, the cells density was 5000cells/well in 24 well plates, ~ 
940 cells/well in 96well plate and ~ 220,000 cells/75cm2 in T75 flasks. Figure 3.1 
describes the seeding of cells in the 96 well plate.  
 
Figure 3.1 Summarizes the design for the seeding of osteoblast cells in the 96 well plate for 
measuring ALP activity. 
A: represents the control osteoblasts seeded in medium containing their respective half maximum FBS 
concentration compared to osteoblasts grown in CM containing the same, respective FBS 
concentrations. B: represent the control osteoblast seeded in half maximum FBS compared to 
osteoblast in co-culture. 
 Alkaline phosphatase activity assay 3.2.9.1
Osteoblasts show alkaline phosphatase activity, which is increased during 
differentiation. ALP was also analysed in PC3RFP cultures over time courses. 
Alkaline phosphatase can easily be measured by using p-Nitophenyl phosphate 
(pNPP) as a soluble substrate that gives a yellow color when it reacts with ALP. The 
intensity of color can be measured by spectrophotometer at wavelength of 405 nm 
(Xiao et al. 2006). Cells were washed twice with ice cold phosphate buffer saline 
(PBS) and permeabilised with 20µl of 0.1% Triton and were incubated on a shaker 
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
57!!
for 20 min at room temperature. One pNPP Tablet and one tris buffer Tablet were 
dissolved in 20ml of water and 200µl of this solution were added carefully to the cells. 
ALP activity was measured by reading the absorbance at 405nm every 5min for 90 
min. The following formula was used to calculate ALP activity 
!"#!!"#$%$#& = (!" !! !!"(!!)×!"""×!"#$%!!"#$%&!"#$×! !".!" ×!"#!!"#$%! !.!"#$ ×!"#$%&'(%)#   
Where OD(t1) is the last optical density, OD(t0) is the start optical density, ε is constant 
and path length is the length of 200 volume of sample in 96 well plate. The value of 
ALP activity is expressed as U/ml/min/ug DNA.  
 PicoGreen assay 3.2.9.2
Alkaline phosphatase activity was normalized with osteoblast DNA concentration 
using the picogreen assay. PicoGreen double-strand DNA (dsDNA) quantitation 
reagent is a fluorescent nucleic acid stain used to quantify dsDNA (Xiao et al. 2006). 
1X of TE buffer was prepared from 20X stock solution by adding 1ml of the 20X to 
19ml of DNase free water. DNA standard with 2µg/ml concentration was prepared by 
adding 8µl of 100µg/ml DNA standard stock to 392µl of 1X TE buffer. A typical 
standard curve was prepared according to Figure (3.2). 
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Figure 3.2 illustrate the DNA standard curve and the concentration that were used in the 
picoGreen assay. 
Different DNA standard concentration was prepared from 2µg/ml DNA stock solution to form the 
following concentrations (5, 10, 20, 40, 60, 80 and 100) ng/well. 100 µl of 1X TE buffer was added to 
DNA standard and unknown. 100µl of 1:200 dilution of picoGreen reagent was added to each 
unknown and standard samples. The DNA was then measured by exciting samples at 485nm and 
detecting fluorescence emission intensity at 530nm.   
100µl of 1X TE buffer was added to standard and unknown DNA concentration of the 
osteoblast in a 96 well plate. 100µl of 1:200 dilution of picoGreen reagent was added 
to each unknown and standard samples, and incubated in the dark at room 
temperature on a shaker for 5min. The DNA was then measured by exciting samples 
at 485nm and detecting fluorescence emission intensity at 530nm.   
 Alizarin red staining  3.2.9.3
When osteoblasts become fully differentiated they start to deposit calcium in the 
matrix. Calcium can be specifically stained bright orange-red using Alizarin red. Cells 
were washed twice with cold PBS and fixed with 1ml of ice cold 100% ethanol for 1h 
DNA standard curve 
20 40 60 80 100
-100
0
100
200
300
DNA (ng)/well
O
D
48
5 
nm
Concentration 
ng/well 
Amount of 1X TE buffer 
in µl 
Amount of DNA standard 
0 100 0 
5 97 3 
10 95 5 
20 90 10 
40 80 20 
60 70 30 
80 60 40 
100 50 50 !
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
59!!
at 4ºC. Cells then were rehydrated with water for 5min. 1ml of 1% alizarin red (pH 
4.2) was added to each well and incubated for 10min at room temperature. The stain 
was removed from the plate and the cells were washed several times to remove 
excess stain. The plates were allowed to dry overnight at 25ºC. ImageJ software was 
used to quantify the red colour of alizarin orange/red staining.  
 Differentiation gene expression (Runx2, Osterix and COL1A)    3.2.9.4
Cells were seeded in seven T75 flasks for generating RNA to assess the expression 
of genes involved in osteoblast differentiation, 24 hour after seeding and every 48 h 
until day 12. Cells were washed twice with PBS, total RNA was extracted from 
primary osteoblasts, and cDNA was synthesized as described in Chapter 2 section 
(2.3.5). Runx2 mRNA, COL1A2 mRNA and Osterix mRNA primers (see Table 3.1 in 
materials and methods) were used to quantify the expression of these genes during 
osteoblast differentiation using TaqMan Universal Master Mix (Applied biosystems, 
UK). Specific gene of interest expression levels were normalized by using GADH as 
housekeeping gene Chapter 2 section (2.3.6). In co-culture experiments, populations 
were sorted using FACS Aria and the PC3-RFP separated from Saos2/MG63 on the 
basis of red fluorescence. The purity of all cells that were used in all further 
experiments after sorting was above 92%.  RNA was then extracted from separate 
populations as above. 
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3.3 Results 
3.3.1 Characterization of Osteoblastic cell lines 
In order to study the basic growth and differentiation characteristics of osteoblastic cell 
lines (SaOS2 and MG63), growth curves were done followed by serum titration curve. 
Growth curves were initially conducted using standard media DMEM with 10% FBS. Both 
cell lines had an exponential growing phase that started when cells reached ~10,000 
cells on day 2 in a 24 well plate and finishes around day 8. However, SaOS2 cells 
tended to grow at a slower rate in Figure (3.3) (A) and Figure (3.4) (A) respectively.   
FBS concentrations significantly modulated the growth of both cell lines SaOS2 and 
MG63 in a concentration dependent manner (1 way ANOVA, Bonferroni). Within the 
range 0-20% FBS DMEM both cell lines had their maximum growth at a concentration of 
10% FBS DMEM and had a half maximum cell growth at concentrations of 2% and 4% 
respectively at day 6 Figure (3.3) (B) and Figure (3.4) (B).  Growth curves were also 
conducted at the half maximum serum concentration to define the growth characteristics 
of both cell lines Figure (3.3) (A) and Figure (3.4) (A) respectively.  
 
 
Figure 3.3 Characterization of SaOS2 cell. 
(A) Representative growth curves in both concentration maximum and half maximum Showing the 
beginning of the exponential phase around day 2 and ending around day 8. (B). Serum titration curve 
of the SaOS2 cells showing maximum growth at 10% with half maximum at 2% P=0.001 (1 way 
ANOVA, Bonferroni). All data are displayed with mean± SEM of 3 independent experiments. 
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Figure 3.4 Characterization of MG63 cells. 
(A) Illustrating growth curve in both concentration maximum and half maximum (B). Illustrate Serum 
titration curve of the MG63 cells showing maximum growth at 10% with half maximum at 4%. All data 
are displayed with mean± SEM of 3 independent experiments. 
3.3.2 Characterization of the PC3-RFP prostate cancer cell line 
Growth curves were initially conducted for PC3RFP using the standard DMEM 10%FBS 
to define the onset and duration of exponential growth. PC3RFP had an exponential 
growing phase that started when cells reach ~10,000 cells on day 2 in a 24 well plate 
and finished around day 8 Figure (3.5) (A). FBS concentrations significantly modulate the 
growth of the PC3RFP cell line in a concentration dependent manner (1 way ANOVA, 
Bonferroni).  Within the range 0-20% FBS DMEM cells had their maximum growth at a 
concentration of 10% FBS DMEM and had a half maximum cell growth at a 
concentration of 2% at day 6 Fig (3.5) (B). Another growth curve was done using the half 
maximum FBS concentration Figure (3.5) (A).   
 
  
Figure 3.5 Characterization of PC3RFP cell. 
(A) Growth curves in both concentration maximum and half maximum (B) Serum titration curve of the 
PC3RFP cells showing maximum growth at 10% with half maximum at 2% with P=0.002 (1 way 
ANOVA, Bonferroni). All data expressed as mean ± SEM of 3 independent experiments.   
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3.3.3 Studies of the effect of various conditioned media concentrations on the 
growth of osteoblastic cell lines. 
Osteoblastic cells were challenged with different conditioned media concentrations, 
collected over PC3RFP, in order to select the best concentration to use in further 
experiments. The concentrations tested were: 0, 5,10,25,50 and 100%. SaOS2 were 
counted in two time point day6 and day10 Figure (3.6) (A) and Figure (3.6) (B) 
respectively. Maximum cell number was found to be associated with 50% on day10.  
 
Figure 3.6 Assessment of the effect of different CM concentrations on the growth of SaOS2 
cells during exponential growth. 
(A) Illustrates the number of SaOS2 counted on day 6 (B) Illustrates the number of SaOS2 counted on 
day10. All data expressed as mean ± SEM of 3 independent experiments. 
3.3.4 Studies of the effects of conditioned media on the proliferation of 
Osteoblastic cell lines 
Growth curves were done with both SaOS2 and MG63 cells using 50% conditioned 
media (CM) to test the effects on the proliferation of osteoblastic cell lines SaOS2 
and MG63. Conditioned media significantly stimulated the growth of SaOS2 (p˂0.05, 
1way ANOVA, Bonferroni) Figure (3.7) but it did not have a significant effect on 
MG63 cells Figure (3.8).  
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Figure 3.7 Conditioned media (CM) increased the proliferation of SaOS2 cells. 
Growth curves showing the effect of 50% conditioned media (2% FBS) on the growth of SaOS2 cells 
compared to their growth in standard, unconditioned medium containing 10%FBS of fresh media (FM) 
or half maximum 2%FBS (FM). Conditioned media (CM) stimulated the growth of SaOS2 cell p˂0.05 
(1way ANOVA, Bonferroni). All data expressed as mean ± SEM of 3 independent experiments. 
 
 
Figure 3.8 Conditioned media (CM) did not affect the proliferation of MG63 cells. 
Growth curves showing the effect of 50% conditioned media (4% FBS) on the growth of MG63 cells 
compared to their growth in standard, unconditioned medium containing 10%FBS fresh media (FM) 
and half maximum 4%FBS (FM). All data expressed as mean ± SEM of 3 independent experiments. 
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3.3.5 Differentiating MG63 cells by using differentiation media 
ALP activity and Alizarin red were measured in MG63 cells grown in differentiation 
media for 4 weeks. The activity of ALP enzyme was measured initially on day 1 
before the addition of the differentiation media and then on days 2, 4, 7, 10, 14, 21 
and 28.  ALP activity increased at the beginning of the experiment showing maximum 
level during day 4 Figure (3.9) (A). The density of alizarin red was measured in MG63 
cells on the same days as ALP activity was measured. The density of stain colour 
increased with time until day 21, indicating an increase in the calcification of MG63 
Figure (3.9) (B).   
 
 
Figure 3.9 Assessment of the effects of differentiating media on MG63. 
(A) illustrates the level of ALP activity in MG63 cells during 4 weeks under the influence of 
differentiating media containing 10mM β- glycerophosphate and 50µL ascorbic acid. ALP activity was 
measured at day 0 before the addition of the differentiation media and continue to be measured 
afterword during (2, 4, 7, 10, 14, 21, 28) days, Showing maximum level on day 4. (B) illustrates the 
density of alizarin red stain in MG63 cells during 4 weeks under the same conditions.  
3.3.6 Assessment of the effects of conditioned media on the proliferation of 
differentiated MG63 
MG63 were differentiated for 4 days using differentiation media. Growth curves were 
then done using differentiated MG63 grown in standard 4% media and in 50% CM 
(4% FBS). Growth in these cultures was compared with that of undifferentiated cells.  
Both differentiated and undifferentiated MG63 were not affected by CM (Figure 3.10). 
Since there were no difference between differentiated and undifferentiated MG63 the 
undifferentiated MG63 were used in all other experiments.  
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Figure 3.10 Condition media had no effect on the proliferation of differentiated MG63 cells. 
Growth curves show the effect of 50% condition media on the growth of differentiated MG63 cells 
grown in standard 4% media and in 50% CM compared to the growth of undifferentiated MG63 grown 
in 4% media and in 50% CM. There was no difference between differentiated and undifferentiated 
cells grown in 50% CM and CM had no effect on the growth of either differentiated or non-
differentiated cells.  All data is expressed as mean ± SEM of 3 independent experiments. 
3.3.7 Assessment of the effect of CM and co-culture on the differentiation of 
osteoblastic cell lines 
 Analysis of alkaline phosphatase activity in osteoblasts  3.3.7.1
Alkaline phosphatase activity was measured as an early indicator of osteoblast 
differentiation in both osteoblast cell lines, SaOS2 and MG63, grown individually in 
their respective standard medium containing half maximum FBS concentrations (2% 
and 4% respectively) compared to 50% CM containing the same respective serum 
concentrations and growing in co-culture together with PC3RFP. Co-culture 
experiments were also done in the respective half maximal serum concentration for 
each osteoblast cell line. Conditioned media significantly decreased the 
differentiation of the SaOS2 cells on days 1, 2, 6, 8, 10 and 12 (1 way ANOVA, 
Bonferronis n=3, p˂0.0019, p˂0.0036, p˂0.0036, p˂0.0001, p˂0.0057 and p˂0.0003 
respectively, Figure 3.11). In addition, growing the SaOS2 cells in direct contact with 
PC3RFP had a similar effect on their differentiation during day1, 2, 4, 6, 10 and 12 
(1wayANOVA, Bonferronis n=3, p˂0.0019, p˂0.0019, p˂0.0001, p˂0.019, p˂0.0057 
and p˂0.0001 respectively) Figure (3.11). Conditioned media showed the same effect 
of decreasing the differentiation of MG63 cells on day 1, 2, 6, and 10 (1 way ANOVA, 
Bonferronis n=3, p˂0.0001, p˂0.0001, p˂0.019 and p˂0.0057 respectively) as seen 
in Figure (3.12). Growing MG63 together with PC3RFP inhibited MG63 differentiation 
only at the beginning of the experiment until day 4 (1 way ANOVA, Bonferronis n=3, 
p˂0.0057, p˂0.0001and p˂0.0001) but stimulated their differentiation on day 6 and 
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10 only (1 way ANOVA, Bonferronis n=3, p˂0.003 and p˂0.0001) Figure (3.12). All 
data for the effects of CM and co-culture in both cell lines presented in Figures 3.11 
and 3.12 are compared in Figure 3.13.  ALP was measured in cultures of PC3RFP 
cells grown alone, on day 1,2,4,6,8,10 and 12 Figure 3.14. ALP levels were around 
1U/ml/min/ug DNA on day 1 and 2 but then declined <0.5 U/ml/min/ug DNA at all 
other time points. This suggests that PC3RFP derived ALP did not significantly 
contribute to levels measured in co-culture with SaOS2 (levels >400 U/ml/min/ug 
DNA in all cultures) but may have a small contribution to the levels present in MG63 
co-cultures where ALP levels were lower. 
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Figure 3.11 Differentiation of SaOS2 cells were decreased by CM. 
The graphs illustrate ALP activity in SaOS2 cells grown individually in standard medium (2% FBS) 
compared to 50%CM and in co-culture with PC3RFP over 12 days. Conditioned media significantly 
decreased differentiation of SaOS2 on days, 6, 8, 10 and 12 p˂0.0019, p˂0.0036, p˂0.0001, p˂0.0057 
and p˂0.0003 respectively. The co-culture group showed significant increase during day1, 2, 4, 6, 10 
and 12 p˂0.0019, p˂0.0019, p˂0.0001, p˂0.019, p˂0.0057 and p˂0.0001 respectively (1 way ANOVA, 
Bonferronis). All data is expressed as mean ± SEM of 3 independent experiments. 
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Figure 3.12 Differentiation of MG63 cells was decreased by CM and co-culture at some time 
points. 
The graphs show ALP activity in MG63 cells grown individually in standard medium (4% FBS) 
compared to 50% conditioned media and in co-culture with PC3RFP during 12 days. Conditioned 
media decreased differentiation of MG63 with statistically significance on days 1, 2, 6 and 10 
(p˂0.0001, p˂0.0001, p˂0.019 and p˂0.0057 respectively). Co-culture significant decreased 
differentiation in MG63 only on days 1, 2 and 4 (p˂0.0057, p˂0.0001 and p˂0.0001 respectively). 
Differentiation increased in the co-culture group starting from day6 until day12 but showing 
significance only at day6 and 10 p˂0.003 and p˂0.0001 respectively (1 way ANOVA, Bonferronis). All 
data is expressed as mean ± SEM of 3 independent experiments. 
day1
U
/m
l/m
in
 / D
N
A
(u
g)
MG
63
 co
ntr
ol 
in 
4%
 FB
S (
FM
)
MG
63
 in
 4%
 FB
S (
CM
)
MG
63
 co
 cu
ltu
re
0.0
0.5
1.0
1.5
2.0
2.5
MG63 control in 4% FBS (FM)
MG63 in 4% FBS (CM)
   ****
**
MG63 co culture
day2
U
/m
l/m
in
 / D
N
A
(u
g)
MG
63
 co
ntr
ol 
in 
4%
 FB
S (
FM
)
MG
63
 in
 4%
 FB
S (
CM
)
MG
63
 co
 cu
ltu
re
0
1
2
3
MG63 control in 4% FBS (FM)
MG63 in 4% FBS (CM)
****
****
MG63 co culture
day4
U
/m
l/m
in
 / D
N
A
(u
g)
MG
63
 co
ntr
ol 
in 
4%
 FB
S (
FM
)
MG
63
 in
 4%
 FB
S (
CM
)
MG
63
 co
 cu
ltu
re
0
1
2
3
4
MG63 control in 4% FBS (FM)
MG63 in 4% FBS (CM)
**
MG63 co culture
day6
U
/m
l/m
in
 / D
N
A
(u
g)
MG
63
 co
ntr
ol 
in 
4%
 FB
S (
FM
)
MG
63
 in
 4%
 FB
S (
CM
)
MG
63
 co
 cu
ltu
re
0.0
0.5
1.0
1.5
2.0
2.5
MG63 control in 4% FBS (FM)
MG63 in 4% FBS (CM)
*
***
MG63 co culture
day8
U
/m
l/m
in
 / D
N
A
(u
g)
MG
63
 co
ntr
ol 
in 
4%
 FB
S (
FM
)
MG
63
 in
 4%
 FB
S (
CM
)
MG
63
 co
 cu
ltu
re
0
1
2
3
4
MG63 control in 4% FBS (FM)
MG63 in 4% FBS (CM)
MG63 co culture
day10
U
/m
l/m
in
 / D
N
A
(u
g)
MG
63
 co
ntr
ol 
in 
4%
 FB
S (
FM
)
MG
63
 in
 4%
 FB
S (
CM
)
MG
63
 co
 cu
ltu
re
0.0
0.5
1.0
1.5
2.0
2.5
MG63 control in 4% FBS (FM)
MG63 in 4% FBS (CM)
**
****
MG63 co culture
day12
U
/m
l/m
in
 / D
N
A
(u
g)
MG
63
 co
ntr
ol 
in 
4%
 FB
S (
FM
)
MG
63
 in
 4%
 FB
S (
CM
)
MG
63
 co
 cu
ltu
re
0.0
0.5
1.0
1.5
2.0
2.5
MG63 control in 4% FBS (FM)
MG63 in 4% FBS (CM)
MG63 co culture
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
69!!
 
Figure 3.13 Differences in ALP activity in Osteoblastic cell lines evaluated over 12 days in the 
presence/absence of CM or co-culture with PC3RFP. 
(A) ALP activity in SaOS2 cells (B) ALP activity in MG63 cells.  
 
Figure 3.14 Differences in ALP activity in PC3RFP cell lines evaluated over 12 days. 
ALP was measured in cultures of PC3RFP cells grown alone, on day 1,2,4,6,8,10 and 12. On day 1 
and 2 ALP levels were around 1U/ml/min/ug DNA but then declined <0.5 U/ml/min/ug DNA at all other 
time points.  
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 Analysis of mineralisation measured by alizarin Red staining in 3.3.7.2
osteoblastic cell lines 
Alizarin red was used to assess mineralization in osteoblastic cells. The SaOS2 cells 
started to mineralize from day 6. In the SaOS2 co-culture group mineralization 
increased significantly on days 8, 10 and 12 (1 way ANOVA n=3, p˂0.0073, 
p˂0.0097 and p˂0.018 respectively) as seen in Figure (3.15). In MG63 mineralization 
started by day 2, earlier than in cultures of SaOS2 cells Figure (3.16). Conditioned 
media significantly increased the mineralization only at day 4 while, mineralization in 
MG63 co-culture group was significantly induced at day 8 compared to control (1way 
ANOVA, Bonferroni) n=3, p˂0.019 and p˂0.019 respectively) Figure (3.17). The 
mineralization increased over time in all groups in all osteoblastic cell lines Figure 
(3.18).   
 
Figure 3.15 Mineralisation in SaOS2 cells was significantly increased in co-cultures with PC3-
RFP but not by CM. 
Graphs show mineralization (assessed by Alizarin Red staining) was increased significantly in co-
culture group on days 8, 10, and 12 (p˂0.0073, p˂0.0097 and p˂0.018 respectively) (1 way ANOVA, 
Bonferroni).  All data expressed as mean ± SEM of 3 independent experiments. 
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Figure 3.16 Differences between SaOS2 and MG63 in Alizarin Red staining during 12 days. 
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Figure 3.17 Mineralization in MG63 was varyingly affected by CM and in co-cultures with 
PC3RFP. 
Graphs show that mineralization (assessed by Alizarin Red staining) increased significantly in 
condition media group at day 4 and on day 8 in the co-culture group (p˂0.019 and p˂0.019 
respectively) (1 way ANOVA, Bonferroni).  All data is expressed as mean ± SEM of 3 independent 
experiments. 
 
 
 
day2
%
A
re
a
4%
FB
S (
FM
)
4%
FB
S (
CM
)
co
-cu
ltu
re
0
1
2
3
4
4%FBS (FM)
4%FBS (CM)
co-culture
day4
%
A
re
a
4%
FB
S (
FM
)
4%
FB
S (
CM
)
co
-cu
ltu
re
0
5
10
15
20
25
4%FBS (FM)
4%FBS (CM)*
co-culture
day6
%
A
re
a
4%
FB
S (
FM
)
4%
FB
S (
CM
)
co
-cu
ltu
re
0
5
10
15
20
25
4%FBS (FM)
4%FBS (CM)
co-culture
day8
%
A
re
a
4%
FB
S (
FM
)
4%
FB
S (
CM
)
co
-cu
ltu
re
0
10
20
30
40
50
4%FBS (FM)
4%FBS (CM)
co-culture
*
day10
%
A
re
a
4%
FB
S (
FM
)
4%
FB
S (
CM
)
co
-cu
ltu
re
0
20
40
60
4%FBS (FM)
4%FBS (CM)
co-culture
day12
%
A
re
a
4%
FB
S (
FM
)
4%
FB
S (
CM
)
co
-cu
ltu
re
0
20
40
60
80
4%FBS (FM)
4%FBS (CM)
co-culture
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
73!!
 
Figure 3.18 Differences in Alizarin Red staining in Osteoblastic cell lines during 12 days. 
(A) alizarin red stain in SaOS2 cells (B) alizarin red stain in MG63 cells.  
 Expression of osteoblast differentiation genes COL1A, Osterix and 3.3.7.3
Runx2 in osteoblastic cell lines.  
The level of expression of osteoblast markers; Runx2, COL1A2 and osterix genes 
were analysed using TaqMan. Expression of these genes was normalised to the 
expression of a housekeeping gene, GAPDH. Figure (3.19) (A) shows the level of 
COL1A mRNA expression in SaOS2 in three groups (control SaOS2 in DMEM 2% 
FBS, SaOS2 in 50% CM and SaOS2 in co-culture, 2% FBS) (B) shows the level of 
osterix mRNA expression in SaOS2 in the same three groups (C) shows the level of 
RUNX2 mRNA expression in SaOS2 again in the three groups. There was no 
significant difference in the expression of all differentiation markers COL1A, osterix 
and RUNX2 between all groups except for osterix and RUNX2 which were 
significantly increased in SaOS2 treated with CM group at day 8 P=0.03 and P=0.03 
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respectively (1 way ANOVA, Bonferroni). Although the expression of these 
differentiation markers COL1A, osterix and RUNX2 was lower in the co-culture group 
during the three time point day (6, 8 and 10) but with no statistical significance. 
Figure (3.20) (A) shows the level of COL1A mRNA expression in MG63 in three 
groups (control MG63 in DMEM 4% FBS, MG63 in 50% CM and MG63 in co-culture) 
(B) shows the level of ostrix mRNA expression in MG63 in the same three groups (C) 
shows the level of RUNX2 mRNA expression in MG63 again in the three groups. 
Moreover, there was no significant change in the expression of all differentiation 
markers COL1A, ostrix and RUNX2 between all groups. Co-culture group expressed 
lower amount of these markers but with no statistical significance.  
 
   
Figure 3.19 Summary of the levels of expression of osteoblast markers; Runx2, COL1A2 and 
osterix in the SaOS2 cell line. 
(A) shows the level of COL1A mRNA expression in SaOS2 in three groups (control SaOS2 in DMEM 
2% FBS, SaOS2 in 50% CM and SaOS2 in co-culture) (B) shows the level of osterix mRNA 
expression in SaOS2 in the same three groups (C) illustrates the level of RUNX2 mRNA expression in 
SaOS2 again in the three groups. There was no significant differences in the expression of all three 
markers in all groups during day 6 and 10 while, both Runx2 and Osterix showed significant increase 
during day 8 P=0.03 and P=0.03 respectively (1 way ANOVA, Bonferroni). All data is expressed as 
mean ± SEM of 3 independent experiments.  
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Figure 3.20 Summary of the levels of expression of osteoblast markers; Runx2, COL1A2 and 
osterix in the MG63 cell line. 
(A) illustrates the level of COL1A mRNA expression in MG63 in three groups (control MG63 in DMEM 
4%FBS, MG63 in 50% CM and MG63 in co-culture) (B) illustrates the level of osterix mRNA 
expression in MG63 in the same three groups (C) illustrates the level of RUNX2 mRNA expression in 
MG63 again in the three groups. There were no significant differences in the expression of all three 
markers in all groups. All data is expressed as mean ± SEM of 3 independent experiments.    
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3.4 Discussion 
3.4.1 Cells Growth Characteristics 
Determination of the growth characteristics of cell lines is an essential prerequisite 
before undertaking experiments where effects of agents on growth of cells are to be 
considered. Understanding the standard behaviour of cells through generating 
growth curves is also important to ensure that cancer cell lines are behaving in a 
reproducible manner. Any deviation in the predicted trajectory of the curve serves is 
a warning that either the cells are changing, something is wrong in the culture 
environment or that contamination has occurred. Under regular growth conditions 
using the standard medium containing 10% FBS all cell lines (PC3-RFP, SaOS-2 and 
MG63) have relatively consistent growth rates, generating growth curves where they 
entered the exponential phase around day 2 after culture initiation and this phase 
ended around day 8 for all cell types.  
The effect of FBS concentration was tested on the growth of prostate cancer cell line 
(PC3RFP) and osteosarcoma cell lines (SaOS-2 and MG63). The concentration that 
gave maximal growth rate in all cell lines was ~10%. 2% and 4% FBS concentrations 
were used in subsequent experiments for SaOS2 and MG63 respectively. This 
concentrations provided the population sizes of SaOS2 and MG63 that were half 
those observed when these cells were grown in 10% FBS at day 6 (i.e. in mid-
exponential growth). The rational for using 2% and 4% was that by using these 
concentrations it would be subsequently possible to test effects of treatments on final 
population sizes. However, with higher FBS concentration, the cells would have been 
growing maximally and it may not have been possible to rigorously test proliferative 
or inhibitory effects in this environment with cell proliferation proceeding as fast as 
was possible. Conversely, with lower FBS concentration cells where would not grow, 
it would be impossible to test anti-proliferative effects and be certain that the lack of 
any induction of proliferation was a real observation or simply a result of cells not 
having sufficient basic nutrients to grow or survive. 
3.4.2 The effect of prostatic cancer cells on the proliferation and 
differentiation of osteoblast cells 
The experiments presented in this chapter were conducted to investigate the 
proliferative and differentiation response of cultured osteoblasts (SaOS2 and MG63) 
cells to conditioned media from prostatic PC3RFP cells. Prostate cancer cells 
produce many soluble factors that alter bone remodelling including RANKL, OPG and 
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TGF-β (Dai, Hall et al. 2008, Weilbaecher, Guise et al. 2011, Theriault and Theriault 
2012). These factors which are secreted into the media stimulate the proliferation of 
osteoblast cells and may inhibit their differentiation (Koutsilieris et al. 1987; Martínez 
et al. 1996). In this study, PC3RFP conditioned media (PC3RFP-CM) was found to 
stimulate the growth of SaOS2 especially when cells become close to confluence but 
PC3RFP-CM did not have any effect on MG63. I initially thought that these 
differences could be due to differences in the native differentiation status of SaOS2 
vs MG63 however, even when, MG63 were differentiated using osteogenic media for 
4 days, PC3RFP-CM did not affect proliferation of the latter. Perkel et al, Rabbani et 
al and Martinez et al reported the same finding with SaOS2 suggesting that PC3 
conditioned media contains many components other than urokinase-like plasminogen 
activator (u-PA) contributing to these proliferative stimuli (Perkel et al. 1990; Rabbani 
et al. 1990; Martínez et al. 1996). Many studies have indicated that prostatic cancer 
produce and secrete into their media different growth factors including Fibroblast 
growth factor-2 (FGF-2) and platelet derived growth factor (PDGF) (Sitaras et al. 
1988; Lawson 1990). A study done by (Hughes-Fulford and Li 2011) suggested that 
the rate of osteoblast proliferation was depending on the amount of FGF-2, TGF-β 
and PGE2 since FGF-2 was found to down regulate genes associated with 
mineralization while it increases genes associated with osteoblast proliferation. 
Osteoblast differentiation is characterized by three stages: Cell proliferation, matrix 
secretion/maturation that is associated with increased level of ALP activity and finally 
matrix mineralization. Specific genes encoding structural proteins such as COL1A, 
osteiocalcin, osterix and Runx2 are expressed at various times during differentiation 
to functional osteoblasts (Stein and Lian 1993; Kasperk et al. 1995). Once 
mineralization is completed calcium deposition can be visualized by Alizarin red 
staining. SaOS2 cells have a more mature osteoblastic phenotype, associated with 
intrinsically high ALP activity, compared to MG63 cultures which contain both mature 
and immature osteoblast phenotypes and a have generally very low ALP activity 
(Chichester et al. 1993; Voegele et al. 2000).  
My results, showed that either growing the more differentiated osteoblast cells 
SaOS2 cells in PC3RFP conditioned media or in direct contact with the PC3RFP in 
co-culture both decreased the differentiation of these cells. These treatments had 
similar effects on MG63, but this was confined to the beginning of the experiment as 
the cells were starting to differentiate up to day 4. After this time point the 
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differentiation of MG63 were increased in co-culture group only. My findings 
contradict the results found in a study done by (Jung et al. 2004; Nishimori et al. 
2012) showing an increase in ALP activity when the prostate cancer LNCaP cells 
came in contact with the bone stromal cell line MC3T3 cells, with the addition of 
exogenous BMP-2 to the CM. It was suggested that the addition of BMP2 into the 
media stimulated differentiation of mouse bone stromal cells by activating Sonic 
hedgehog (SHH) signalling through Smad dependent pathway. However these 
effects may also be due to secretion of endothelin 1, urokinase-type plasminogen 
activator and prostate specific antigen by prostate cancer cells, any/all of which could 
stimulate differentiation of osteoblasts. Other studies have shown that PC3-CM 
affects ALP activity only during proliferative phase suggesting that prostate cancer 
cell produce various stimuli for cell growth allowing osteoblasts to retain proliferative 
status and by inhibiting differentiation genes (Martínez et al. 1996). Many previous 
studies have confirmed the expression of BMP and its receptors in bone cells and 
that this signalling system promotes the differentiation of osteoblasts and plays an 
important role in bone remodelling. These signalling molecules also bind with high 
affinity to an antagonist, Noggin and this results in blocking their biological effects 
(Iwasaki et al. 1995; Zimmerman et al. 1996; Zehentner et al. 2002).  
My results showed an increase in the mineralization of SaOS2 and on day 4 in MG63 
when osteoblast cells were in direct contact with prostatic cancer cells in co-cultures. 
This was similar to studies reported previously (Larson et al. 2014) where prostate 
cancer cells promoted the mineralization in osteoblast MC3T3 and that these cells 
secrete high level of prostatic acid phosphatase (PAP). The divergences found in my 
results; the reduction of ALP activity and increased mineralization in co-culture and 
CM treated groups, would suggest that prostate cancer cells produce factors 
affecting different stages of osteoblast differentiation: the initial signals controlling 
matrix production and those regulating mineralization and its progression. Alkaline 
phosphatase is important only in the initiation stage of osteoblast differentiation but 
not in its progression since once mineralization is initiated this may proceed even in 
the absence of high phosphate level produced by ALP (Tenenbaum 1987). Another 
study done by Tenenbaum et al reported that in cultures of chick periosteal the 
induction of mineralization by β-glycerophosphate was associated with decreased 
alkaline phosphatase activity (Tenenbaum et al. 1989). The expression of COL1A 
was not affected in SaOS2 by the presence of PC3-CM. on the other hand; osterix 
and Runx2 were not affected in SaOS2 by the presence of PC3-CM during day 6 and 
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10 while, on day 8 both osterix and Runx2 were significantly increased in CM treated 
group. In a study done by Thomas et al reported that Runx2 were underexpressed in 
many osteosarcoma cell lines including SaOS2 cells compared to osteoblast-like 
reference cells he reported also in his study that SaOS2 cells express the osteoblast-
specific MASN isoform of Runx2 which have the ability to stimulate osteocalcin the 
gene responsible for mineralization but not ALP (Harada et al 1999; Thomas et al 
2004).  In co-culture, the levels of expression of these genes were not reduced. This 
finding was similar in MG63 cells. Fan reported that down regulating Noggin 
enhanced the expression of Runx2, Col1A and ALP in adipose derived stem cells 
(Fan et al. 2013), which suggests that the presence of such inhibitors of BMP 
signalling would have the opposite effect. The potential production of regulators of 
TGFβ superfamily members by tumour cells and osteoblasts will be investigated in 
the next chapter.  
In conclusion the results presented in this chapter support the hypothesis that 
prostate cancer cells produce soluble factors in CM that can stimulate the growth and 
decrease the differentiation of one osteoblastic cell line, SaOS2. However this effect 
appears to be confined to the early stages of differentiation and mineralization was 
not significantly affected. Conversely co-culture of prostate cancer cells with SaOS2 
significantly increased mineralization, suggesting that direct contact between cells 
had a separate effect to that produced by soluble factors derived from tumour cells. 
In the second cell line, MG63, growth was not affected by CM, but an early marker of 
differentiation was significantly suppressed at early stages of differentiation. This 
effect was reversed at later time points when these cultures became more strongly 
mineralised. The expression of known regulators of osteoblast differentiation in the 
osteoblast cell lines grown under the conditions used here will be examined in the 
next chapter. 
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4.1 Introduction 
The TGF-β superfamily contributes in many cellular functions including embryonic 
development, angiogenesis, proliferation, differentiation and apoptosis (Bello-
DeOcampo and Tindall 2003). In normal epithelium, TGF-β1 inhibits their growth by 
arresting the cells in the G1 cell cycle thus stimulating them to undergo differentiation 
or apoptosis (Wikström et al. 2001). In contrast, deregulation of TGF-β1 signalling has 
been associated with the pathogenesis of many diseases such as cancer (Moses and 
Barcellos-Hoff 2011). Cancer cells become resistance to the growth inhibitory effect of 
TGF-β1 and continue to proliferate even with its presence (Steiner et al. 1994). In 
addition as the tumour progress TGF-β become a tumour enhancer by altering the 
tumour microenvironment, stimulating angiogenesis, migration and metastasis (Bello-
DeOcampo and Tindall 2003). There are two suggested routes by which TGF-β 
signalling pathway contributes to tumour progression; first it may be caused by 
mutations in gene encoding TGF-β receptors such as TGFβR2 or by impaired TGF-β 
receptors availability at the cell surface. Second, due to disturbance in the TGF-β 
signalling pathway by epigenetic mechanisms such as activation of Ras pathway thus 
leading to a weakened growth inhibitory response drawing more attention towards 
activities that increases tumour progression (Knaus et al. 1996; Kim et al. 2000; 
Derynck et al. 2001).   
One of the largest subgroup of TGF-β superfamily are bone morphogenetic proteins 
(BMPs) group of extracellular signalling molecules (Chang et al. 2002). Previously 
these proteins were known by their ability to induce bone formation at extra skeletal 
sites but are now known to play an important role in the regulation of many cellular 
functions such as proliferation, differentiation and motility mainly during development 
(Hogan 1996; Wozney et al. 1998; Wozney 2002). BMPs are additionally thought to 
be involved in cancer development, especially in tumours that form bone metastases 
such as prostate cancer. This may be due to their role in bone formation and turnover 
(Alarmo et al. 2006; Feeley et al. 2006). Metastatic prostate cancer may stimulate 
new bone formation by producing various factors, including BMPs, which directly 
stimulate osteogenic differentiation and activity (Goltzman et al. 1992; Koeneman et 
al. 1999). BMPs 2-4, 6 and 7 have been reported to be over expressed by prostate 
cancer and prostate cancer cell lines (Bentley et al. 1992; De Pinieux et al. 2001). 
Several studies showed that BMP6 was associated with cancer progression and may 
have direct osteoinductive role in facilitating prostate cancer metastasis to bone 
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(Hamdy et al. 1997; Autzen et al. 1998; Dai et al. 2005). On the other hand, BMP7 
has been shown anti-proliferative effects on tumour growth of androgen –insensitive 
prostate carcinoma cells in vivo (Miyazaki et al. 2004).    
Noggin is another protein that belongs to TGF-β, which is expressed in conjunction 
with BMPs during embryological development. This protein plays a key role in 
defining the final shape and size of BMP-derived structures such as bones and joints 
(Brunet et al. 1998). BMPs signalling are regulated extracellular by this soluble 
inhibitor, which physically bind to BMPs preventing their receptor binding (Walsh et al. 
2010). In vitro experiments have indicated that Noggin binds with different affinities to 
BMP-2, -4, -5, -6, -7, -13, -14 and variably inhibiting their action (Figure 4.1) 
(Zimmerman et al. 1996; Gamer et al. 2005; Song et al. 2010). Noggin expression in 
osteoblast was found to be increased in the presence of BMP-2, -4, -5, -6, and -7 
(Gazzerro et al. 1998; Song et al. 2010).  
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Figure 4.1 over view of Noggin antagonist affect on BMPs proteins during bone and cartilage 
formation. 
This Figure illustrates the differentiation of the mesenchymal stem cells (MSCs) into osteoblast in 
bone and chondroblast in cartilage under the influence of BMPs. This effect of BMPs is regulated by 
Noggin. This figure is modified from (Krause et al. 2011).  
In this chapter, the levels of expression of 43 genes that belong to TGF-β superfamily 
were studied in prostate cancer cells (PC3RFP) and in osteoblast cells (SaOS2, 
MG63). The expression in these cells grown alone under control conditions was 
compared to that when prostate cancer cells were co-cultured with osteoblast cells or 
when the latter were exposed to PC3-RFP conditioned medium (CM). The 
expression of Noggin, a gene shown to be differentially expressed in these 
experiments in osteoblasts was further studied at both mRNA and protein level.  
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Aim 
The aim of this study was to determine the expression of TGF-β superfamily genes in 
human prostate cancer cells grown alone and in direct contact or when osteoblasts 
were exposed to products of prostate cancer cells present in conditioned medium. 
Levels of expression of these genes in these populations will be compared and 
important differences investigated further. 
Hypothesis  
Interactions between osteoblast cells with prostate cancer cells either by direct 
contact or by indirect interaction studied by treating the osteoblasts with PC3RFP-
CM, alter the expression of TGF-β family genes associated with the regulation of 
growth and differentiation in osteoblast lineage cells. 
Objectives  
1- To determine the expression of TGF-β superfamily in prostate cancer and 
osteoblast individually during the confluent phase using Taqman expressed 
plate. 
2- To determine the differences in the expression of the TGF-β superfamily after 
co-culturing prostate cancer with osteoblast or when treating osteoblast with 
PC3RFP-CM (Taqman express plates).  
3- To investigate the effect of the presence of PC3RFP cells or PC3RFP-CM on 
Noggin expression in osteoblast cells both in mRNA by QPCR or protein level 
by western blot and flow cytometry.  
4- To illustrate the patterns of colonization that PC3RFP cells form when seeded 
over osteoblast cells.  
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4.2 Material and method 
4.2.1 Materials and Disposable Equipment 
Item Supplier 
TaqMan Universal master Mix  Applied Biosystem 
Human GAPDH(20X) Applied Biosystem 
TaqMan Array 96-well fast plate TGF-β custom format 
48 plus candidate endogenous control genes 
Applied Biosystem 
MicroAmp 96-wellreaction plate (0.1ml) Applied Biosystem 
Enzyme-linked immunosorbent assay (ELISA) kit for 
Noggin (NOG) 
Uscn Life Science 
Inc. 
Negative control Rabbit immunoglobulin fraction Dako 
BD phosflow perm/wash buffer I BD Biosciences 
TaqMan gene expression assay Noggin Applied Biosystem 
Normal donkey serum abcam 
Anti-Noggin antibody abcam 
Donkey anti-rabbit IgG H&L (Alexa Fluor488) abcam 
Formaldehyde  Simport  
Bovine-serum Albumin Sigma-Aldrich 
DAPI nuclear stain Invitrogen 
Triton Sigma-Aldrich 
 
4.2.2 Identifying the ability of PC3RFP to form colonies when seeded over 
Osteoblast cell lines 
In order to test the ability of PC3RFP to form colonies with/over osteoblasts (SaOS2, 
MG63) PC3RFP were seeded over 70% confluent osteoblast cells. Osteoblast cells 
either SaOS2 or MG63 were seeded in T75 flask using the same densities that were 
used previously. When osteoblastic cells became confluent, PC3RFP cells were added 
at the same cell density that was used in all other experiments. To assess the 
behaviour of colonized PC3RFP cells Images were acquired during day 2, 4, 6 and 9 
after seeding PC3RFP cells using Leica fluorescent inverted microscope as seen in 
Figure 4.2 and Figure 4.3 respectively.  
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Figure 4.2 Fluorescent images of PC3RFP colonies formed over SaOS2 cells. 
PC3RFP cells (red stain) were seeded over 70% confluent SaOS2 cells (A) illustrates PC3RFP 
seeded over SaOS2 cells after the first 2 days where few cells were observed. (B) illustrates colonies 
of PC3RFP formed by day 4. (C) illustrates colonies of PC3RFP during day 6. (D) illustrates colonies 
of PC3RFP by day 9. Images were obtained by Leica fluorescent microscope with 20X objective.    
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Figure 4.3 Fluorescent images of PC3RFP colonies formed over MG63 cells. 
PC3RFP cells (red stain) were seeded over 70% confluent MG63 cells (A) illustrates PC3RFP seeded 
over MG63 cells after the first 2 days where few cells were observed. (B) illustrates colonies of 
PC3RFP formed by day 4. (C) illustrates colonies of PC3RFP by day 6. (D) illustrates colonies of 
PC3RFP by day 9. Images were obtained by Leica fluorescent microscope with 20X objective.   
4.2.3 Real-time RT-PCR using TaqMan Expresstm plates to evaluate TGF β 
superfamily gene expression in prostate cancer cell line and osteosarcoma cell 
lines 
RNA was extracted from PC3RFP, SaOS2 and MG63 cell lines during exponential and 
confluent growth phases. The RNA was quantified by Nanodrop and its integrity was 
tested by Bioanalyzer as discussed in Chapter 2 section (2.3.3) and (2.3.4). This was 
followed by cDNA synthesis as described in chapter 2 section (2.3.5). The quality of 
the cDNA produced was tested by checking the expression of the housekeeping gene 
(GAPDH) in all samples by QRT-PCR as discussed in Chapter 2 section (2.3.6). 
Taqman Array 96-well plate custom format with TGF-β superfamily genes was used to 
quantify the RNA expression of all samples. Table (4.1) shows the design of the 
Express plate and list of gene analysed. The Taqman 96 well plate was centrifuged at 
1000rpm for 1min. A reaction mix was made for each sample by adding 500µl of water, 
40 µl of cDNA and 540 µl master mix. Twenty microliter of the samples were loaded 
into each well. After loading the two samples each to its designated position in the 
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plate, the plate was sealed properly and was centrifuged again at 1000rpm for 1min 
and was run on StepOne plus real time PCR as described in chapter 2 section (2.3.6).  
4.2.4 Real-time RT-PCR using TaqMan Express tm plates to evaluate TGFβ 
superfamily gene expression in co-cultured cells. 
PC3RFP cells were seeded with osteoblast cells in a T75 flask using the density 
equivalent to the density used in growth curves. ~ 220,000 cells of PC3RFP were 
seeded with ~660,000 cells of either SaOS2 or MG63 in T75 flask in standard 10%FBS 
media. After 48h, cells were washed with PBS and the media were changed with 2% 
for co-culture SaOS2 and 4% for co-culture MG63. When cultures were 80% confluent, 
around day 7, cells were harvested and sorted using FACS Aria. RNA was extracted 
from both cells PC3RFP, SaOS2 and PC3RFP, MG63 and cDNA were synthesized as 
described previously in chapter 2 section (2.3.5). Taqman Array 96-well plate Table 
(4.1) custom format with TGF-β superfamily genes was used to quantify the RNA 
expression of all samples as described earlier (4.2.3).  
4.2.5 Analysis of Noggin protein concentrations in PC3RFP Condition media 
by ELISA 
Enzyme-linked immunosorbent assay kit was used to detect the presence of Noggin 
protein in condition media collected over PC3RFP cells. All kit components and 
samples were brought to room temperature prior to use. Standard Noggin stock 
solution of a concentration 10ng/ml was prepared by adding 1ml of the standard diluent 
to lyophilized standard and was mixed gently without foaming. Different standard 
concentrations were made by serial dilution using the standard stock solution as seen 
in Figure (4.4). Both detection reagent A and B were spun down prior to use and both 
assays diluent A and B were prepared by adding 2ml of diluent A or B to 2ml deionized 
water. Detection reagent was then added to the prepared assay diluent in 1:100 
dilution (40µL). 100µL of standard and condition media were then loaded in duplicate 
on the ELISA plate. The plate was covered with the plate sealer and was incubated for 
2h at 37ºC. The liquid were removed from all wells without washing the plate and 
100µL of detection reagent A was added to each well without touching the sides of the 
wells, the plate was covered and incubated for 1h at 37ºC. Wash solution was 
prepared by adding 20ml of washing solution to 580ml deionized water. After an 
incubation of 1h, the solution was aspirated from the wells and the wells were washed 
with 350µL of washing solution. This process was repeated three times. The remaining 
liquid was removed from the plate completely by inverting the plate on absorbent 
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paper. 100µL of detection reagent B were added to each well and the plate was 
recovered and incubated for 30min at 37ºC. After this, the washing step was repeated 
as previously, 5 times. 90µL of substrate solution TMB were added to each well and 
the plate was covered and incubated for 15-25 min at 37ºC in the dark. Finally, 50µL of 
stopping solution were added to each well. The colour in the wells changed from blue 
to yellow and the intensity of the colour was measured by using microplate reader at 
wavelength of 450nm. The concentrations of the unknowns were calculated from 
standard curves. 
 
Figure 4.4 Preparing serial standard dilutions from stock standard solution for ELISA. 
Standard stock solution of a concentration 10ng/ml was prepared by adding 1ml of the standard 
diluent to lyophilized standard and was mixed gently without foaming. 6 tubes were prepared by 
adding 500µL of standard diluent in each tube.  500µL from stock standard solution was added to the 
first tube mixed well and 500 µL transferred to the next tube and so on making the following 
concentrations (5, 2.5, 1.25, 0.625, 0.312 and 0.156) ng/ml.  !
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Table 4.1 illustrate the design of the TaqMan TGF-β Express plate that was used to quantified the RNA expression in all samples by real time PCR. 
(18s,GAPDH,HPRT1 and GUSB were housekeeping genes) ( the TGF-β superfamily include: Activin receptor 1 ACVR1, Transforming growth factor beta 
receptor 1 TGFBR1, Transforming growth factor beta receptor 2 TGFBR2 , Transforming growth factor beta receptor 3 TGFBR3, endoglin ENG, Growth 
differentiation  Factor 1 GDF1;LASS1, Growth differentiation Factor 3 GDF3, Growth differentiation  Factor 9 GDF9, Bone morphogenetic protein 4 BMP4, 
Bone morphogenetic protein 2 BMP2, Bone morphogenetic protein 7 BMP7, Bone morphogenetic protein 6 BMP6, Bone morphogenetic protein 3 BMP3, 
Chordin CHRD, Bone morphogenetic protein 5 BMP5, Bone morphogenetic protein 10 BMP10, Growth differentiation  Factor 7GDF7, Growth differentiation  
Factor 6 GDF6, Bone morphogenetic protein 8B BMP8B, Bone morphogenetic protein 8A BMP8A, Growth differentiation  Factor 2 GDF2, Growth 
differentiation  Factor 11 GDF11, Bone morphogenetic protein receptor 1 A BMPR1A, Bone morphogenetic protein receptor 1 B BMPR1B, Bone 
morphogenetic protein receptor 2 BMPR2, Sclerostin SOST, Gremlin 1 GREM1, Noggin NOG, Cerbeus 1 CER1, Neuroblastoma 1 NBL1, Follistatin FST, 
Activin receptor type-1B ACVR1B, Activin receptor type-2 A  ACVR2A, Activin receptor type-2 B ACVR2 B, inhibin alpha INHA, Transforming growth factor 
beta 2 TGF-β2, Transforming growth factor beta 3 TGF-β3, Transforming growth factor beta 1 TGF-β1, Lefty 2 LEFTY2, Latent-transforming growth factor 
beta binding protein 1 LTBP1, inhibin beta B INHBB, inhibin beta A INHBA, inhibin beta C INHBC, inhibin beta E INHBE) 
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4.2.6 Further analysis of the effects of PC3RFP-CM and co-culture on Noggin 
expression in osteoblast cell lines using QRT-PCR 
The expressions of Noggin in mRNA of osteoblast cells were measured using Taqman 
single gene assay of Noggin. PC3RFP cells were seeded with osteoblast cells using 
the same cells density and procedure that were used earlier (4.2.3). Cells (SaOS2 and 
MG63) were seeded individually again in the same way but the media was changed 
with PC3RFP-CM after the first 48h. CM was generated over PC3-RFP cells as 
described in Chapter 3 section (3.2.4) using 2% and 4% FBS respectively. RNA was 
extracted from all cells groups co-culture and treated with PC3RFP-CM and cDNA 
were synthesized as described previously in Chapter 2 section (2.3.5). Noggin 
expression was measured with relative expression to housekeeping gene GAPDH as 
described earlier in Chapter 2 section (2.3.6). 
4.2.7 Immunofluorescence detection of Noggin in co-culture and in osteoblast 
grown in PC3RFP-CM  
Immunofluorescent microscopy was used to identify Noggin in cells using specific 
antibodies. Rabbit polyclonal anti-Noggin antibody (abcam, UK) and donkey anti-rabbit 
IgG H&L (Alexa Fluor 488) antibodies (abcam, UK) were used as primary and 
secondary antibodies. SaOS2 ~ 10,000 cells/cm2 and PC3RFP 3000cells/ cm2 were 
seeded in 8 chamber slides (BD, UK) and cultured in DMEM containing 10% FBS, 1% 
penicillin/ streptomycin as seen in Figure 4.2. After, 48hour the cells were washed with 
PBS, and the media were changed to the same formulation but with 2%FBS in the co-
culture group and controls (SaOS2 and PC3RFP) or with PC3RFP-CM (Saos2 cells). 
After cultures had become 80% confluent they were washed twice with PBS and fixed 
with 200µl of 10% neutral buffered formalin for 10 min at room temperature. Cells were 
washed again twice with PBS, and permeablised with 200µL 0.1% Triton in PBS for 10 
min at room temperature on shaker. Cells were washed twice with PBS at room 
temperature blocked with 200µL 10% normal donkey serum in PBS for 30 min at room 
temperature.  
In optimising antibody concentrations, cells were incubated overnight at 4°C with 200µl 
of anti-Noggin antibody (abcam, UK) in different dilutions in 10% Donkey serum (1:50), 
(1:100), and (1:200). The same dilutions of negative control rabbit immunoglobulin 
isotype (Dako,UK) were added to the negative controls champers.  
Cells were washed twice with 500µL PBS for 3 min on a shaker at room temperature. 
100µL of the secondary donkey anti-rabbit IgG H&L (Alexa Fluor 488) antibody in 10% 
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donkey serum was added in (1:200) dilution to each well. The slides were incubated for 
1h in the dark at room temperature. The washing step was repeated again and slides 
were mounted using ProLong Antifade Reagents mounting medium containing DAPI 
stain (Invitrogen, UK), DAPI stain was used to stain nuclei. Images were acquired 
using Leica fluorescent microscope. 1:100 dilutions of primary antibody with 1:200 
secondary antibodies were identified as the optimum primary and secondary antibody 
concentrations respectively and were used. Subsequent experiments used the 
optimum antibody concentration.  
 
Figure 4.5 Layout for 8 well chamber slides. 
The Figure illustrates the set-up for cell cultures in three 8 well chamber slides with different antibody 
concentrations (1/50, 1/100 and 1/200) on the left top well in each slide, PC3RFP was stained with 
anti-Noggin antibody (Anb) on the top right PC3RFP was stained with Isotype IgG (iso) as negative 
control. The rest of the wells were as labelled, with one side of the slide stained with Noggin antibody 
and the other with the isotype control. 
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4.2.8 Detection of Noggin protein in co-cultures and in osteoblasts treated 
with PC3RFP-CM by using flow cytometry 
Flow cytometry is a useful technique for separating and measuring particles such as 
cells, cell surface antigen and intracellular proteins based on fluorescence detection. 
When cell passes through laser beam the flow cytometry records how the cells or 
particle distributes incident laser light and releases fluorescence. Noggin protein was 
detected in osteoblasts grown alone and staining was compared to that in co-cultured 
SaOS2 and in SaOS2 treated with PC3RFP-CM by using BD FACS Aria flow 
cytometry.  
 Preparation of cells 4.2.8.1
PC3RFP cells were seeded with SaOS2 cells using the density equivalent to the 
density used in growth curve. Around 220,000 cells of PC3RFP were seeded with 
~660,000 cells of SaOS2 in T75 flask in standard DMEM 10%FBS media. ~660,000 
cells of SaOS2 were seeded in an additional two T75 flasks, one of which was used as 
negative control. Around 220,000 cells of PC3RFP were seeded in a T75 and these 
were used as controls to set the gate on the flow cytometer. After 48h, cells were 
washed with PBS and the media were changed with PC3RFP-CM in one of the SaOS2 
flask and with DMEM 2% FBS for co-culture, SaOS2 control and PC3RFP control 
flasks. When cultures were 80% confluent around day 7, cells were harvested with 
trypsin and counted as described in Chapter 2 section (2.2.3) and (2.2.5). From each 
flask three tubes were made (primary antibody, isotype and control) with ~1×106 cells 
in each tube. These were transferred to 1.5ml eppendorf tubes and washed with 1ml 
PBS cells were centrifuged at 500 xg for 3 min. PBS was removed and the cells were 
fixed with 300µL of 4% formalin in PBS at room temperature on a rotator for 10 min. 
Cells were washed again with 1ml PBS and centrifuged at 500 xg for 3 min. Cell pellets 
were re-suspended in 0.1% triton in order to permeablised cell membrane for 10 min. 
Cells were washed twice with PBS to remove all traces of fixative and detergent. Cells 
were blocked using 10% donkey serum diluted in 0.5% BSA solution for 30 min at 
room temperature. Cells were washed once more with PBS. Supernatant was removed 
thoroughly by inversion on an absorbent paper and 20µL of BD phosflow perm/wash 
buffer I 1X solution, which was made from 10X stock solution, and was added to cell 
pellet. BD phosflow perm/wash buffer was used to permeabilize the cells; it also acts 
as an antibody diluent and cell wash buffer at the same time. 100µL of 1/200 of rabbit 
anti-Noggin polyclonal antibody was added and cells incubated in the dark for 30 min. 
Cells were washed with PBS and centrifuged and the liquid was removed completely. 
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100µL of 1/2000 of secondary donkey anti-rabbit IgG H&L (Alexa Fluor 488) polyclonal 
antibody was added to the cells and incubated for 30 min in the dark. Cells were 
washed with PBS once and twice with 1X perm buffer. Finally, cells were re-suspended 
in 300µL of 1X perm buffer and cells were analysed by using BD FACS Aria flow 
cytometry.        
 
Figure 4.6 Scheme showing how samples were prepared for flow cytometry. 
The Figure illustrates the distribution of cells from each flask in to three test tubes. Cells were counted 
from the T75 and around 1×106 cells were placed in each tube. Tube (A) primary antibody 1/200 
dilution and 1/2000 secondary antibody (B) Isotype used as negative control 1/200 dilution isotype 
with secondary antibody 1/2000 (C) is a control without the addition of any antibodies.  
4.2.9 Detection of Noggin protein in co-cultures and in osteoblast treated with 
PC3RFP-CM using western blot 
PC3RFP cells were seeded with osteoblast cells using the same cell densities and 
procedure that were used earlier (4.2.3). SaOS2 was seeded individually again in the 
same way but the media was changed to either PC3RFP-CM or to 2% DMEM as a 
control after the first 48h. Protein was extracted from 80% confluent flasks for all cells, 
PC3RFP-CM and control and quantified as described in Chapter 2 section (2.4.1) and 
(2.4.2). 40 µg of protein samples were separated on 12% SDS-PAGE, blotted on PVDF 
membranes and probed with anti-Noggin and anti-β-actin and anti-GAPDH as 
housekeeping genes using the concentration as described in Chapter 2 sections 
(2.4.4), (2.4.5), (2.4.6) and (2.4.7).   
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4.3 Results 
4.3.1 Analysis of TGF-β superfamily expression 
The expressions of 43 genes of the TGF-β superfamily were quantified by real time 
PCR using Taqman custom format 48 (TGF-β) plate. The expression of each gene 
was firstly assessed as high (ct<25), moderate (ct=25-30), low (ct=31-35) or non 
expressed (ct>35). After adjustment for housekeeping gene expression (GAPDH), 
delta ct values were compared between cell lines/treatment groups.  
 Comparison of PC3-RFP/SaOS2 gene expression in exponential and 4.3.1.1
confluent phase 
There were no differences between SaOS2 cells or PC3-RFP cells grown in different 
growth phases Figure (4.7) and Figure (4.8) (for detailed information about the ct 
value and the calculated Δdct value see Table 1A and Table 2A in the Appendix A). 
Since this was the case, all subsequent experiments were done with cells in 
confluent phase. This maximised RNA yields in these experiments. 
 
Figure 4.7 Array plate analysis in exponential SaOS2 compared to confluent SaOS2 in TGF- β 
superfamily genes 
This Figure shows the differences between exponential SaOS2 and Confluent SaOS2 in terms of fold 
change after being adjusted to housekeeping gene (GAPDH). The Fold Change was calculated by 
using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments.  
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Figure 4.8 Array plate analysis in exponential PC3RFP compared to Confluent PC3RFP in TGF-
β superfamily genes. 
This Figure shows the differences between exponential PC3RFP and Confluent PC3RFP in terms of 
fold change after being adjusted to housekeeping gene (GAPDH). The Fold Change was calculated by 
using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments.  
 Comparison of PC3RFP and SaOS2 cells grown alone in confluent 4.3.1.2
phase 
As in 4.3.1.1, there were no genes in the TGF-β superfamily that were expressed at 
high levels in PC3RFP. As seen in Figure (4.9) the following genes were not 
expressed by PC3RFP: bone morphologic protein 5 (BMP5), bone morphologic 
protein 7 (BMP7), Cerebus (CER1), Endoglin (ENG), Growth differentiation Factor 1 
(GDF1), Growth differentiation Factor 7 (GDF7), Inhibin beta B (INHBB), LEFTY 2. In 
SaOS2 cells only bone morphologic protein 4 (BMP4) and transforming growth factor 
beta 1 (TGFβ1) were highly expressed. The following genes were not expressed by 
SaOS2: bone morphologic protein 10 (BMP10), bone morphologic protein 5 (BMP5), 
bone morphologic protein3 (BMP3), Chordin (CHRD), Growth differentiation Factor 7 
(GDF7), Growth differentiation Factor 9 (GDF9), Inhibin beta C (INHBC), LEFTY 2, 
Sclerostin (SOST). The rest of the TGF-β superfamily genes were expressed at 
either moderate or low levels in either cell line. There were clear differences in the 
levels of expression after adjustment for housekeeper expression shown as (Δdct) 
value (as seen highlighted in Table 3A in the Appendix A). The major differences 
presented as relative expression after adjusting with housekeeping gene (GAPDH) 
was shown in Figure 4.10. 
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Figure 4.9 Array plate analysis of TGF-β superfamily! genes in PC3RFP compared to SaOS2 
during the Confluent Phase.  
This Figure shows the differences between PC3FP and SaOS2 in terms of fold change after being 
adjusted to housekeeping gene (GAPDH). The Fold Change was calculated by using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments.  
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Figure 4.10 Array plate analysis of the major differences between confluent PC3RFP and 
Confluent SaOS2 in TGF-β superfamily genes. 
This Figure shows the differences between confluent PC3RFP and Confluent SaOS2 in terms of 
relative expression after being adjusted to housekeeping gene (GAPDH). The following genes were 
expressed at a higher level in SaOS2 cells: GDF1, TGF-β1, TGF-β2, INHBA, INHBB, BMP4 and ENG. 
While, PC3RFP showed an increase in BMP3 and Noggin expression compared with these genes in 
SaOS2 cells. Relative expression was calculated after calculating dct and Δdc then Δdc was raised to 
the square root.  Data expressed as mean of 3 independent experiments.  
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 Comparison of PC3RFP and MG63 cells grown alone in confluent 4.3.1.3
phase 
As in 4.3.1.1, there were no genes in the TGF-β superfamily that were expressed at 
high levels in PC3RFP while, only (ENG) was expressed at high levels in MG63. As 
seen in Figure (4.11) the following genes were not expressed by MG63: BMP3, 
BMP6, CER1, GDF3, INHBB, INHBC and LEFTY2. The rest of the genes were 
expressed at either moderate or low levels in either cell line. There were clear 
differences in the levels of expression after adjustment for housekeeper expression 
shown as (Δdct) value (as seen highlighted in Table 4A in the Appendix A). The 
major differences presented as relative expression after adjusting with housekeeping 
gene (GAPDH) was shown in Figure 4.12 
 
Figure 4.11 Array plate analysis of TGF-β superfamily! genes in MG63 compared to PC3RFP 
during the Confluent Phase.  
This Figure shows the differences between MG63 and PC3RFP in terms of fold change after being 
adjusted to housekeeping gene (GAPDH). The Fold Change was calculated by using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments.  
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Figure 4.12 Array plate analysis of the major differences between confluent PC3RFP and 
Confluent MG63 in TGF-β superfamily genes. 
This Figure shows the differences between confluent PC3RFP and Confluent MG63 in terms of 
relative expression after being adjusted to housekeeping gene (GAPDH). The following genes were 
expressed at a higher level in MG63 cells: GDF1, TGF-β1, INHBB, BMP5, BMP7, BMP4, Activin 
receptor 1 (ACVR1), GDF7, GDF9, Transforming growth factor beta receptor 2 (TGFBR2), 
Transforming growth factor beta receptor 3 (TGFBR3) and ENG. While, PC3RFP showed an increase 
in BMP3 and Noggin expression compared with these genes in SaOS2 cells. Relative expression was 
calculated after calculating dct and Δdc then Δdc was raised to the square root. Data expressed as 
mean of 3 independent experiments.   
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 Comparison of SaOS2 gene expression grown alone and in co-culture 4.3.1.4
with PC3RFP 
Osteoblast cells (SaOS2) were seeded together with PC3RFP cells in co-culture and 
they were incubated together for 7 days until they become confluent. The cells were 
sorted using BD FACS Aria. The expression of the same 43 genes of the TGF-β 
superfamily were quantified by real time PCR using the same Taqman custom format 
48 (TGF-β) Expresstm plate that was used with confluent cells. As in 4.3.1.1, both 
BMP4 and TGF-β1 were expressed at high level in both confluent SaOS2 and co-
cultured SaOS2. As seen in Figure (4.13) the following genes continued not to be 
expressed by co-cultured SaOS2: BMP10, BMP5, CHRD, GDF7, GDF9, Inhibin beta 
C INHBC, LEFTY2 and SOST. The rest of the genes were expressed at either 
moderate or low levels in either cell line. There were no differences in most of the 
genes between confluent SaOS2 and co-cultured SaOS2 the only clear differences in 
the levels of expression after adjustment for housekeeper expression shown as 
(Δdct) value were found in BMP3, BMP6, GREM1 and Noggin being expressed more 
in SaOS2 after being co-cultured with PC3RFP (as seen highlighted in Table 5A in 
the Appendix A). The major differences presented as relative expression after 
adjusting with housekeeping gene (GAPDH) was shown in Figure (4.14). 
 
Figure 4.13 Array plate analysis of TGF-β superfamily!genes in co-cultured SaOS2 compared to 
control SaOS2 during the Confluent Phase.  
This Figure shows the differences between co-cultured SaOS2 and control SaOS2 in terms of fold 
change after being adjusted to housekeeping gene (GAPDH). The Fold Change was calculated by 
using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments.  
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Figure 4.14 Array plate analysis of the major differences between confluent SaOS2 and co-
cultured SaOS2 in TGF-β superfamily genes. 
SaOS2 cells were cultured together with PC3RFP for 7 days. The cells were then sorted using BD 
FACS Aria. RNA was collected and cDNA was run on the same Taqman expressed plate.  This Figure 
shows the differences between confluent SaOS2 and co-cultured SaOS2 in terms of relative 
expression after being adjusted to housekeeping gene (GAPDH). The following genes were expressed 
at a higher level in co-cultured SaOS2: BMP3, BMP6, Noggin and GREM1. Noggin was significantly 
increased (P=0.0001) unpaired t test. Relative expression was calculated after calculating dct and Δdc 
then Δdc was raised to the square root. Data expressed as mean of 3 independent experiments.   
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 Comparison of PC3RFP gene expression in these cells grown alone 4.3.1.5
and in co-culture with SaOS2  
There were no differences in relative gene expression between confluent PC3RFP 
cells and PC3RFP being co-cultured with SaOS2 cells as seen in Figure (4.15) (for 
detailed information about the ct value and the calculated Δdct value see Table 6A in 
the Appendix A).  
 
Figure 4.15 Array plate analysis of TGF-β superfamily! genes in co-cultured PC3RFP/with 
SaOS2 compared to control PC3RFP during the Confluent Phase.  
This Figure shows the differences between co-cultured PC3RFP/with SaOS2 and control PC3RFP in 
terms of fold change after being adjusted to housekeeping gene (GAPDH). The Fold Change was 
calculated by using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments.  
 Comparison of MG63 gene expression in these cells grown alone and 4.3.1.6
in co-culture with PC3RFP 
Osteoblast cells (MG63) were seeded together with PC3RFP cells in co-culture and 
they were incubated together for 7 days until they become confluent. The cells were 
sorted using BD FACS Aria. The expressions of the same 43 genes of the TGF-β 
superfamily were quantified by real time PCR using the same Taqman custom format 
48 (TGF-β) Expresstm plate that was used with confluent cells. There were no genes 
in the TGF-β superfamily that were expressed at high level except for ENG which 
was expressed at high level in both MG63 confluent and in MG63 co-cultured with 
PC3RFP. The same genes that were not expressed in confluent MG63 were also not 
expressed when cells were cultured with PC3RFP as seen in Figure (4.16). The clear 
differences in the relative gene expression after adjusting with housekeeping gene 
GAPDH was seen in Noggin, CHRD and Active receptor 2 B (ACVR2B) being 
expressed more in co-culture group. While, Active receptor 2 A (ACVR2A) was found 
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to be expressed more in confluent MG63 (as seen highlighted in Table 7A in the 
Appendix A). These differences were presented as relative gene expression in Figure 
4.17.   
 
Figure 4.16 Array plate analysis of TGF-β superfamily!genes in co-cultured MG63 compared to 
control MG63 during the Confluent Phase.  
This Figure shows the differences between co-cultured MG63 and control MG63 in terms of fold 
change after being adjusted to housekeeping gene (GAPDH). The Fold Change was calculated by 
using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments.  
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Figure 4.17 Array plate analysis of the major differences between confluent MG63 and co-
cultured MG63 in TGF-β superfamily genes. 
MG63 cells were cultured together with PC3RFP for 7 days. The cells were then sorted using BD 
FACS Aria. RNA was collected and cDNA was run on the same Taqman expressed plate.  This Figure 
shows the differences between confluent MG63 and co-cultured MG63 in terms of relative expression 
after being adjusted to housekeeping gene (GAPDH). The following genes were expressed at a higher 
level in co-cultured MG63: ACVR2B, CHRD, Noggin and GREM1. Confluent MG63 express more 
ACVR2A compared to MG63 co-cultured with PC3RFP. Relative expression was calculated after 
calculating dct and Δdc then Δdc was raised to the square root. Data expressed as mean of 3 
independent experiments.   
 Comparison of PC3RFP gene expression in these cells grown alone 4.3.1.7
and in co-culture with MG63 
As in 4.3.1.1, there were no genes in the TGF-β superfamily that were expressed at 
high level in PC3RFP co-cultured with MG63. Most of the genes that were not 
expressed in confluent PC3RFP remained unexpressed even after being co-cultured 
with MG63 cells. The rest of the TGF-β superfamily genes were expressed at either 
moderate or low levels in PC3RFP co-cultured with MG63 cells as seen in Figure 
(4.18). There were clear differences in the relative gene expression between the two 
groups in ENG, INHBE and GDF1 (as seen in Table 8A in the Appendix). The major 
differences presented as relative expression after adjusting with housekeeping gene 
(GAPDH) was shown in Figure (4.19). ! !
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Figure 4.18 Array plate analysis of TGF-β superfamily!genes in co-cultured PC3RFP/with MG63 
compared to control PC3RFP during the Confluent Phase.  
This Figure shows the differences between co-cultured PC3RFP/with MG63 and control PC3RFP in 
terms of fold change after being adjusted to housekeeping gene (GAPDH). The Fold Change was 
calculated by using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments. 
 
 
Figure 4.19 Array plate analysis of the major differences between co-cultured PC3RFP with 
MG63 compared to control PC3RFP cells in TGF-β superfamily genes 
MG63 cells were cultured together with PC3RFP for 7 days. The cells were then sorted using BD 
FACS Aria. RNA was collected and cDNA was run on the same Taqman expressed plate.  This Figure 
shows the differences between confluent PC3RFP and PC3RFP co-cultured with MG63 in terms of 
relative expression after being adjusted to housekeeping gene (GAPDH). The following genes were 
expressed at a higher level in co-cultured PC3RFP: ENG, GDF1 and INHBE. Relative expression was 
calculated after calculating dct and Δdc then Δdc was raised to the square root. Data expressed as 
mean of 3 independent experiments.   
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 Comparison of SaOS2 gene expression in these cells grown in 4.3.1.8
standard control medium and in SaOS2 treated with PC3RFP-CM 
Osteoblast cells (SaOS2) were treated with PC3RFP-CM. The expressions of the 
same 43 genes of the TGF-β superfamily were quantified by real time PCR using the 
same Taqman custom format 48 (TGF-β) Expresstm plate and was compared to the 
gene expression profile of confluent SaOS2 cells. As in 4.3.1.1, there were no genes 
of the TGF-β superfamily that were expressed at high level in SaOS2 treated with 
PC3RFP conditioned media. As seen in Figure (4.20) the following genes continued 
not to be expressed by SaOS2 treated with PC3RFP conditioned media: bone 
morphologic protein 10 (BMP10), BMP5, Chordin (CHRD), GDF7, Growth 
differentiation Factor 9 (GDF9), Inhibin beta C (INHBC), GDF2, LEFTY, Sclerostin 
(SOST), (CER) with the addition of other gene BMPR1B. The rest of the genes were 
expressed at either moderate or low levels in either cell line. There were no 
differences in most of the genes between confluent SaOS2 and SaOS2 treated with 
PC3RFP-CM the only clear differences in the levels of expression after adjustment 
for housekeeper expression shown as (Δdct) value were found is in Noggin being 
significantly expressed more in SaOS2 after being treated with C3RFP-CM with 
p=0.008 by using unpaired t test as seen in Figure 4.21 (for detailed information 
about the ct value and the calculated Δdct value see Table 9A in the Appendix A) 
!
Figure 4.20 Array plate analysis of TGF-β superfamily!genes in Confluent SaOS2 compared to 
SaOS2 treated with PC3RFP-CM.  
This Figure shows the differences between confluent SaOS2 and SaOS2 treated with PC3RFP-CM in 
terms of fold change after being adjusted to housekeeping gene (GAPDH). The Fold Change was 
calculated by using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments. 
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Figure 4.21 Array plate analysis of the major differences between confluent SaOS2 and SaOS2 
treated with PC3RFP-CM in TGF-β superfamily genes. 
This Figure shows the differences between confluent SaOS2 and SaOS2 treated with PC3RFP-CM in 
terms of relative expression after being adjusted to housekeeping gene (GAPDH). Noggin gene was 
found to be expressed more in the SaOS2 treated group (p=0.008) unpaired t test. Relative 
expression was calculated after calculating dct and Δdc then Δdc was raised to the square root. Data 
expressed as mean of 3 independent experiments.   
 Comparison of MG63 gene expression grown alone and in MG63 4.3.1.9
treated with PC3RFP-CM  
There were no genes of the TGF-β superfamily that were expressed at high level in 
MG63 treated with PC3RFP conditioned media. The same genes that were not 
expressed in confluent MG63 contained to be unexpressed when cells were treated 
with PC3RFP-CM as seen in Figure (4.22). The clear differences in the relative gene 
expression after adjusting with housekeeping gene GAPDH was seen in BMP5, 
ENG, GDF11, TGFBR1, TGFBR2 and TGFBR3 being expressed less in the treated 
group (as seen highlighted in Table A10 in the Appendix) and were presented as 
relative gene expression in Figure (4.23).   
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Figure 4.22 Array plate analysis of TGF-β superfamily!genes in Confluent MG63 compared to 
Mg63 treated with PC3RFP-CM.  
This Figure shows the differences between confluent MG63 and MG63 treated with PC3RFP-CM in 
terms of fold change after being adjusted to housekeeping gene (GAPDH). The Fold Change was 
calculated by using the equation Δdct!.! ×−10. Data expressed as mean of 3 independent experiments. 
 
 
Figure 4.23 Array plate analysis of the major differences between confluent MG63 and MG63 
treated with PC3RFP-CM in TGF-β superfamily genes. 
This Figure shows the differences between confluent MG63 and MG63 treated with PC3RFP-CM in 
terms of relative expression after being adjusted to housekeeping gene (GAPDH). The following 
genes were expressed more in confluent MG63 that MG63 treated with PC3RFP-CM: BMP5, BMP7, 
ENG, GDF11, TGFBR1, TGFBR2 and TGFBR3. Relative expression was calculated after calculating 
dct and Δdc then Δdc was raised to the square root. Data expressed as mean of 3 independent 
experiments.  
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4.3.2 Detection of Noggin protein in PC3RFP Condition media by ELISA 
Condition media collected over PC3RFP was tested for the presence of Noggin protein 
by ELISA. Noggin protein was detected in Condition media collected from different 
flasks. The concentration of Noggin was measured from three independent batches of 
CM and was calculated using standard curve Figure 4.24. The concentration of Noggin 
present in PC3RFP conditioned media was found to be 0.293±0.0046ng/mL.!
!
Figure 4.24 Noggin Standard curve. 
This Figure represent Noggin standard curve with standard value of (0.156, 0.312, 0.625, 1.250, 2.5 
and 5) ng/ml. Samples of conditioned media from 3 different flasks and standards were measured in 
duplicate. This curve was used to calculate the concentration of Noggin present in PC3RFP 
conditioned media. All data expressed as mean ± SEM of 3 independent experiments.    
4.3.3 Effect of PC3RFP-CM and co-culture on Noggin expression in 
osteosarcoma cells using QRT-PCR 
The result obtained from the express plate was tested by measuring mRNA Noggin 
expression as a single gene assay, using QRT-PCR. Treating SaOS2 cells with 
PC3RFP-CM or growing them in direct contact with PC3RFP cells in co-culture both 
increased the mRNA Noggin expression significantly (p=0.0002) by using (1 way 
ANOVA, Bonferroni) Figure (4.25). On the other hand, treating MG63 cells with 
PC3RFP-CM or growing the cells together with PC3RFP both increased Noggin 
mRNA expression but this did not reach significance. These results confirmed the 
expressed plate data presented previously in this chapter. 
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Figure 4.25 Noggin mRNA expression was increased in osteoblast cells. 
(A) illustrates mRNA Noggin expression in SaOS2 cells in standard DMEM 2% media compared to 
treated SaOS2 cell with PC3RFP-CM and co-cultured SaOS2. Both PC3RFP-CM treated cells and co-
cultured cells showed significant increase in the expression of Noggin mRNA with p=0.0002 (1 way 
ANOVA, Banferroni). (B) illustrate mRNA Noggin expression in MG63 cells in standard DMEM 4% 
media compared to treated MG63 cell with PC3RFP-CM and co-cultured MG63. There were no 
significant change in the expression of Noggin mRNA in either co-culture or CM treated compared to 
controls although there was an increase in Noggin expression in both groups. Relative expression was 
calculated after calculating dct and Δdc then Δdc was raised to the square root.  All data expressed as 
mean ± SEM of 3 independent experiments.    
4.3.4 Immunofluorescence detection of Noggin in co-culture and in osteoblast 
grown in 50%PC3RFP-CM  
SaOS2 cells were seeded in 8 well chamber slides either treated with PC3RFP-CM or 
were grown in direct contact with PC3RFP in co-culture. These cells were then labeled 
with Rabbit polyclonal anti-Noggin antibody (abcam, UK) and donkey anti-rabbit IgG 
H&L (Alexa Fluor 488) antibodies (abcam, UK) as primary and secondary antibodies. 
Images were acquired using a Leica fluorescent microscope. The level of Noggin 
protein, detected as green stain was increased in SaOS2 cells treated with PC3RFP-
CM and in co-culture group compared to control SaOS2 in standard media as seen in 
Figure (4.26).     
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Figure 4.26 The level of Noggin protein fluorescent was increased in co-culture and PC3RFP-
CM groups. 
Fixed and permeablised cells were stained with rabbit polyclonal primary anti-Noggin antibody or 
isotype control normal rabbit IgG antibody. Nuclei were stained with DAPI (blue fluorescence). Images 
were obtained by Leica fluorescent microscope with 20X objective. (A) Shows Isotype 1/100 with no 
staining in SaOS2 treated with CM, co-cultured SaOS2, SaOS2 control in standard media and 
PC3RFP control in standard media. (B) Shows SaOS2 grown alone labelled with Noggin (green 
fluorescent) Antibody 1/100 dilution. (C) Illustrates SaOS2 cells treated with PC3RFP-CM labelled with 
Noggin (green fluorescent) Antibody 1/100 dilution. (D) Illustrate co-cultured SaOS2 cells labelled with 
Noggin (green fluorescent) Antibody 1/100 dilution.   
4.3.5 Detection of Noggin protein in co-cultured SaOS2 and in SaOS2 treated 
with PC3RFP-CM by using flow cytometry 
Flow cytometry was used to detect the presence of Noggin protein in SaOS2 
osteoblast cells and to compare the amount of Noggin protein present in control 
SaOS2 in standard media with both co-cultured SaOS2 and SaOS2 treated with 
PC3RFP-CM. Rabbit polyclonal anti-Noggin antibody 1/200 dilution (abcam, UK) and 
donkey anti-rabbit IgG H&L (Alexa Fluor 488) antibody 1/2000 (abcam, UK) were used 
as primary and secondary antibodies respectively. Normal rabbit IgG antibody was 
used as Isotype control. Cells were analysed using BD FACS Aria as seen in Figure 
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4.28 A and B. Noggin protein expression increased significantly p=0.0001 (1 way 
ANOVA, Banferroni) in the SaOS2 treated with PC3RFP-CM group but not in the co-
cultured group. While, the expression of Noggin protein was found to be decreased 
significantly in the PC3RFP co-culture group p=0.0001 (1 way ANOVA, Banferroni) 
compared to PC3RFP as control as seen in Figure (4.27).  
 
Figure 4.27 Noggin protein expression was significantly increased in SaOS2 cells treated with 
PC3RFP-CM and significantly decreased in co-cultured PC3RFP compared to control cells. 
Fixed and permeabilized cells were stained with rabbit polyclonal primary anti-Noggin primary 
antibody 1/200 dilution or isotype control normal rabbit IgG antibody. Donkey anti-rabbit IgG H&L 
(Alexa Fluor 488) was used as secondary antibody 1/2000 dilution. Cells were analyzed using BD 
FACS Aria. This Figure illustrates significantly increased Noggin protein expression in SaOS2 cells 
treated with CM (p=0.0001) (1 way ANOVA, Bonferroni) but not in the co-cultured group. Noggin 
expression was significantly decreased in the co-cultured PC3RFP with (p=0.0001). The % of Noggin 
positive cells from each group of cells was subtracted from its isotype to give the real % value. All data 
expressed as mean ± SEM of 3 independent experiments.    
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Figure 4.28 A: Analysis of Noggin protein expression in SaOS2 treated with PC3RFP-CM 
compared to control cells using BD FACS Aria. 
Fixed and permeabilized cells were stained with rabbit polyclonal primary anti-Noggin primary 
antibody 1/200 dilution or isotype control normal rabbit IgG antibody. Donkey anti-rabbit IgG H&L 
(Alexa Fluor 488) was used as secondary antibody 1/2000 dilution. Cells were analyzed using BD 
FACS Aria. Panels (1, 3 and 5) show control normal rabbit IgG antibody Isotype 1/200 dilution in 
control PC3RFP, control SaOS2 and control SaOS2 treated with PC3RFP-CM. Panels (2, 4 and 6) 
shows Noggin protein expression in control PC3RFP, control SaOS2 and control SaOS2 treated with 
PC3RFP-CM. All data expressed as mean ± SEM of 3 independent experiments.    
 
 
 
 
 
A 
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Figure 4.28 B: Analysis of Noggin protein expression in co-culture SaOS2 cells using FACS 
Aria. 
Fixed and permeabilized cells were stained with rabbit polyclonal primary anti-Noggin primary 
antibody 1/200 dilution or isotype control normal rabbit IgG antibody. Donkey anti-rabbit IgG H&L 
(Alexa Fluor 488) was used as secondary antibody 1/2000 dilution. Cells were analyzed using BD 
FACS Aria. Panel (1) represents control normal rabbit IgG antibody Isotype 1/200 dilution in co-
cultured cells (SaOS2 and PC3RFP). Panel (2) represents Noggin protein expression in in co-cultured 
cells (SaOS2 and PC3RFP). All data expressed as mean ± SEM of 3 independent experiments.  
4.3.6 Detection of Noggin protein in osteoblasts in co-culture and in 
osteoblasts treated with PC3RFP-CM by using western blot 
Polyclonal rabbit anti-Noggin was use as primary antibody and donkey anti-rabbit IgG 
as secondary antibody to detect Noggin in co-cultured SaOS2, SaOS2 treated with 
PC3RFP-CM, in SaOS2 cells as control in standard media, co-cultured PC3RFP and in 
control PC3RFP by using western blot. Protein was collected from cells grown 
individually and from co-cultured cells after sorting the cells with BD FACS Aria. 
Recombinant Noggin was used as positive control. SaOS2 cells treated with PC3RFP-
CM were found to produce more Noggin protein than control cells or cells in co-culture. 
On the other hand, PC3RFP cells produced less Noggin protein after being co-cultured 
with SaOS2 cells as seen in Figure (4.29), which shows Noggin expression in SaOS2 
control, SaOS2 treated with PC3RFP-CM, co-cultured SaOS2, co-cultured PC3RFP, 
and control PC3RFP as indicated. The second line shows the expression of β-actin 
house keeping protein production in all of these cells is also shown as a loading 
control.  
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Figure 4.29 Protein Noggin expression in PC3RFP, co-cultured PC3RFP, SaOS2 treated with 
PC3RFP-CM and co-cultured by western blot. 
This Figure illustrates the differences in Noggin protein levels in SaOS2 and PC3RFP cells seeded in 
standard media as control compared to levels after being in co-culture and in SaOS2 cells treated with 
PC3RFP-CM. These were compared to recombinant Noggin as positive control. Loading of protein 
was confirmed by using β-actin expression. Mwt of Noggin is 26KD and Mwt of β-actin is 42KD.  
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4.4 Discussion 
4.4.1 The expression of the TGF-β superfamily in individual prostate cancer 
and osteoblastic cell populations and in cultures where these cells are in 
indirect (i.e.via CM) or in direct contact in a co-culture model 
The communication between prostate cancer cells and cells within the bone 
microenvironment is thought to play a important role in secondary tumour formation 
and progression as tumour cells need to communicate with local microenvironment 
physically in order to adhere, invade, survive and proliferate in the metastatic site 
(Bhattacharyya and Stern 2003). 
Co-culturing prostate cancer cells and bone cells is one method for studying the 
interaction between these cells. In order to investigate the ability of PC3RFP to 
attach to/grow with bone cells, images were taken after seeding PC3RFP on 
confluent osteoblast cells (SaOS2/or MG63). PC3RFP was found to form colonies on 
or with both osteoblast cell types. In this chapter the expression of 43 members of 
the TGF-β superfamily genes were studied in both prostate cancer (PC3RFP) cells 
and osteosarcoma (SaOS2, MG63) cells. When grown separately, most of these 
genes were expressed at the same level in both prostate cancer and osteoblast cells 
with the following exceptions: BMPs 3, 4 and 6, Noggin, endoglin (ENG), Growth 
differentiation Factor 1 (GDF1;LASS1), inhibin beta A (INHBA), inhibin beta B 
(INHBB), TGF-β1 and TGF-β2. PC3-RFP was found to express BMP3, BMP6 and 
and the BMP antagonist Noggin at higher levels than osteoblast cells. Similar 
findings were reported by Masuda and Hamdy, who showed the presence of BMPs in 
prostate cancer, predominately BMP6 (Hamdy et al. 1997; Masuda et al. 2003). A 
model was developed in this study where prostate cancer cell (PC3RFP) were co-
cultured with either SaOS2 a mature osteoblast like sarcoma cell line or with MG63 
an immature osteoblastic cell type able to differentiate in culture. Once more, the 
expression of 43 members of the TGF-β superfamily genes were analysed and 
expression compared between these cells grown alone and when cell were grown 
together. The levels of expression of these genes were changed when cells become 
in direct contact with each other in the co-culture model. As mentioned previously, 
the purity of the cells used after sorting was around 95%. There was a possibility that 
contaminating SaOS2 cells could ‘piggy-back’ on top of PC3RFP and visa versa 
accounting for this 5% contamination. However, the relative expression of Noggin in 
co-cultured cells was 88.3 times higher than that measured in control SaOS2 cells. 
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This is a substantial increase and would have required much higher levels of 
contamination with PC3RFP cells than 5%. In absolute terms, the levels of Noggin 
expression were higher in the co-cultured SaOS2 cells than in control PC3RFP or co-
cultured PC3RFP making it extremely unlikely that the observed increase in Noggin 
expression in co-cultured SaOS2 cells was a result of contaminating PC3RFP cells. 
Our results were similar to a study done by Wang et al investigated the molecular 
mechanisms of prostate cancer bone metastases by creating two models bi-
compartmental system where prostate cancer cell (PC3) and bone marrow stromal 
cells (BMSC) isolated from the calvaria of neonatal mice share the same culturing 
media but without direct contact and heterotypic contact system gene expression 
profiles were then analysed and compared between these groups. His results 
revealed that certain genes were modified only by direct cells contact including 
collagen III, IV,X,XII, integrin α1, α2, MMP-2, MMP-9, uPA, biglycan, osteopontin and 
raf-1 in PC3, and collagen VIII, IX, BMP6, TGFβ1, Smad6 and Twist in BMSC cells. 
Other genes were modified only by soluble factors (Wang et al. 2006). This was also 
suggested by another study investigating the effect of PC3 on the bone marrow 
hMSCs, which indicated that bone metastatic PC3 cells could regulate bone 
remodelling by altering the expression profile and differentiation ability of hMSCs 
(Fritz et al. 2011). In this study, the expression of Noggin, BMP6 and BMP3 were all 
changed to be expressed at higher levels in osteoblast (SaOS2 and MG63) when 
they were co-cultured with PC3RFP cells. This study focused on Noggin expression 
since Noggin was expressed at moderate levels by prostate cancer cells compared 
to low levels in osteoblasts grown alone but expression was dramatically induced in 
the latter when co-cultured with PC3-RFP cells. This finding was confirmed by single 
assay gene analysis investigating expression of Noggin in osteoblast cells in both 
mRNA and reflected in Noggin protein level present in cells.  
4.4.2 Effect of prostate cancer cells on Noggin expression by osteoblasts 
Recently high level of interest has focused on Noggin as bone metastasis promoter 
(Virk et al. 2011). It is well known from previous studies that bone metastasis 
associated with prostate cancer was characterized by osteoblastic lesions (Keller and 
Brown 2004). However, many studies showed that prostate cancer related bone 
metastasis could be a mixture of both osteoblastic and osteolytic lesions with 
unknown mechanisms or impact on tumour growth/survival (Logothetis and Lin 2005; 
Secondini et al. 2011). To date, studies of how Noggin stimulates such phenotype 
have commonly focussed on osteolytic lesions in prostate cancer ( Secondini et al. 
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2011). A study done by Haudenschild reported that prostate cancer cell LNCaP 
express both Noggin and BMP6 (Haudenschild et al. 2004). The same finding was 
reported by Laurila, who studied the expression of Noggin in normal prostate tissue 
biopsies and in prostate cancer tissue samples confirming the expression of Noggin 
in prostate cancer cells grown alone (Laurila et al. 2013). In this study, we aimed to 
investigate the effect of prostate cancer cells on osteoblast cells either by direct 
contact or by treating the cells with conditioned media collected over PC3RFP. The 
use of conditioned media in this study tested the hypothesis that inductive signals 
regulating Noggin in osteoblasts were soluble. Many studies have assessed the 
composition of conditioned media and found it to be a rich source of potential 
signalling molecules, protein and biomarkers (Xue et al. 2008; Dowling and Clynes 
2011). The ability of prostate cancer cells (PC3RFP) to produce Noggin and secrete 
it into the media, was tested by measuring Noggin concentration in PC3RFP-CM by 
ELISA. A detectable and potentially biologically active concentration of Noggin 
protein was found in the PC3-RFP conditioned media. The expression of mRNA 
Noggin was significantly increased in co-cultured osteoblasts (SaOS2) and in SaOS2 
cells treated with PC3RFP-CM compared to control SaOS2 cells, while the increase 
in Noggin expression in MG63 cells were less and not significant. These results, 
obtained from qPCR, were reflected by flow cytometry and immunofluorescence, 
which detect increased production of Noggin protein in SaOS2 cells associated with 
PC3-RFP cells and more prominently in SaOS2 treated with PC3RFP-CM. The clear 
effect of CM may be due to the large number of cells that were used in generating 10 
ml of conditioned media, around 100,000cells/cm2 in T75 flask. This large number of 
cells would contribute higher levels of potential mediators regulating cellular 
behaviour and the expression of Noggin in SaOS2 cells than would be available in 
the co-culture model, where PC3RFP were seeded in lower numbers: 5000cell/cm2 in 
the T75 flask with SaOS2 cells. These findings do suggest that at least some of the 
induction of Noggin in SaOS2 cells was mediated by soluble factors derived from 
PC3-RFP cultures. Although, western blot was conducted several times on co-
cultured and conditioned media treated samples we were able to detect increased 
production of Noggin protein in SaOS2 treated with PC3RFP-CM group only once. 
This was probably due to inadequate protein concentration in the remaining samples 
where Noggin levels were below or at the limit of detection of the Western blot 
analyses.  
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There were no significant differences in the expression of Noggin at the mRNA level 
between control PC3RFP grown alone and those co-cultured with SaOS2 cells. 
However, there were significant decreases in Noggin protein present when the cells 
came into direct contact with SaOS2, seen by flow cytometry and western blot. As 
the regulation of protein production can occur at many different levels, there can be a 
weak or no correlation between mRNA and protein levels (Tian et al. 2004). The 
changes in protein expression in PC3RFP after co-culture may be linked to the 
proposal that prostate cancer cells have osteomimetic properties making them more 
osteoblast–like cells and allowing them to metastasis, adhere, survive and grow in 
bone (Koeneman et al. 1999). From our results and other studies BMP6 and Noggin 
were over expressed in prostate cancer cells (Haudenschild, Palmer et al. 2004). 
BMP6 is associated with the progression of prostate cancer (Dai et al. 2005; Darby et 
al. 2008; Yuen et al. 2008). Many studies have found that BMP6 is upregulated in 
prostate cancer compared to nodular hyperplasia and with low-grade prostate cancer 
(Barnes et al. 1995; Hamdy et al. 1997). Noggin has been shown to modify BMP 
signalling in prostate cancer and is upregulated by increased BMP signalling 
(Sutherland et al. 2004). These findings suggest that the activities of BMP6 and 
Noggin ate inter-regulated by this negative feed back loop (Haudenschild et al. 2004; 
Feeley et al. 2006) where BMP induces Noggin gene expression by activating 
signalling cascades involving Smad-1, Smad-5 and Smad-8 as well as the 
transcription factor Osterix (Ishida et al. 2000; Nakashima et al. 2002) and secreted 
Noggin causes an inhibition of BMP action (Wu et al. 2003). It may be that the 
balance between BMP and Noggin is critical in controlling the balance between bone 
formation/lysis in tumour induced bone disease (Simonet et al. 1997).  
The Wnt and BMP pathways were also shown to interact in prostate cancer bone 
metastasis (Schwaninger et al. 2007). A study done by Dai showed that treating 
MC3T3 cells with CM collected from DKK1 pre-treated prostate cancer cell line 
results in blocking osteoblast differentiation. This was a result of inhibiting both Wnt 
and BMP activity indicating that BMP activity depends on Wnt. Whereas, treating 
MC3T3 cells with CM collected from Noggin pre-treated prostate cancer cell line 
results in loss of BMP activity only. There was no affect on Wnt indicating that Wnt 
activity does not dependent on BMP activity. (Dai et al. 2008).  
There are other factors that may affect Noggin expression either by enhancing or 
repressing its expression. For example, both Wnt and Sonic Hedgehog (SHH) 
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stimulate Noggin expression (Hirsinger et al. 1997). FGF18 was found to repress 
Noggin gene expression and consequently facilitate BMP signalling, which in turn 
stimulated osteoblast differentiation (Reinhold et al. 2004). Moreover, another study 
done by Fakhry et al revealed that FGF2 and FGF9 induce the expression of BMP2 
and TGF-β1 genes in osteoblast while they inhibited Noggin expression thus 
amplifying BMP effect on osteoblast activity (Fakhry et al. 2005).  
The presence of Noggin either induced in osteoblasts by interactions with prostate 
cancer cells or produced directly by the latter would tend to suppress osteoblast 
differentiation in osteoblastic cell lines. Reduced differentiation would be likely to 
produce conditions that would favour proliferation. This may account for the effects of 
PC3-RFP CM on proliferation of SaOS2 cells presented in Chapter 3, where 
differentiation was suppressed and proliferation increased. 
In conclusion the data tends to support the hypothesis posed in the aims section that 
prostate cancer cells alter the expression of TGF-β family genes in osteoblast cells 
thus affecting their proliferation and differentiation.  
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Figure 4.30 diagram summarizing gene expression pattern in prostate cancer cells and 
osteoblast cells during different experimental condition compared to control cells. 
(A) PC3RFP and SaOS2 cells seeded individually in standard DMEM 2% media (Control) (B) Noggin 
expression was increased in SaOS2 treated with PC3RFP-CM (C) Noggin, BMP3 and BMP6 
expressions were increased in co-cultured SaOS2 cells while Noggin expression was decreased in co-
cultured PC3RFP cells. This Figure shows that BMP secreted by tumour cells promote organ-specific 
metastasis to bone stimulus the bone microenvironment through paracrine signalling. 
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Chapter 5 Noggin knockdown in PC3RFP and the effect of 
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5.1 Introduction 
Metastasis requires the concerted effects of several biological processes in order to 
enable tumour cells to leave from primary site survive in the circulation and seed and 
colonize a specific organ. Some of these processes depend upon the tumour 
characteristics and primary site, while others are supplied by the metastatic niche 
(Tarragona et al. 2012). This phenomenon has highlighted the importance of 
communication signals that occur between tumour cells and site of metastasis 
(Morales et al. 2011). The interactions between TGF-β and BMP signalling pathways 
in tumour and non-tumour populations are potentially part of these interactions of 
biological significance. It has been suggested that disturbances in these signalling 
pathways are vital to tumourigenesis and tumour progression in cancer cell-
dependent and independent manner (Massagué and Gomis 2006). Among the 
different factors that could control the TGF-β/BMP signalling pathway and its 
contribution, we focused on Noggin, since, it has been identified as an important 
player in bone metastasis given its action on bone remodelling processes, as well as 
in defining the stroma capacity to maintain cancer stem cells and their niche (Tang et 
al. 2007; Mani et al. 2008).  The Noggin gene resides within a single exon and 
encodes a polypeptide with a expected molecular weight of 22KDa, however it is 
secreted as homodimeric glycoprotein with molecular weight of 64KDa (Kavsak et al. 
2000). Noggin is one of the mediators involved in Spemann organizer activity during 
embryo development during dorsalization and the formation of neural tissue from 
ectoderm. However, the expression and function of Noggin is well known and not 
limited to the brain and Spemann organizer (Valenzuela et al. 1995). Although, 
Noggin expression in osteoblasts is limited, exposing the cells to exogenous BMP2, 4 
or 6, can induce its production suggesting that this may be a protective mechanism to 
prevent excessive exposure of skeletal cells to BMPs (Gazzerro et al. 1998). In 
general, Noggin inhibits the effect of BMPs in both differentiated and undifferentiated 
cells of osteoblastic lineage. Thus addition of Noggin to osteoblasts in culture, blocks 
the stimulatory effect of BMPs on collagen, non collagen protein synthesis and 
alkaline phosphatase activity (Gazzerro et al. 1998). Osteoblasts produce and 
release the receptor activator of nuclear factor-kB (NFkB) ligand (RANKL), which 
binds to its receptor on osteoclast precursors causing them to become mature 
osteoclast cells. Osteoprotegerin (OPG) is also secreted by osteoblasts and 
modulates RANKL activity as a decoy receptor. It is clear that the net rate of bone 
growth/loss is a product of the activities of signalling molecules, their antagonists, 
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receptors and decoy receptors. BMPs stimulate bone formation by shifting the 
equilibrium between OPG and RANKL toward the accumulation of OPG. However, 
Noggin might shift this equilibrium to the opposite direction favouring the 
accumulation of mature Osteoclast cells (Logothetis and Lin 2005). Noggin over 
expression in osteoblastic lineage cells reduces their differentiation; while Noggin 
down regulation in these cells increases the expression of osteogenic differentiation 
markers (Gazzerro et al. 2003; Wan et al. 2007). In addition, Noggin down regulation 
in vivo was found to enhance the regeneration of bone defects (Wan et al. 2007).  
In this Chapter, several trials were done to establish PC3RFP knockdown Noggin 
(PC3RFP-KD) cells in order to determine the effect of tumour derived Noggin on 
osteoblast (SaOS2) proliferation. Growth curves were done using conditioned media 
collected from PC3-KD and from cells transduced to express a non-Noggin targeting 
shRNA (PC3-mock cells). These growth curves were compared with control medium 
and with cultures challenged with recombinant Noggin. 
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Aim 
The aim of this study was to evaluate the effect of conditioned media collected from 
PC3-KD cells on the proliferation of osteoblast (SaOS2) cells compared to 
conditioned media collected from PC3-mock cells and to determine the effect of 
exogenous recombinant Noggin on the growth rate of osteoblast cells.  
Hypothesis 
Noggin a BMP antagonist made by prostate cancer cells that plays an important role 
in osteoblast proliferation.  
Objective 
1- Establishment of Noggin knockdown and sham/mock knock down PC3RFP cells 
using shRNA lentvirus. 
2- Generate SaOS2 growth curves using conditioned media collected over PC3-KD 
cells and compare these to SaOS2 growth curve using condition media collected 
over Mock cells. 
3- Generate SaOS2 growth curves using exogenous recombinant Noggin and 
compare these to the growth of SaOS2 cells grown in regular DMEM 2% FBS media.  
 
 !
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5.2 Material and method 
5.2.1 Materials and Disposable Equipment 
Item Supplier 
Noggin shRNA (h) Lentiviral Santa-Cruz SC-42138-V 
Polybrene  Santa-Cruz SC-134220 
Puromycin Santa-Cruz SC-108071-A 
Recombinant human Noggin R&D systems 
 
5.2.2 Knockdown Noggin in PC3RFP using Noggin short hairpin RNA (shRNA) 
Lentiviral 
The expression of the Noggin gene was partially blocked in PC3RFP cells using 
short hairpin RNA (shRNA). Lentiviral vectors were used to infect cells. Vectors 
contained shRNA targeting sequences for the Noggin transcript or a non-targeting 
sequence to create both Noggin knockdown (PC3RFP-KD) and a negative control 
(PC3RFP-Mock) respectively. The stability of the transfected PC3RFP produced was 
derived by selection with Puromycin. Polybrene was used to increase the cell 
sensitivity to the virus. Polybrene and Puromycin killing curve were conducted before 
PC3RFP was transfected with shRNA virus.  
 Polybrene killing curve 5.2.2.1
Polybrene (Santa-Cruz SC-134220) was used to increase the efficiency of infection 
of cells with retrovirus in cell culture. The lyophilised powder was re-suspended in 
1ml PBS making a stock concentration of 25mg/ml.  
Cells were harvested from T75 flask and counted. The same cell density that was 
used in normal growth curve was used. Cells were seeded in 3x24 well plates and 
were fed normally with DMEM 10% FBS. After cultures reached 70% confluence, 
around day6, cells were washed with PBS and the media were changed with DMEM 
10% FBS containing different Polybrene concentrations (1µg/ml, 2.5µg/ml, 5µg/ml, 
7µg/ml and 10µg/ml). Cells viability was assessed by counting the cells using a 
Coulter counter and visually by phase contrast microscopy on day 2, day4 and day6. 
Cells in the first plate were counted after 48h for monitoring the growth. While, the 
media on the remaining 2 plates were removed and replaced with freshly made 
Polybrene media.  
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 Puromycin killing curve 5.2.2.2
Puromycin (Santa-Cruz SC-108071A) is used in cell biology as selective agent in cell 
culture systems. It is toxic but cells infected with either lentiviral vector used would 
become resistance to puromycin. The recommended dose as a selection agent in 
cell cultures is within a range of 1-10 µg/ml, although it can be toxic to some cells at 
concentrations as low as 1 µg/ml. It acts quickly and can kill up to 99% of 
nonresistant cells within 2 days. The purpose of the experiment was to test different 
puromycin concentrations on PC3-RFP to select the best concentration to use in the 
knockdown experiment. The lyophilised powder was re-suspended in 1ml PBS 
making a stock concentration of 10mg/ml. Cells were harvested from T75 flasks and 
counted. The same cell density that was used in the normal growth curves was used. 
Cells were seeded in 3x24 well plates and were fed normally with DMEM 10% FBS. 
After cultures reached 70% confluence, around day6, the cells were washed with 
PBS and the media were changed with DMEM 10% FBS containing different 
Puromycin concentrations (1µg/ml, 2.5µg/ml, 5µg/ml, 7µg/ml and 10µg/ml). The cells 
viability was assessed by counting the cells using Coulter counter and visually using 
phase contrast microscopy on day 2, day 4 and day 6. Cells in the first plate were 
counted after 48h for monitoring the growth. While, the media on the remaining 2 
plates were removed and replaced with freshly made Puromycin media.  
 Lentiviral infection/transduction of PC3RFP 5.2.2.3
PC3RFP were seeded in 48 well plate in a density of around 2500cell/well. After 72h, 
cells were exposed to the virus supernatant, at multiplicity of infection (MOI) of 20 in 
the presence of Polybrene (5µg/ml). Cells were incubated for 18h then cells were 
washed with normal media and the media was replaced with complete media of 
DMEM 10% FBS. Cells were allowed to grow for 72h then the media were replaced 
with DMEM 10% FBS containing (1µg/ml) Puromycin. Media were changed every 
72h with freshly prepared Puromycin containing media until cells reached confluent. 
RNA and protein were extracted from part of the cells for the assessment of Noggin 
knock down in PC3RFP cells remaining cells were sub-cultured and continued to 
grow. 
5.2.3 Detecting the presence of Noggin gene in PC3RFP-KD by QPCR 
The stability of Noggin knockdown in PC3RFP cells was measured using Taqman 
single gene assay of Noggin. RNA was extracted from PC3RFP at different time point 
after viral transduction and cDNA were synthesized as described previously in chapter 
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2 section (2.3.5). Noggin expression was measured relative to the expression of a 
housekeeping gene GAPDH as described earlier in Chapter 2 section (2.3.6).  
5.2.4 Detecting the presence of Noggin protein in knockdown PC3RFP by 
western blot 
On the protein level the stability of Noggin knockdown in PC3RFP cells was detected 
by western blot. Protein was extracted and quantified from 80% confluent PC3RFP 
cells at different time points after viral infection as described in Chapter 2 section 
(2.4.1). 30 µg of protein samples were separated on 12% SDS-PAGE, blotted on 
PVDF membranes and probed with anti-Noggin and anti-GAPDH as described in 
Chapter 2 section (2.4.2). Noggin band intensity was measured by densitometry (Gel 
Documentation system, Bio-Rad).   
5.2.5 Detecting the presence of Noggin protein in conditioned media collected 
over knockdown PC3RFP by ELISA 
The amount of secreted Noggin protein present in media collected over knockdown 
cells at various time points was compared to the amount of protein found in control 
cells, measured by ELISA as described in Chapter 4 section 4.2.8.  
5.2.6 Collecting conditioned media from PC3-KD and PC3-Mock cells 
PC3-KD and PC3-Mock cells were seeded as described in 3.2.4. Conditioned media 
were then collected over both cell strains as described in 3.2.4 for the use in further 
experiments. 
5.2.7 Analysing the effects of PC3-KD Condition media on the proliferation of 
osteoblast (SaOS2) cells 
SaOS2 cells were seeded into 24 well plates at the same densities that were used in 
growth curves previously. Cells were challenged with 50% PC3-KD CM or with 50% 
PC3-Mock CM as control.  
Cells were counted in quadruplicate cultures every 48h until day 12 and the mean 
cell number was calculated for each day. The media was changed every 4 days 
during the growth curve in all groups.   
5.2.8 Selecting Recombinant Noggin concentrations 
Recombinant Noggin was prepared by adding 400µL of 0.1% BSA in PBS to the 
lyophilized powder to make a final concentration of 250µg/ml stock solution. SaOS2 
cells were seeded in the same cell density that was used in previous growth curves. 
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Cells were fed normally with DMEM 2% FBS containing recombinant Noggin with 
different concentrations (25ng/ml, 50ng/ml and 100ng/ml). Cells were counted in 
quadruplicate cultures after 6 days and after 10 days to determine the optimum 
concentration to be used in further experiments.  
5.2.9 Effect of recombinant Noggin on the proliferation of Osteoblast (SaOS2) 
cells 
SaOS2 cells were seeded into 24 well plates at the same densities that were used in 
previous growth curves. Cells were grown in DMEM 2% FBS containing 100ng/ml 
recombinant Noggin.  
Cells were counted in quadruplicate cultures every 48h until day 12 and the mean 
cell number was calculated for each day. The media was changed every 4 days 
during the growth curve in all groups.    
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5.3 Results 
5.3.1 Polybrene and Puromycin killing curve 
In order to knockdown Noggin in PC3RFP cells using shRNA lentiviral virus the 
sensitivity of the cells to Polybrene and Puromycin was tested. The viability of the 
cells was assessed by counting the cells or by their appearance under the 
microscope. The growth of PC3RFP was not affected by any of Polybrene 
concentrations Figure 5.1 (A). 5µg/ml of Polybrene was the recommended 
concentration to be used according to the kit data sheet and this was subsequently 
used. PC3RFP cells were highly sensitive to Puromycin. Cells were killed by the 
lowest concentration of Puromycin (1µg/ml) after the first 48h Figure 5.1 (B).  
 
Figure 5.1 Polybrene and Puromycin killing curve.  
(A) This illustrates the proliferative effect of Polybrene on the PC3RFP cells. Cells were not affected by 
any of the concentrations used (1, 2.5, 5, 7.5 and 10) µg/ml. (B) This illustrates the effect of different 
concentration of Puromycin (1, 2.5, 5, 7.5 and 10) µg/ml on PC3RFP cells. Cells were killed by the 
lowest concentration 1µg/ml after the first 48 h.  
5.3.2 Validation of Noggin knockdown in PC3RFP cells by QPCR 
Expression of the Noggin gene in PC3RFP-KD cells produced from our experiment 
was first measured by QPCR using Noggin single gene assay and this was 
compared to PC3RFP-Mock cells as controls. Noggin gene was 61% knockdown in 
PC3RFP-KD cells compared to mock cells. The stability of Noggin knockdown in cells 
was tested after growing the cells and passaging them twice. Cells were significantly 
knockdown P=0.0001 during the first passage of cells but not after this time (Figure 
5.2).  
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Figure 5.2 Noggin expression in PC3RFP-KD and PC3RFP-Mock. 
(A) This shows the reduction in Noggin expression in PC3RFP-KD cells by 61% with P value= 0.009, 
unpaired t test compared to mock cells. (B) Confirmation of the reduction of Noggin expression in 
PC3RFP-KD cells during the first passage of cells with P value= 0.0001, unpaired t test. (C) This 
shows that after passaging the cells twice cells, the expression of Noggin was similar in the KD and 
Mock cells. Relative expression was calculated after calculating dct and Δdc then Δdc was raised to 
the square root. All data are displayed with mean± SEM of 3 independent experiments. 
 
5.3.3 Validation of Noggin knockdown in PC3RFP cells by ELISA 
Noggin protein produced by PC3RFP-KD cells was measured by ELISA  compared 
to the amount of Noggin protein produced by PC3RFP-Mock cells. Conditioned 
media was collected from both PC3RFP-KD and PC3RFP-Mock cells at the same 
time point that the levels of expression of the Noggin gene were analysed by QPCR. 
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Results obtained from the ELISA assay matched the QPCR results. Noggin protein 
was reduced in KD cells compared to mock cells at the beginning of the experiment 
(P value = 0.01 and P value= 0.02 respectively) but not after passage 2 (Figure 5.3).  
 
Figure 5.3 Noggin protein levels in PC3RFP-KD and PC3RFP-mock conditioned media. 
This Figure illustrates the significant reduction in Noggin protein production in PC3RFP-KD cells at the 
beginning of the experiment (P value = 0.01 and P value= 0.02 respectively, unpaired t test) compared 
to mock cells. However, Noggin production was similar in both strains after passaging the cells twice. 
All data are displayed as means ± SEM of 3 independent experiments. 
5.3.4 Validation of Noggin knockdown in PC3RFP cells by western blot 
The expression of Noggin protein was assessed by western blot to validate the 
stability of the knockdown. Western blot results were with an agreement with 
previous results of QPCR and ELISA, indicating that Noggin protein expression was 
only reduced initially but not with further passaging to the cells (Figure 5.4). 
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Figure 5.4 Noggin protein production profile in PC3RFP-KD and PC3RFP-mock cells. 
The Figure shows western blot analyses of protein protein production by PC3RFP-KD and PC3RFP-
mock cells during different time point (A) illustrates reduction in Noggin expression in PC3RFP-KD 
cells compared to mock cells during the beginning of the experiment (B) PC3RFP-KD cells retained 
Noggin expression back to normal after passaging the cells several times. First lane shows Noggin 
expression and s lane shows GAPDH expression as house keeping protein.  
5.3.5 Validation of the stability of Noggin knockdown in PC3-KD Clone 14 cells 
by QPCR and western blot 
The failure to establish a stable PC3RFP Noggin knock down cell strain was a major 
set back to my work. Even after several attempts I was unable to generate strains 
that had stable reductions in Noggin production. A stable Noggin knock-down clone, 
PC3-KD (clone 14) and a mock transfected (random sequence) PC3-mock (clone 4) 
cells were thankfully given to us by Dr. Marco G. Cecchini from the Urology Research 
Laboratory University of Bern, Bern Switzerland. The stability of knockdown in PC3-
KD cells given by Dr. Marco G. Cecchini were tested by both QRT-PCR and western 
blot after passaging the cells for several times before using them in the next 
experiments. PC3-KD cells were stably knocked down for Noggin as shown by QRT-
PCR which revealed a significant reduction in Noggin gene expression in PC3-KD 
cells by 75% (P value= 0.004) compared to mock cells. These results were confirmed 
by western blot which showed a significant reduction in Noggin protein expression in 
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PC3-KD cells compared to mock cells with P value= 0.0001 Figure 5.5.  
 
Figure 5.5 Noggin expressions in PC3-KD and PC3-mock cells. 
(A) This illustrates 75% reduction in Noggin gene expression in PC3-KD cells compared to mock cells 
(P value= 0.004, unpaired t test). (B) illustrate a significant reduction in Noggin protein level in PC3-KD 
cells compared to mock cells (P value= 0.0001, unpaired t test). Relative expression was calculated 
after calculating dct and Δdc then Δdc was raised to the square root. All data are displayed with 
mean± SEM of 3 independent experiments 
5.3.6 Effects of PC3-KD Condition media on the proliferation of osteoblast 
(SaOS2) cells 
Conditioned media was collected from both PC3-KD and PC3-mock cells. The 
growth rates of Osteoblast (SaOS2) cells were studied when they were seeded in 
conditioned media from PC3-KD and in PC3-mock cells. Conditioned media collected 
from PC3-KD cells significantly decreased the proliferation of SaOS2 cells compared 
to PC3-mock cells with P value= 0.04 Figure 5.6.  
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Figure 5.6 Conditioned media from Noggin knockdown PC3-KD cells reduced the proliferation 
of SaOS2 cells. 
This Figure demonstrates that conditioned media from Noggin knockdown PC3 (PC3-KD) caused a 
significant reduction on the proliferation of SaOS2 cells compared to conditioned media collected from 
mock cells (PC3-Mock) (P value= 0.006, unpaired t test). All data are displayed with mean± SEM of 3 
independent experiments. 
5.3.7 Selecting Recombinant Noggin concentration 
Several recombinant Noggin concentrations (25ng/ml, 50ng/ml and 100ng/ml) were 
tested in order to select the best concentration to be used with osteoblast (SaOS2) 
cells. SaOS2 cells were seeded in media containing different concentrations of 
recombinant Noggin. Cells were counted at two time points, days 6 and 10. 100ng/ml 
was found to be the dose that stimulated the growth of SaOS2 cells the most Figure 
5.7. Therefore 100ng/ml of recombinant Noggin was used in further experiment.  
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Figure 5.7 The effect of various recombinant Noggin concentrations on the growth of SaOS2 
cells. 
Different recombinant Noggin concentrations (25ng/ml, 50ng/ml and 100ng/ml) were used to evaluate 
the optimum dose to be used in further experiment. Osteoblast (SaOS2) cells were counted at two 
time points day 6 and day 10. 100ng/ml of recombinant Noggin was found to be the optimum 
concentration and was used in further with SaOS2 cells. All data are displayed with mean± SEM of 3 
independent experiments. 
5.3.8 Effect of recombinant Noggin on the proliferation of Osteoblast (SaOS2) 
cells 
Recombinant Noggin was found to stimulate the growth of osteoblast (SaOS2) cells 
significantly compared to SaOS2 cells grown in regular DMEM 2%FBS media. This 
effect was similar to the effect of PC3RFP-CM on the proliferation of osteoblast cells 
Figure 5.8. 
 
Figure 5.8 Recombinant Noggin stimulates SaOS2 proliferation. 
This Figure showed that recombinant Noggin enhanced the proliferation of SaOS2 cells significantly 
(P value= 0.04, 1 way ANOVA). This increase in proliferation by Noggin was to the same extent 
caused by PC3RFP-CM. All data are displayed as means ± SEM of 3 independent experiments.   
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5.4 Discussion  
In this chapter I tried to establish my own knockdown Noggin PC3RFP cells. 
PC3RFP cells were initially knocked down for Noggin expression by infecting the 
cells with the Noggin shRNA Lentiviral. At the beginning of the experiment, a 61% 
reduction in Noggin mRNA levels was observed (determined by QPCR), and a 77% 
reduction in secreted Noggin as determined by ELISA was demonstrated but 
knockdown was not stable and after several passages, Noggin expression and 
protein production were the same in both KD and Mock strains but cells continued to 
be Puromycin resisted. This was unfortunate and appears to an effect of silencing of 
at least part of the transduced sequences by the infected cells. This may imply that 
suppression of Noggin by shRNA induces a growth disadvantage to these cells. More 
likely is the recognition of viral promotors by the cells led to silencing of sequences 
regulated.  
PC3-KD clone 14 and PC3-mock clone 4 cells were kindly provided by Dr. Marco G. 
Cecchini. The stability of Noggin knockdown in these cells after several passages 
was tested before they were used in further experiments. Cells were stably knocked 
down, with a 75% reduction in Noggin mRNA level this was measured by QRT-PCR 
and 70% reduction in Noggin protein level as measured by western blot. Conditioned 
media was collected from both PC3-KD and PC3-mock cells. The effect of these 
media on the proliferation of SaOS2 was assessed by conducting growth curves in 
which SaOS2 cells were grown in conditioned media collected over PC3-KD cells 
and was compared to their growth in PC3-Mock cell conditioned media. Conditioned 
media collected over PC3-KD cells caused a significant reduction in SaOS2 cells 
proliferation compared to those grown in PC3-Mock conditioned media. The addition 
of exogenous recombinant Noggin to the media resulted in significant increased 
SaOS2 proliferation. My result are in agreement with a study done by Hsu et al that 
reported Noggin overexpressing melanoma cells showed a growth advantage in 
response to subsequent BMP7 transduction both in vitro and in vivo, whereas, 
Noggin knockdown melanoma cells exhibited a growth inhibition. This result 
suggested that advanced melanoma cells might escape from BMP7-mediated 
autocrine growth inhibition through corresponding Noggin upregulation (Hsu et al. 
2008). Abnormal BMP7 expression during tumour progression is not specific to 
melanoma. Elevated levels of BMP7 have been associated with bone metastasis of 
prostate cancer (Masuda et al. 2003). The roles of BMP7 on growth regulation have 
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been studied widely in carcinogenesis since BMP7 has been shown to have 
divergent effect acting as both growth stimulation and inhibition (Pouliot et al. 2003; 
Baade Ro et al. 2004). BMP7 has been shown to either induce apoptosis or inhibit 
proliferation of androgen insensitive prostate cancer such as PC3 through causing 
cell cycle arrest in G0-G1 phase (Baade Ro et al. 2004; Miyazaki et al. 2004). In 
contrast, in androgen sensitive LNCaP prostate cancer cell line, BMP7 seems to 
promote cell survival suggesting that various cells type respond differently to BMP7 
as a result of cross talk with other signalling pathways (Ide et al. 1997; Yang et al. 
2005). Our results was also similar to a study done by Tarragona et al investigating 
the role of Noggin in breast cancer metastasis to bone which revealed that over 
expression of Noggin increased the growth rate of bone metastasis in orthotopic 
mouse model. In the same study it was found that silencing Noggin by using 
transfection with shRNA targeting Noggin gene caused growth rate reduction of bone 
metastases (Tarragona et al. 2012). These results suggested that Noggin modulates 
the initiation of breast cancer metastasis through DNA-binding protein inhibitor 2 
(ID2) and by altering RANKL levels thus linking the possibility of metastatic cells 
expressing high level of Noggin with chemotherapy resistance (Schramek et al. 
2010). Noggin has been linked not only to the ability of metastatic cells to 
successfully metastasize to the bone but also to the ability of self-renewal activity 
acquired by metastatic cells (Tarragona et al. 2012). This might explain the elevated 
levels of expression of Noggin mRNA during early phase of fracture healing in mice 
reported by Yoshimura et al in his study (Yoshimura et al. 2001).  In another study 
Canalis et al, the physiological function of Noggin in osteoblasts was determined by 
generating tissue specific null Noggin mice. This was achieved by mating Noggin 
conditional knock out mice, where the Noggin allele is flanked by loxP sequences, 
with mice expressing the Cre recombinase under the control of the Osteocalcin 
promoter (Oc-Cre). Their study showed that Noggin conditional null mice presented 
with a decreased in body weight, shorter femoral length and generalized osteopenia. 
Demonstrating that Noggin inactivation causes osteopenia suggests that excessive 
exposure to BMP may have detrimental effect in bone (Canalis et al. 2012). Wu et al 
found that overproduction of Noggin by infecting preosteoblastic U-33 cells with a 
retrovirus containing Noggin gene or in transgenic mice with more Noggin in their 
mature osteoblast resulted in osteoblast differentiation inhibition and reduced bone 
formation and net bone loss (Wu et al. 2003). In addition, another study investigated 
the effects of BMP2 on osteoblast apoptosis by using different osteoblast cells with 
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different degrees of maturation including human mesenchymal stem cells (MSCs) 
immature osteoblast (MG63 cells), mature normal human osteoblast (HNOst) and 
MG63 with silenced Noggin (shNog-MG63). Both MSCs and HNOst cells were 
treated with exogenous BMP2 while, shNOG-MG63 cells were used a model system 
with increased endogenous BMP signalling as result of Noggin silencing. Apoptosis 
was higher in mature osteoblast HNOst and in shNOG-MG63. This, suggested that 
BMP2 induced apoptosis depending on the maturation state of the cells and the 
effect was under the regulation of Noggin (Hyzy et al. 2012). The same finding was 
reported by other investigators indicating that increased apoptosis was associated 
with loss of function of Noggin transgenic mice during palatogenesis (He et al. 2010). 
Overexpression of Noggin in transgenic mice resulted in decreased apoptosis in 
eyelid epithelium (Sharov et al. 2003). This was not the case in oesophageal cancer 
cell line EC109 expressing high level of BMP6 and weak expression of SOST. 
Knockdown of Noggin in these cells resulted in enhanced non adherent cells growth 
(Yuen et al. 2012).     
In this chapter, our results supported the hypothesis that Noggin plays an important 
role in the regulation of osteoblast cell proliferation. This was shown by increased 
growth rate when SaOS2 cell were treated with recombinant Noggin. When SaOS2 
cells were treated with conditioned media collected over PC3-KD cells, the growth 
enhancement seen with CM from standard PC3RFP or PC3-Mock cells was 
reversed, suggesting that Noggin is one of the reasons behind increased proliferation 
of osteoblast cells when treated with conditioned media collected over PC3RFP cells 
seen in chapter 3.  
However, the amount of recombinant Noggin that were needed to a chive maximum 
growth in the SaOS2 cells were much higher than the amount of Noggin present in 
the conditioned medium collected over PC3RFP cells which, was only 0.293 ng/ml. 
Suggesting that the level of Noggin produced by the SaOS2 cells in response to PC3 
conditioned medium is much more important than Noggin produced by the PC3 
themselves.  
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6.1 Introduction 
Bone microenvironment is a rich source of survival and growth signalling molecules 
for bone cell populations potentially making it a favourable site for the metastasis of 
cancers, including prostate cancer (Kyle et al. 2003; Hess et al. 2006). Clinically 
significant metastases can occur years to decades after the removal of primary 
tumour after periods where patients appear to be disease free. This phenomenon is 
observed in clinical cases, but also has parallels in animal experimental studies 
(Shen et al. 2014). Both osteoclast and osteoblast cells that originate from 
hematopoietic and mesenchymal progenitors respectively play essential role in bone 
remodelling processes during which renewal of adult human skeleton takes place 
(Parfitt 1994; Manolagas and Jilka 1995). Skeletal homeostasis requires a 
continuous and regular supply of these cells therefore; any increase or decrease in 
the production or any change in the rate of apoptosis or proliferation of these cells 
may results in imbalance between bone resorption and formation. Such imbalances 
underlie bone disease including osteoporosis and tumour associated bone disease 
associated with metastases (Jilka et al. 1992; Hughes et al. 1996; Weinstein et al. 
1998). Once cancer reaches the bone it becomes difficult to treat, since bone 
provides a niche in which cancer cell may lay dormant and as such are resistant to 
chemotherapies that rely on targeting proliferating cells (Mundy 2002).  
A study done by Jung et al, reported that in murine model of prostate cancer most of 
the lesions were found in the hind limb regions (Jung et al. 2012). This suggests that 
these bones (tibias and femurs) may represent a consistent and relevant model for 
tumour growth in the skeleton. 
From the in vitro study in previous chapters, conditioned media collected over 
PC3RFP cells stimulated the growth rate in the osteoblastic cell line, SaOS2. In 
addition, the presence of prostate cancer with osteoblast cells (SaOS2) either directly 
or in direct through conditioned media caused an increase in Noggin expression in 
mRNA and protein level by osteoblast cells. Treating SaOS2 cells with recombinant 
Noggin had the same effect of PC3RFP-CM on SaOS2 proliferation while silencing 
Noggin in PC3 cells, suggested that the effects observed with CM on SaOS2 growth 
was at least in part mediated by Noggin. This suggests that prostate cancer derived 
Noggin contributes to the proliferation and differentiation of osteoblastic cells and, in 
vivo, have an effect on bone remodelling and tumour growth. To test this hypothesis, 
both PC3-mock and PC3-KD described in Chapter 5 were injected intracardiac, into 
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immunosuppressed BALB/c nude mice to determine their ability to metastases to the 
bone.  
Aim  
To determine the tumour take of PC3-Luc (Noggin knockdown/ mock control) 
prostate cancer cells in the BALB/c mice. 
Hypothesis  
Knockdown Noggin in PC3 cells reduces tumour metastases to bone. 
Objective  
1- Evaluate the effects of Noggin knock down compared to controls on:  
a) the total tumour frequency (bioluminescent in vivo monitoring and post-
mortem histology) 
b) the structure of bone in tumour bearing animals (micro CT) 
2- Evaluate the immunolocalisation of Noggin in bones/tumours post-mortem 
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6.2 Material and method 
6.2.1 Materials and Disposable Equipment 
Item Supplier 
DiD cell labeling solution Invitrogen 
EDTA Fisher Scientific 
SingleStain Boost IHC detection reagent (HPR, 
Rabbit) universal secondary antibody 
Cell signaling technology 
ImmPACT DAB peroxidase substrate Vector laboratories  
 
6.2.2 Cell lines 
The cell lines that were used in the in vivo study were the cells thankfully given by Dr. 
Marco G. Cecchini PC3-KD clone 14 and PC3-mock clone 4 cells. These cells were 
stably transfected with a luciferase gene Luc and were called PC3-KD and PC3-
mock.  
6.2.3 Mice 
The in vivo studies were performed using 20 male BALB/c nude 
immunocompromised mice aged 12 weeks. These animals were housed in a 
controlled environment with a 12 h light/dark cycle at 22°C. All procedures complied 
with the UK animals (scientific procedures) and were reviewed and approved by local 
Research Ethics Committee of the University of Sheffield (Sheffield, UK).  
6.2.4 In vivo imaging system (IVIS) 
Mice were injected with 30mg/kg D-luciferin (100µl subcutaneously) and were 
anesthetised using Isoflurane (3% isoflurane and oxygen 3% in an anaesthesia 
induction chamber) for 1-2 min. Mice were transferred to the Xenogen IVIS Lumina 
11 (California, USA) in vivo imaging system. Images were taken 5 min after luciferin 
injection with the instrument set to automatic exposure for luminescence detection in 
an area/dimension adjusted for mouse imaging. The duration of acquiring the images 
varied between 1-2 min at day 0 (injecting day) and few seconds as the tumours 
grew and signals became stronger. Mice were allowed to recover in an incubator set 
at 30°C and monitored during recovery from the anaesthetic in line with the Home 
Office Project License governing the work. The mice were monitored at 4,7,8,9 and 
10 weeks after injection of the cells.     
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6.2.5 PC3-mock and PC3-KD cells labelling with DiD solution 
One T75 flask from each PC3-mock and PC3-KD were harvested by trypsinization 
and were counted. Around 2,000,000 cells from each cell type were taken and were 
mixed with 14µL of DiD cell labelling solution. Cells were covered with foil and 
incubated for 20 min in the incubator. Cells were centrifuged for 3 min at 500xg in 
order to remove excess dye; as a result a blue pellet of cells was obtained. The pellet 
formed was washed twice with PBS. The cells were re-suspended in 2 ml of PBS.   
6.2.6 Intra-cardiac injection of PC3-mock and PC3-KD cells into 
immunosuppressed mice 
20 old BALB/c nude male mice aged 12 weeks were divided into two groups 10 mice 
in each group were Intracardiac injected with 100µL of either PC3-mock or PC3-KD 
cells suspension. Mice were monitored throughout the entire experiment duration; 
weights and in vivo images (IVIS) were taken at the beginning of the experiment and 
every week until the tumour develops Figure (6.1).  
 
Figure 6.1 Experimental design of the in vivo study. 
20 BALB/C nude male 12 weeks old mice were Intracardiac injected with approximately 0.1 million of 
either PC3-mock or PC3-KD cells. Mice were monitored during the entire duration of the experiment 
by using in vivo imaging system (IVIS). At week 12 the mice were sacrificed and trabecular bone were 
taken from both legs for further investigations.  
6.2.7 Harvesting trabecular bone from mice 
Trabecular of tibia bones of the mice were taken from both legs. Left leg was snap 
frozen by dipping in liquid nitrogen. Bone was transferred and stored at -80 °C for 
high-resolution micro-computed tomography (µCT) scanner. For 
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immunohistochemistry right leg were excised carefully and stored in 10% of neutral 
buffered formalin (NBF) for a minimum of three days and decalcified in EDTA for 14 
days. Bones were washed with distilled water to remove EDTA and through graded 
alcohols to remove water. Sections of tibial trabecular bones were taken every 3µM 
using a Leica microsystems microtome RM 2265. Sections were floated for 30 min in 
a 45°C water bath, transferred onto glass slides, dried for 30 min on a 45°C hotplate, 
incubated overnight at 37°C, and stored at 4°C until staining.  
6.2.8 High-resolution micro–computed tomography (µCT) 
High-resolution µCT scanner (model 1172; Skyscan, Belgium) is an imaging 
technique that uses x-rays to produce cross-sectional images of an object that can 
be restructured to produce a three-dimensional model. It allows for non-destructive 
quantitative analysis of the density, geometry and microarchitecture of bone 
(Bouxsein et al 2010). µCT scanner was used to scan tibia bones. Image captured 
every 0.35° through a 360° rotation with 4.1 pixel size. Scanned images were 
remodeled using Skyscan NRecon software (version 1.5.1.3, Skyscan, Belgium) and 
analysed using Skyscan CT analysis software (version 1.8.1.2, Skyscan, Belgium). 
Trabecular volume, trabecular thickness and trabecular number were evaluated in a 
standardized region of interest. Trabecular bone within this region was quantitated. 
6.2.9 Immunohistochemistry detection of Noggin in trabecular bone 
Bone sections were dipped twice in xylene for 5 min to remove wax and re-hydrated 
twice in absolute alcohol, 95% alcohol and 70% alcohol for 5 min and washed briefly 
in water. Sections were incubated in 3% hydrogen peroxide in water for 15 min to 
block the endogenous peroxidase activity. Sections were washed in water to stop the 
enzymatic reaction. Slides were incubated in PT module preheating machine at 
temperature ranges between 87°C-85°C for 10 min. Sections were kept in warm 
PBS. Bone sections were blocked with 5% normal donkey serum in 0.1% 
PBS/Tween for 1 hour at room temperature, and followed by an incubation overnight 
at 4°C with 100µl of anti-Noggin antibody (abcam, UK) (1:500 dilution in 
PBS/Tween). 100µl of normal rabbit IgG antibody (R&D systems, UK) was used as a 
negative control (1:500 dilution in PBS/Tween). Bone sections were washed 3 times 
with PBS/Tween at room temperature to remove unbound antibody, and incubated 
with 100µl of SingleStain Boost IHC detection reagent (HRP, Rabbit) secondary 
antibody, for 30 min at room temperature. The washing steps were repeated again 
with PBS/Tween as described above, and incubated with 300µl of Immpact DAB for 3 
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min at room temperature. Cells washed with water for 5 min, counter stained with 
haematoxyline for 20 s to stain nuclei, and washed again with water for 5 min. Bone 
sections were de-hydrated in 70% alcohol for 5 min, 95% alcohol, twice in absolute 
alcohol for 5 min each and dipped twice in xylene for 5 min to remove alcohol. Slides 
were mounted and covered using cover slip. 
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6.3 Result 
6.3.1 Effect of knockdown of Noggin in prostate cancer cells on bone and their 
ability to form tumours  
PC3-mock and PC3-KD cells were intra-cardiac injected into BALB/c nude male mice 
aged 12 weeks. The mice were monitored throughout the experiment period of 12 
weeks. Images were taken by in vivo imaging system (IVIS) during week 4, 7, 10 and 
11 as seen in Figure (6.2) and Table (6.2). On the 12th week the mice were culled 
and tibiae were carefully dissected. The overall tumour formation rate in animals 
injected with these cell strains that had been genetically altered and cloned was 
below that expected with the parental PC3 cell line in 12 week old mice (~30%, in 
long bones). At the early time points, up to week 7, there were more tumours, when 
all sites were taken in consideration, in the animals injected with the PC3-mock than 
with the PC3-KD cells. Only one mouse developed a lesion in the long bones and 
that was in the PC3-KD group. Trabecular of tibia bones were analysed using a high 
resolution µCT scanner (model 1172; Skyscan, Belgium) to determine the effect of 
injecting PC3-mock and PC3 knockdown Noggin on bone disease Figure (6.3) panel 
(A) shows bone µCT images of mice injected with PC3-mock cells as a control panel 
(B) shows bone µCT images of mice injected with PC3-Noggin knockdown cells. 
Figure (6.3) panel (C), (D) and (E) shows that there were no differences in the 
trabecular bone volume, trabecular number and trabecular thickness of mice injected 
with PC3-KD cells compared to mice injected with PC3-mock cells as a control 
respectively. 
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Figure 6.2 In vivo imaging of PC3 mock and PC3KD (Noggin) in cohorts of mice using 
bioluminescence detected using the IVIS  system.  
This figure shows images of two groups of mice: the first group was injected with PC3-mock (control) 
the second group was injected with PC3-KD. Mice in both groups developed tumours mainly in the 
jaw, right eye, paw and vertebra/hip only one mouse (m13) from the KD group developed a tumour in 
the right leg and was culled after weeks 10. Animals were assessed from the front and back and 
whole body mages were taken on week 4, 7, 10 and 11. 
Week 4 
Control 
Knockdown 
Week 7 
Control 
Knockdown 
1 2  9  10  11  12   17    18    19    20 
   Back   Front 
1 2   9   10   11   12   17   18    19    20 
 3    4    6    7    8    13    14    15    16     3     4      6      7     8    13    14    15     16  
1   9  10  11 12 17   18   19    20 1    9   10   11  12   17   18   19    20 
  3    4    6      7     8  13     14   15    16     3      4     6      7       8   13    14   15    16  
Week 10 
Control 
Knockdown 
Week 11 
Control 
Knockdown 
  1   9 10   11  12  17  19   20   1  9 10   11  12   17  19   20 
  3   4  6  7  8 13  14  15  16   3   4   6  7   8  13    14   15   16 
  1 9 10  11  12 17  19 20  1 9 10 11   12   17       19          20 
  3   4  6 7 8  14 15 16   3  4   6  7  8   14  15     16 
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Table 6.1 summaries IVIS images of mice in all groups. 
control wk 3 wk 4 wk 7 wk 10 wk 11 
m1 
 
Right shoulder Right shoulder 
  
m2 
 
Right eye paw 
and jaw culled   
m9 
   
jaw 
 
m10 
  
jaw jaw 
 
m11 
 
jaw 
 
jaw 
 
m12 
 
vertebra/hip vertebra/hip 
  
m17 
     
m18 
 
Right eye paw 
and jaw 
Right  eye paw 
jaw and vert. culled  
m19 
     
m20 
     
  
5/10 5/10 3/10 1/10 
knockdown 
     
m3 
     
m4 
 
Right eye paw 
and jaw jaw   
m5 Died (6.7.13)     
m6 
     
m7 
     
m8 
     
m13 
 
Right leg Right leg and vert 
Right leg 
and vert culled 
m14 
    
jaw 
m15 
     
m16 
     
  
2/10 2/10 1/10 1/10 
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Figure 6.3 Effect of knockdown Noggin in prostate cancer cell line on bone disease in 
trabecular tibia bone using BALB/C nude male mice aged 12 weeks. 
DiD labeled mock and knockdown Noggin PC3-KD cells were Intracardiac injected into BALB/c nude 
male mice aged 12 weeks. Mice were sacrificed after 12 weeks (24 weeks old) and tibia bone were 
dissected. Panels A and B show 3D µCT-reconstructed images of tibias in mice injected with mock 
cells (but no tumour present) and with Noggin-KD cells only one tumour was present, respectively. 
White colour shows the trabecular bone. Panel C, D and E shows show that there was no difference in 
the trabecular bone volume (BV/TV), trabecular number (Tr No) and trabecular thickness (Tr Th) 
between the two groups.  
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6.3.2 Noggin was expressed on the bone lining cells and bone surface in vivo 
in BALB/C nude male mice 
20 BALB/C nude male mice were intra-cardiac injected with either PC3-mock cells or 
PC3-Noggin knockdown both were DiD labeled. After 12 weeks mice were harvested 
but only one mouse in the knockdown group developed a tumour in the tibia. Tibia 
bones were dissected for immunohistochemistry. Several dilutions of anti-Noggin 
primary antibody were tested to minimize non-specific binding of the antibody Figure 
(6.4) panel A shows Noggin antibody with different dilution (1/175, 1/500 and 1/2500) 
panel B shows the corresponding isotype with the same dilution. 1/500 primary 
antibody dilution was used in all immunohistochemistry slides. Figure (6.5) panel (A) 
shows strong Noggin staining in osteoblasts in the bone marrow of control mice. 
Panel (B) shows weak Noggin staining in bone marrow of mice injected with PC3-KD 
cells. Panel (C) shows strong Noggin staining on the bone lining cells and bone 
surface where tumour came close to the endosteal bone of control mice. Panel (D) 
shows very weak Noggin staining on the bone lining cells and bone surface when 
tumour cells were located close to the endosteal bone surface of mice injected with 
PC3-KD cells. Panel (E) shows strong Noggin staining in within the tumour cells itself 
in control mice.  Panel (F) there was no Noggin staining presented in the tumour cells 
in mice injected with PC3-KD cells. 
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Figure 6.4 Immunohistochemistry optimization of Noggin protein in trabecular tibia bone. 
Bone sections were stained with rabbit polyclonal anti- Noggin primary antibody or isotype control, 
normal rabbit IgG antibody. Nuclei were counterstained with haematoxyline. Cells were examined 
under microscope with 20x objective. Panel (A) shows Noggin antibody with different dilution (1/175, 
1/500 and 1/2500) panel (B) shows the corresponding isotype with the same dilution.  
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Figure 6.5 Noggin was expressed on the bone lining cells and bone surface in vivo in BALB/C 
nude male mice. 
Illustrate Noggin distribution in bone section from two groups of mice injected with either PC3-mock or 
PC3-KD cells where arrow indicate dark brown staining of Noggin protein panel (A) shows strong 
Noggin staining in osteoblasts in bone marrow of control mice. Panel (B) shows weak Noggin staining 
in bone marrow of mice injected with PC3-KD cells. Panel (C) shows strong Noggin staining on the 
bone lining cells and bone surface when tumour cells came close to the bone of control mice. Panel 
(D) shows very weak Noggin staining on the bone lining cells and bone surface when tumour came 
close to the bone of mice injected with PC3-KD cells. Panel (E) shows strong Noggin staining within 
the tumour cells in control mice.  Panel (F) there was no Noggin staining presented in the tumour cells 
in mice injected with PC3-KD cells. 
 
  
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
152!!
6.4 Discussion  
Many difficulties have confronted the demonstration of bone homing in prostate 
cancer preclinical studies due to restriction in available cell lines and to technical 
problems in reproducing bone metastasis in vivo (Rucci and Angelucci 2014). Many 
prostate cancer cell lines that were used in experimental animals were genetically 
engineered by either overexpression or by deletion of specific genes prior to use 
(Kaplan-Lefko et al. 2003). These animal models partially demonstrate the 
progression of human disease and metastases to the bone. (Isaacs et al. 1986; 
Gingrich et al. 1996). In this study bone metastases was induced by introducing PC3-
mock cells as a control and Noggin knockdown PC3-KD cells into 
immunocompromised mice through intra-cardiac injection. Direct injection into the left 
cardiac ventricle has been shown to increase the incidence of bone metastases 
compared to intravenously injection into the tail (Arguello et al. 1988). However, the 
frequency of tumour development in the two groups throughout the entire duration of 
the experiment, which was 12 weeks, was below that expected. This difficulty in 
achieving adequate bone metastases in vivo models using tumour cells strains has 
been reported by others (Rucci and Angelucci 2014). This may be due to several 
factors including the long latency time in natural development of bone metastases 
and the phenotypic modification induced by in vitro culture of cancer cell lines/strains 
and their cloning, which may result in reduction in their tumourigenicity (Shevrin et al. 
1988; Nemeth et al. 1999; Rucci and Angelucci 2014). Recent studies in my group 
suggest that the frequency of tumour formation depends on numbers of metastasis 
initiating cells (Kang et al. 2003)  and it is possible that these were not included in the 
cells selected and cloned during the generation of PC-3Mock or KD cells. 
 In this study there was no difference in the trabecular bone volume (BV/TV), 
trabecular number (Tr No) and trabecular thickness (Tr Th) between the two groups. 
This is different from a study done by Secondini et al where she found that the bones 
of BALB/c nude male mice aged 7-8 weeks xenografted with Noggin silenced PC3 
cells were characterized by structural and histological modification: tibia in mice 
xenografted with Noggin knockdown PC3 had higher BV/TV ratio than those 
engrafted with mock clones. Moreover, these studies showed that in the xenograft 
model, silencing Noggin in cancer cells had a moderate impact on their proliferation 
in vivo initially they grow with similar rate compared to xenograft model with mock or 
control PC3 cells, but tumour growth slowed down in Noggin knockdown group at 
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later time points. Injecting the PC3 control and mock cells through intra-cardiac 
injection in mice caused systematic bone metastases mostly to the jaw limiting the 
duration of the experiment making it difficult to compare between control, mock group 
and knockdown group (Secondini et al. 2011). In a study done by Feeley et al it was 
reported that when PC3 control, PC3 mock and PC3 over expressing Noggin cells 
were injected directly into the tibias of SCID mice aged 8 weeks, PC3 control cells 
implanted into tibia formed osteolytic lesions as early as 2 weeks and completely 
destroyed the tibia after 8 weeks while, cells over expressing Noggin inhibited the 
expansion of this lesions (Feeley et al. 2006). In another study, Schwaninger et al 
studied the effect of Noggin on the osteoblast response in bone metastases by 
injecting osteoinductive prostate cancer cells (C4-2B) or the over expressing Noggin 
clone (C4-2B-Nog) into the tibia of SCID and BALB/c nude mice aged 7 weeks.  The 
tibia inoculated with C4-2B-Nog cells showed a significantly lower expression of the 
structural parameters of excesses of bone formation, such as high total bone area 
(TBA), trabecular bone area (TrBA) and content (TrBC) compared with tibia 
implanted with parental C4-2B or mock cells. He concluded that over expression of 
Noggin in Prostate cancer cells (C4-2B) cells caused an elimination of their 
osteoinductive activity (Schwaninger et al. 2007). However, a study done by Canalis 
reported that both male and female Noggin conditional null mice had decreased 
trabecular bone volume compared to control mice thus inactivation of Noggin in adult 
male and female mice caused osteopenia, indicating that Noggin is important not 
only in skeletal development but also in normal postnatal bone remodelling (Canalis 
et al. 2012). In addition Noggin was found to be an essential actor in providing breast 
metastatic cancer cells with bone colonization capabilities. Following Intra-cardiac 
injection of breast cancer bone metastatic cell line 1833 and these cells knocked-
down for Noggin into nude male BALB/c mice aged 8 weeks, Noggin knockdown 
cells had dramatically reduced the capacity to form bone metastases as well as 
reduced metastatic weight after the first week of injecting and continued throughout 
the entire experiment. On the other hand, forced over expressing Noggin in SKBr3 
cells, which normally express low level of Noggin and poorly colonize to bone led to a 
significant increase in the probability to develop bone metastases and an intense 
increase in the metastatic weight during the 9 weeks experiment. This suggests that 
Noggin provides cancer cells with the ability to home, seed and colonize the bone by 
increasing their self renewal function as well as through altering the bone 
microenvironment (Tarragona et al. 2012).   
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In this study histologic sections of tibial trabecular bones from both groups were 
taken after the 12th weeks. Immunohistochemistry using Noggin antibody was used 
to localize Noggin protein in both bone and tumour. Noggin protein represented by 
dark brown stain was found to be on the bone surface and bone lining cells when 
tumour came close to bone. Earlier studies revealed that Noggin was expressed 
mainly in the osteoblast, chondrocyte, mesenchymal and in macrophages cells 
(Warren et al. 2003; Wu et al. 2003). In addition other investigators has detected 
Noggin by using immunocytochemically techniques at fracture sites and where BMP 
induced formation is high (Nakase et al. 1994; Yoshimura et al. 2001).   
In conclusion Noggin was found to enhance the growth of osteoblast cells in vitro. 
This was determined by evaluating the effect of conditioned media from both 
knockdown and mock PC3 cells as well as the effect of supplementing the media 
with recombinant Noggin on the proliferation of osteoblast cells. However there were 
no differences between the two groups injected by either PC3-mock or PC3-KD cells 
in vivo. The low take rate in long bones compared to native PC3 cells that had not 
been genetically manipulated suggests that the experiment may have been 
compromised by factors associated with the cloning process. The association of 
Noggin staining with bone surfaces adjacent to tumour foci is an interesting and 
novel finding.   
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7.1 General Discussion 
Prostate cancer is one of the most common types of cancer in men worldwide and 
around 90% of patients with advanced prostate cancer develop bone metastases 
(Larson et al. 2014). Bone metastasis is a key event responsible for the morbidity in 
these patients since once the tumour reaches the bone (Özdemir et al. 2014), the 
disease is incurable. The formation of metastases is a multistep process. After local 
invasion of tumour cells in the primary site, metastases proceeds by migration of 
cancer cells through the surrounding extracellular matrix and intravasation into blood 
capillaries. Circulating cancer cells have to survive in the blood before they start to 
colonize and proliferate to the distal organ (Leber and Efferth 2009). In the case of 
prostate cancer bone in the most common single site of metastasis (Saitoh et al. 
1984). The bone microenvironment is a rich source of growth factors, cytokines, 
chemokines and signalling molecules, which potentially aid the survival and growth of 
tumour cells within the bone (Suva et al. 2011). It has been suggested that tumour 
cells interact with bone microenvironment by enhancing osteoblast and osteoclast 
activity which in turn stimulates the release of these growth factors from the bone 
matrix generating a so called “vicious cycle”. This is of great importance in tumour 
growth and progression. There are other reasons why the bone a special site for 
metastases: The blood sinusoids are thin walled and easily invaded and the 
environment also contains specialised ‘niches’ for stem cells (mesenchymal and 
hematopoietic) as well as a rich milieu of growth factors and cytokines and immune 
cells located within the bone marrow (Shiozawa et al. 2011; Chirgwin 2012). 
Disseminated tumour cells have been shown to hijack these niches on arrival in 
bone. The effect of these niches is complex and little understood but they may allow 
tumour cells to remain dormant within bone or induce the formation of micro-
metastases, which afterward progress to clinically detectable lesions (Shiozawa et al. 
2011; Chirgwin 2012). Thus further research is needed in order to acquire agents 
that prevent the development of bone metastases by either preventing tumour cell 
occupancy of niches in bone or by preventing tumour cells escape from dormancy.  
Though radical prostatectomy has a significant effect on survival up to 30% of 
patients may need other treatment in the form of androgen deprivation both by 
surgical or chemical castration and up to 15% in the form of radiotherapy for local 
recurrence and previously undetected metastatic disease (Bill-Axelson et al. 2014). 
This outcome for patients who present with treatable disease initially but who go on 
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to develop life threatening disease sometimes many years later is direct evidence 
that the disease can remain dormant for long periods. The problem with systemic 
treatments is that with time cancer cells become resistant to such therapy (Goktas 
and Crawford 1999). Therefore further research is needed to define the mechanisms 
that are involved in the initiation and progression of metastatic growth in order to help 
in the development of new therapeutic targets for the prevention and treating cancer 
metastases.  
The aim of this study was to investigate the interaction between the osteolytic 
prostate cancer cells (PC3RFP) and osteoblastic cells with different degrees of 
maturation (SaOS2 and MG63) either through direct (co-culture) or indirect contact 
(treating the cells with PCRFP-CM) and to determine how members of the TGF-β 
superfamily contributed to the modification of the bone microenvironment. This study 
will test the hypothesis that tumour derived TGF-β signalling is an important 
component of the signalling between prostate cancer and bone cells. 
This study started by determining general growth characteristics of all the cell lines 
used, since generating this type of information is an essential prerequisite before 
undertaking further experiments. In this study, the expression of 43 members of the 
TGF-β superfamily genes were studied in both prostate cancer (PC3RFP) cells and 
osteosarcoma (SaOS2, MG63) cells grown in isolation, in co-cultures where 
osteoblastic cells came to direct contact with PC3RFP and in experiment were these 
cells were treated with PC3RFP- conditioned medium (CM).  PC3RFP was found to 
express Noggin, which was detectible in conditioned media and also BMP3 at 
elevated levels compared to osteoblastic cells while SaOS2 was found to express 
TGF-β1, TGF-β2 and BMP4 at higher levels than prostate cancer cells. This 
expression pattern changed when these cells came into direct contact with each 
other, where SaOS2 cells expressed more Noggin, BMP3 and BMP6 than when 
these cells were grown alone. Noggin was the only gene in SAOS2 cells where 
expression was affected by treating cells with PC3RFP-CM. PC3RFP conditioned 
media (PC3RFP-CM) was found to enhance the proliferation of SaOS2 
especially when cells become close to confluence and decreased their early 
differentiation stage by decreasing alkaline phosphatase level but with 
increased level of mineralization. This diverse effect of conditioned media on the 
differentiation of osteoblasts cells were reported by other researchers and could be 
related to fundamental difference in the types of bone cells used or might be due to 
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different experimental conditions in each model system (Eaton and Coleman 2003). 
The effect of PC3RFP-CM on the rate of proliferation was only seen in SaOS2 cells 
and not in the MG63. This difference in osteoblast lineage cell responses to 
conditioned media collected over prostatic cancer cells did not appear to be due to 
differences in their native differentiation status, since differentiation of MG63 cells to 
more a osteoblastic phenotype did not alter responses to CM. The transforming 
growth factor beta superfamily which plays an important roles in early development, 
homeostasis is also involved in the pathogenesis of many disease including bone 
metastases. More over, this superfamily is essential in the differentiation of 
mesenchymal stem cells (MSCs) into osteoblasts (Maeda et al. 2004; Janssens et al. 
2005). Some of these factors are produced at higher levels by bone cells while others 
are expressed more highly by prostate cancer cells. For example TGF-β is abundant 
in bone matrix and contribute to osteoblastic bone formation (Wrana et al. 1988). 
TGF-β family members have been associated with tumour progression in many types 
of cancer including prostate cancer and breast cancer. Human prostate cancer 
including PC3 cells is characterized by high-affinity TGF-β receptors (Wilding et al. 
1989; Barrack 1997). A previous study showed that osteoblasts can regulate prostate 
cancer migration and invasion in vitro by producing several factors including TGF-β1, 
which contributes to the increase invasion capacity (Festuccia et al. 1999).  
TGF-β is present in bone matrix in an inactive form thus can be activated upon bone 
resorption through the osteolytic activity of osteoclasts (Oursler 1994; Janssens et al. 
2005). The activated TGF-β stimulates migration of bone mesenchymal stem cells 
(MSCs) to bone-resorptive surface where BMPs induce their differentiation toward 
osteoblast lineage (Tang et al. 2009). De Gorter et al reported that the effect of TGF-
β on BMP-induced osteoblast differentiation depended on timing thus during early 
differentiation stage recruited MSCs respond to both BMP and TGF-β signals that 
enhance the differentiation process. During later stages of differentiation the 
concentration of cytokines found in the bone microenvironment and the responses of 
the differentiated cells changes to a point whereTGF-β is likely to have an inhibitory 
effects on BMP induced signal transduction and osteoblast differentiation. It was 
found in the same study done by De Gorter et al that basal mineralization of hMSCs 
were enhanced through the short term stimulation of TGF-β and this could be 
blocked by Noggin, suggesting that TGF-β stimulates osteoblast differentiation 
induced by BMP produced by the cells themselves. This might explain the inhibitory 
effects of TGF-β that have been reported (de Gorter et al. 2011).  Furthermore, Runt-
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related transcription factor 2 (Runx2) and Osterix act via two important pathways, 
Wnt and BMP signalling, that are involved in the early step of differentiation, 
converting MSCs towards an osteo/chondroprogenitor and then toward an 
osteoblastic phenotype (Del Fattore et al. 2012). Deregulation of these two pathways 
has been associated in prostate cancer bone metastases. Both BMP2 and Runx2 
have overlapping and different effects to promote osteoblast differentiation 
(Ogasawara et al. 2004).  It was reported in a previous study that Runx2 were 
underexpressed in many osteosarcoma cell lines including SaOS2 cells compared to 
osteoblast-like reference cells and that SaOS2 cells express the osteoblast-specific 
MASN isoform of Runx2 which have the ability to stimulate osteocalcin, expression 
the gene product responsible for mineralization but not ALP (Harada et al 1999; 
Thomas et al 2004). 
The TGF-β superfamily including BMPs and their antagonists contribute to the 
pathogenesis of carcinomas at different stages. At an early stage of cancer TGF-β 
acts as tumour suppressor arresting the growth of many cell types, while, at later 
stages these growth factors contribute to cancer progression and tumour 
invasiveness. As tumours progress cancer cells tend to lose the tumour –suppressive 
response to TGF-β (Buijs et al. 2012) acquiring somatic mutations in components of 
the TGF-β-Smad signal transduction pathway allowing cancer cells to escape the 
TGF-β anti-proliferative response. TGF-β in these cells acts as an oncogenic/tumour 
progression factor by inducing their proliferation, angiogenesis, invasion and 
metastases (Seoane 2006). In tumours where TGF-β does not directly inhibit growth, 
tumour cells express high levels of TGF-β, which may be a result of induction of its 
own expression, creating a malignant autocrine positive feedback loop (Seoane 
2006). TGF-β also enhanced tumour progression by suppressing the anti-tumour 
immune response by inhibiting the proliferation and differentiation of immune cells, 
specifically T cells, in tumours that are resistant to the anti proliferative effect of this 
growth factor (Weinberg 2007).  
Mitotic dormancy is a key feature of tumour cells that take up residency in metastatic 
sites in bone (Willis RA 1934; Banys et al. 2012). This may be a survival mechanism 
that allows tumour cells to establish themselves in a new location before being 
activated to divide. The tumour cells that enter the premetastatic niche express 
surface ligands and receptors (integrins, cadherins and fibronectin), which facilitate 
interaction with an accommodating environment for migrating tumour cells (Kaplan et 
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al. 2005). The interaction between receptors in the bone marrow stroma such as 
urokinase receptor, vascular cell adhesion molecule-1, fibronectin and the ligands for 
the latter over-expressed on the tumour cells including β1, α4 β1 and α5 β1 integrin, 
cadherin-11 and CXCR4 facilitates the colonization of circulating cancer cells in the 
bone marrow (Mastro et al. 2003; Yoneda and Hiraga 2005). Growth factors such as 
TGF-βs and BMPs that are stored in the bone matrix are released during bone 
remodelling may aid cancer cell colonization of bone as well as enhancing their 
proliferation (Hauschka et al. 1986; Feeley et al. 2005).  
There are two general histological types of bone metastases classified as either 
osteolytic or osteoblastic but it is generally accepted that patients can have both 
osteolytic and osteoblastic components in their metastases (Coleman 1997; Mundy 
2002). It has been demonstrated that osteoblastic metastases occurring in prostate 
cancer also involve considerable osteolysis since blood and urinary samples from 
these patients contains high levels of bone resorption markers (Garnero et al. 2000). 
Studies showed that BMPs are involved in prostate carcinogenesis (Ide et al. 1997; 
Tamada et al. 2001; Ye et al. 2007). In a study done by Kim et al investigating the 
role of BMPs and their receptors and their correlation with the grade of prostate 
cancer showed that high grade prostate cancer cells lose BMP receptors and this 
also correlated with high frequency of prostate cancer metastases to bone (Kim et al. 
2000). It was reported by a previous study that TGF-β had a significant effects on 
PC3 adhesion to bone endothelial cells. Cooper et al showed that different BMPs 
have different effect on PC3 cell adhesion to bone marrow endothelium and 
specifically that BMP4 increased adhesion (Cooper et al. 2003). It is also reported 
that BMP2 aids the migration of prostate cancer cells through the activation of Akt 
and ERK, which in turn activate NF-kB thus activating β1 and β3 integrins (Lai et al. 
2008). A study done by Buijs et al suggested a cross talk between BMP7, BMP6 and 
TGF-β signalling regulated epithelial to mesenchymal transition (EMT) in tumour cells 
and facilitated their migration into new microenvironments. TGF-β1 and BMP6 where 
found to induce EMT while BMP7 treatment significantly inhibited EMT, inducing the 
reverse process MET and inhibiting bone metastases by breast and prostate cancer 
cells in vivo (Buijs et al. 2007). This results was supported by further investigation 
indicating that BMP7 and its receptor BMPR2 are important in suppressing the 
growth of prostate cancer cells in bone and induce senescence in these cells 
however this effect was reversible upon withdrawal of BMP7. This results suggest 
that BMP7 and its receptor plays essential role in dormancy and recurrent of the 
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disease (Kobayashi et al. 2011). This may be related to tumour cell interaction with 
the metastatic niche: EMT is required to enter the niche in a dormant state and MET 
required to activate proliferation via altered interactions in the niche or exit from this 
structure. 
A recent study done by Naber et al concluded that BMP-7 inhibit bone metastases in 
both breast and prostate cancer and it is able to inhibit the tumour-promoting effect of 
TGF- β through either Smad and non-Smad mechanisms depending on the type of 
cell. He showed that the inhibitory effect of BMP-7 on breast cancer invasion can be 
explained by the inhibition of TGF- β which induced the expression of integrin β3 and 
enhanced EMT (Naber et al. 2012). However, Noggin inhibits BMP-7 but have no 
effect on BMP-6 (Song et al. 2010).  It is now clear that the metastatic process in 
epithelial cancers requires both EMT and MET to be sequentially induced: EMT is 
needed to allow tumour cells to escape the primary tumour and MET is required to 
establish growing lesions in the metastatic site (Chaffer et al. 2007; Polyak and 
Weinberg 2009; van der Pluijm 2011). In order for cancer cell to leave its primary site 
cancer cells must shed many of their epithelial characteristics and acquire a 
mesenchymal migratory phenotype thus increasing their motility and invasiveness 
(Thiery 2002; Kalluri and Weinberg 2009). During cancer progression the expression 
of E-cadherin which are normally expressed by epithelial cells, are either be 
functionally inactive or silenced by many suppressors such as Snail1 and Snail2 
(Thiery 2002). Thus cancer cells switches from E-cadherin to N-cadherin and initiates 
EMT (Chaffer et al. 2007; Kalluri and Weinberg 2009). There are many pathways that 
are involved in the regulation of EMT processes including TGF-β, Notch, Wnt and 
IGF many of these factors are involved in bone metastases. In addition there are 
other factors that are also involved including cell-cell adhesion and others such as 
hypoxia and the effects microRNAs (Chaffer et al. 2007; Dunn et al. 2009; Kalluri and 
Weinberg 2009). On the other hand some BMPs can oppose factors that stimulate 
EMT in many cell types and induce MET (Buijs et al. 2007; Scheel et al. 2011; Buijs 
et al. 2012). BMP expression in this case could be considered to be an important 
protective mechanism preventing tumour cells from further colonization. Conversely 
overexpression of the BMP antagonist Noggin could suppress this control and 
enhance metastatic activity (Gao et al. 2012; Tarragona et al. 2012) Figure 1.7 
summarizes the role of TGF-β, BMP7 and its antagonist Noggin in tumour invasion 
and colonization into the bone. A study done by Van den Hoogen reported the 
association of αv integrin with the invasion and migration capability of prostate cancer 
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cells since silencing this receptors resulted in a decreased stem/progenitor cell 
characteristic and a decreased in the expression of invasion associated genes 
Snail1, Snail2 and Twist (van den Hoogen et al. 2011). This again highlights the 
significance of cellular attachment and EMT/MET status in the metastatic process.   
Among all TGF-β superfamily and their antagonists analysed in this study I focused 
on Noggin as a BMP antagonist as a potential regulator of bone metastasis. In this 
study I found that treating osteoblasts (SaOS2) cells with conditioned media collected 
over PC3RFP cells stimulated the expression of Noggin by SaOS2 cells.   
Noggin is a secreted glycoprotein monomer but normally occurs as a homodimer and 
has a cysteine-rich C-terminal region (Yanagita 2005; Krause et al. 2011). It was 
reported that Noggin bound with different affinities to different BMPs. Noggin binds 
strongly to BMP2 and BMP4 and with lower affinity to BMP6 and BMP7 (Krause et al. 
2011). Sclerostin (SOST) another BMP antagonist has the ability to also bind Noggin 
limiting the inhibitory effect of Noggin and increasing BMP availability (Winkler et al. 
2004). It was reported in an in vivo study using a bone tumour model, that exposing 
the tumour to Noggin reduced the size of bone lesions by a mechanism that involve 
both osteoblastic and osteolytic processes (Ye et al. 2007). Both Noggin and 
follostatin determine cell responses to BMPs, however, the expression of these 
antagonists can be controlled by BMPs themselves via an autocrine or paracrine 
feedback loop (Ye et al. 2007). In an agreement with our results, a study done by 
Yoshimura et al 2001 reported that osteoblast do not normally express Noggin, 
suggesting that the amplified Noggin mRNA signal in osteoblastic cells in this study 
may be as a result of enhanced expression of BMPs and BMP receptors (Gazzerro 
et al. 1998). Therefore growth factors and BMPs BMP2, BMP4, BMP6 and TGF-β 
produced from prostate cancer cells (PC3RFP) may be responsible from stimulated 
Noggin expression in osteoblasts cells (SaOS2) found in my study. A study done by 
Hsu et al reported that Noggin overexpressing melanoma cells showed a growth 
advantage in response to subsequent BMP7 transduction both in vitro and in vivo, 
whereas, Noggin knockdown melanoma cells exhibited a growth inhibition. This 
implies that Noggin up regulation may cause advanced melanoma cells to escape 
from BMP7-mediated autocrine growth inhibition (Hsu et al. 2008). Noggin may have 
a similar the role in breast cancer metastasis to bone since over expression of 
Noggin increased the growth rate of bone metastasis in an orthotopic mouse model. 
Moreover in the same study it was found that silencing Noggin (shRNA targeting 
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Noggin gene) caused growth rate reduction of bone metastases (Tarragona et al. 
2012). Noggin is suggested to modulate cancer cells through stimulating ID2 and 
subsequently may increase the level of RANK expression which is linked to 
chemotherapy resistance (Schramek et al. 2010). It has been suggested that Noggin 
compromised BMP signaling in turn results in the activation of stem cell self-renewal 
pathways (Wakefield and Hill 2013).   This may open the possibility of Noggin being 
linked not only to the ability of metastatic cells to successfully metastasize to the 
bone but also to the ability of self-renewal activity acquired by metastatic cells and to 
acquiring chemotherapy resistant (Tarragona et al. 2012). Schwaninger et al reported 
that forced Noggin expression in an osteoinductive prostate cancer cell line 
suppressed the osteoblastic response observed when these cells were injected into 
bone in vivo, suggesting that lack of Noggin production by cancer cells is part of the 
mechanism controlling the balance between osteolytic and osteoblastc responses in 
bone metastases (Schwaninger et al. 2007).   
In conclusion the in vitro results obtained from this study showed that growth factors 
and other molecules produced by prostate cancer cells affected both proliferation and 
initial differentiation of SaOS2 cells. In addition it showed that prostate cancer cells 
affect the gene expression of TGF-β superfamily genes during their interaction with 
SaOS2 cells either directly or indirect. More attention was given to Noggin, a BMP 
antagonist that was expressed and secreted by PC3RFP cells while being expressed 
in a very low level by SaOS2. This pattern of Noggin gene expression changed after 
treating the cells with conditioned media derived from PC3RFP cells leading to 
enhanced expression of this gene by osteoblastic cells. The effect of Noggin on the 
proliferation of osteoblastic cells was also assessed by either treating the cells with 
PC3-KD conditioned media or by media supplemented with recombinant Noggin. 
Silencing Noggin in PC3 cells inhibited the growth of SaOS2 cells while media 
containing recombinant Noggin stimulated its growth. However the amount of 
recombinant Noggin that were required to increase the growth of SaOS2 cells were 
much higher than the amount of Noggin present in the condition media. This result 
suggests that the enhanced growth of osteoblasts cells may not be due to Noggin 
secreted from prostate cancer cells but due to the stimulated expression of Noggin 
by osteoblast cells themselves. Induced autocrine or even intracrine Noggin activity 
in osteoblasts would be dependent on local levels surrounding or inside cells that 
could reach those present in medium supplemented with recombinant Noggin.         
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In this study, mice injected with either PC3-Mock or with PC3-KD cells did not 
develop the numbers of bone metastases expected for PC3 cells. These cells were 
injected into left cardiac ventricle so it was expected that not all of these cells would 
home to bone and establish metastatic lesions, but it was expected that around 20% 
of controls would develop long bone tumours in 12 week old animals. The problem 
encountered here may be due to clonal selection after genetic manipulation. Difficulty 
in achieving adequate bone metastases in vivo models using tumour cells strains that 
have been genetically modified has been reported by others (Rucci and Angelucci 
2014). This may be due to many different factors including the long latency time in 
natural development of bone metastases and the phenotypic modification induced by 
in vitro culture of cancer cell lines/strains and their cloning, which may result in 
reduction in their tumourigenicity (Shevrin et al. 1988; Nemeth et al. 1999; Rucci and 
Angelucci 2014). Recent studies in my group suggest that the frequency of tumour 
formation depends on numbers of metastasis initiating cells (Kang et al. 2003)  and it 
is possible that these were not included in the cells selected and cloned during the 
generation of PC-3Mock or KD cells.  
In this study histologic sections of tibial trabecular bones were taken from both 
groups and Noggin protein was localized in both bone and tumour. Noggin protein 
represented by dark brown stain was found to be on the bone surface and bone 
lining cells when tumour came close to bone. Moreover, other investigators have 
detected Noggin by using immunocytochemically techniques at fracture sites and 
where BMP induced formation is high (Nakase et al. 1994; Yoshimura et al. 2001).   
The in vitro data suggested that Noggin regulates osteoblastic cell 
differentiation/proliferation and it would be predicted that this would result in the 
formation of osteolytic lesions in vivo. This may also enhance the growth of PC3 cells 
in bone via release of factors sequestered in bone. Conversely, knock down of 
Noggin would result in more osteoblastic lesions and possibly reduced 
tumourigenicity. This will have to be retested in better knock down/knock-out models 
made without clonal selection.  
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Figure 7.1 Scheme showing the role of TGF-β, BMP7 and Noggin in cancer invasion and 
colonization. 
Many EMT effectors are identified including TGF-β, IGF, Notch, Wnt, integrin αvβ3 and other 
microRNA that stimulate EMT processes and make cancer cells losses their epithelial characteristics 
such as E-cadherin and acquiring mesenchymal phenotype. This process could be either blocked by 
BMP7 or enhanced under the influence of BMP antagonist (Noggin). Cancer cells with mesenchymal 
phenotype have the ability to invade and enter the blood vessels and disseminated in distal organ 
most commonly the bone in case of prostate cancer. Bone express normally high level o endogenous 
BMP, which may promote a mesenchymal to epithelial transition, MET in the newly arrived tumour 
cells. They also may maintain the disseminated tumour cells in dormant state this could be overcome 
in tumour cells expressing high level of BMP antagonists Noggin.   
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7.2 Future work   
Metastasis is responsible for the majority of prostate cancer deaths and the primary 
site for metastatic lesions in this disease is the skeleton. Understanding mechanisms 
that facilitate the formation of metastases to the bone is needed if drugs are to be 
designed to prevent or interfere with prostate cancer metastasis. It is known that 
once prostate cancer cells disseminated in the bone, a cross talk between the bone 
microenvironment factors and factors produced from prostate cancer cells contribute 
to the establishment of lesions (Ganguly et al. 2014). In this study most focus has 
been given toward one of the BMP antagonist, Noggin. Noggin is known to play role 
in prostate cancer bone metastases. The finding that tumour cells can induce the 
expression of this potentially autocrine factor in bone cells is an important novel 
finding of the study. Further investigation of factors that regulate the expression of 
this protein is required for better understand this interaction. In addition it may be 
useful to study microRNAs, which, are highly conserved small RNAs molecules that 
regulate gene expression. A study done by Peng et al Compared arrays-based 
miRNA profiles of human primary prostate tumours and matched bone metastases 
and showed that expression levels of miRNA-145, -143, -33a, -100 and -508-5p were 
the most highly down regulated in bone metastases specimen. It was reported in the 
same study that ectopic expression of miRNA-143 and miRNA-145 in the aggressive 
and androgen insensitive PC3 prostate cancer cell line reduced the migratory and 
invasive capacities of these tumour cells in vitro and their tendency to metastasise to 
bone in vivo (Peng et al. 2011). Another study done by Pollari et al identified certain 
types of miRNAs that down regulate a set of genes involved in TGF-β signalling 
(Pollari et al. 2012).  
The host environmental factors play a major role in prostate cancer metastases to 
bone understanding these factors require the use of animal model. The most 
commonly used model is the imunnosuppressed mouse, which differ significantly 
from humans in both the structure and physiology of prostate gland and in the 
support of tumour growth (Ganguly et al. 2014). Adding to this the difficulty of 
initiating bone metastases in mouse model when using genetically modified prostate 
cancer cell lines. These cells were used in in vitro culture where their activity 
appeared to support a role for Noggin but their cloning, may have resulted in a 
reduction in their tumourigenicity. Developing a wider range of Noggin-KD or knock 
out models that have not been cloned would be helpful here. However my own 
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experience attempting to make Noggin-KD models and the difficulties I know others 
have had in generating these cells may mean that this will be a challenge. The 
foregoing certainly suggests that there is a need to develop a better tumour/animal 
models that fully recapitulate the metastatic process as seen in human disease and 
retain tumourogenictiy in vivo after manipulation in order to investigate the molecular 
events associated with prostate cancer metastases further. It may then be possible to 
repeat the experiments presented here to more definitively evaluate the effects of 
TGFβ1, BMPs and Noggin on prostate cancer metastasis.      
 
 
 
 !  
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Appendix A 
Table 1A   Express plate gene expression in exponential and confluent SaOS2 cells. !
Gene Name 
SaOS2 
(exponential) 
Mean ct 
Value 
GAPDH 
Mean  
ct Value 
SaOS2 
(confluent) 
Mean ct 
Value 
GAPDH 
Mean  
ct Value 
Δ dct 
ACVR1 28.72608693 20.94892438 29.27659035 20.79617182 0.703256 
ACVR1B 31.714077 20.94892438 31.86755816 20.79617182 0.306234 
ACVR2A 30.74973933 20.94892438 30.89818891 20.79617182 0.301202 
ACVR2A 30.8026975 20.94892438 30.70807838 20.79617182 0.058133 
ACVR2B 30.95208041 20.94892438 31.12030538 20.79617182 0.320978 
BMP10 37.21621323 20.94892438 36.63376427 20.79617182 -0.4297 
BMP2 30.93817711 20.94892438 31.26523209 20.79617182 0.479808 
BMP3 33.85720189 20.94892438 35.26694616 20.79617182 1.562497 
BMP4 23.51956177 20.94892438 24.28214836 20.79617182 0.915339 
BMP5 36.98243078 20.94892438 35.69938914 20.79617182 -1.13029 
BMP6 30.92572403 20.94892438 31.77471161 20.79617182 1.00174 
BMP7 34.81692123 20.94892438 34.62957382 20.79617182 -0.03459 
BMP8B;BMP8A 31.77512105 20.94892438 32.31136322 20.79617182 0.688995 
BMPR1A 29.50725492 20.94892438 29.27017148 20.79617182 -0.08433 
BMPR1B 30.83174769 20.94892438 30.7936751 20.79617182 0.11468 
BMPR2 26.96928914 20.94892438 27.14547729 20.79617182 0.328941 
CER1 undetermined 20.94892438 undetermined 20.79617182 #VALUE! 
CHRD 36.29343033 20.94892438 36.04893112 20.79617182 -0.09175 
ENG 27.95445506 20.94892438 28.04511897 20.79617182 0.243416 
FST 31.3014946 20.94892438 31.18039767 20.79617182 0.031656 
GDF11 29.91272418 20.94892438 30.27658081 20.79617182 0.516609 
GDF1;LASS1 31.92202314 20.94892438 32.21234194 20.79617182 0.443071 
GDF2 undetermined 20.94892438 undetermined 20.79617182 #VALUE! 
GDF3 undetermined 20.94892438 undetermined 20.79617182 #VALUE! 
GDF6 32.50665283 20.94892438 33.42245674 20.79617182 1.068556 
GDF7 35.64224243 20.94892438 36.16138713 20.79617182 0.671897 
GDF9 34.76025772 20.94892438 35.30661774 20.79617182 0.699113 
GREM1 25.53823471 20.94892438 26.31441498 20.79617182 0.928933 
INHA 35.81718953 20.94892438 36.58116913 20.79617182 0.916732 
INHBA 27.47245407 20.94892438 27.27426974 20.79617182 -0.04543 
INHBB 30.44009717 20.94892438 30.29593849 20.79617182 0.008594 
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Gene Name 
SaOS2 
(exponential) 
Mean ct 
Value 
GAPDH 
Mean  
ct Value 
SaOS2 
(confluent) 
Mean ct 
Value 
GAPDH 
Mean  
ct Value 
Δ dct 
INHBC 36.32163493 20.94892438 36.23087438 20.79617182 0.061992 
INHBE 33.41264852 20.94892438 32.29367383 20.79617182 -0.96622 
LEFTY2 37.05011113 20.94892438 35.69972356 20.79617182 -1.19764 
LTBP1 28.53319105 20.94892438 28.28687859 20.79617182 -0.09356 
NBL1 27.86512693 20.94892438 27.53838603 20.79617182 -0.17399 
NOG 32.84244665 20.94892438 34.09048971 20.79617182 1.400796 
SOST 34.70230484 20.94892438 36.6013298 20.79617182 2.051778 
TGFB1 23.80765279 20.94892438 24.289608 20.79617182 0.634708 
TGFB2 28.61895116 20.94892438 28.49724706 20.79617182 0.031048 
TGFB3 28.80683517 20.94892438 29.29043706 20.79617182 0.636354 
TGFBR1 28.02592913 20.94892438 28.23258909 20.79617182 0.359413 
TGFBR2 27.77650452 20.94892438 27.9066143 20.79617182 0.282862 
TGFBR3 30.98367246 20.94892438 31.18359121 20.79617182 0.352671 
This Table represents the ct values and the differences in Δdct value between SaOS2 cells during 
exponential growth and SaOS2 cells during Confluent Phase. The dct was calculated by subtracting 
the gene of interest from the house keeping gene GAPDH for each cell type. The Δdct value was 
calculated by subtracting dct value of SaOS2 exponential from the dct value of the SaOS2 confluent 
cells. Data expressed as mean of 3 independent experiments.  
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Table 2A  Express plate gene expression in exponential PC3RFP and confluent PC3RFP cells. !
Gene Name 
PC3RFP 
(exponential) 
Mean  
ct Value 
GAPDH 
Mean  
ct Value 
PC3RFP 
(confluent)  
Mean 
 ct Value 
GAPDH 
Mean  
ct Value 
Δ dct 
ACVR1 28.67760 19.71322 29.61977 20.51371 0.14168 
ACVR1B 30.37804 19.71322 31.23541 20.51371 0.05688 
ACVR2A 30.06857 19.71322 30.92702 20.51371 0.05796 
ACVR2A 30.17434 19.71322 30.73866 20.51371 -0.23617 
ACVR2B 31.74068 19.71322 32.49391 20.51371 -0.04726 
BMP10 undetermined 19.71322 undetermined 20.51371 #VALUE! 
BMP2 30.54163 19.71322 30.93080 20.51371 -0.41133 
BMP3 27.92534 19.71322 28.39143 20.51371 -0.33440 
BMP4 31.23007 19.71322 31.89929 20.51371 -0.13126 
BMP5 36.90198 19.71322 37.14349 20.51371 -0.55898 
BMP6 29.72940 19.71322 30.11338 20.51371 -0.41651 
BMP7 38.09402 19.71322 36.89372 20.51371 -2.00078 
BMP8B;BMP8A 30.59572 19.71322 31.34903 20.51371 -0.04717 
BMPR1A 30.25607 19.71322 30.30324 20.51371 -0.75331 
BMPR1B 29.93496 19.71322 30.65239 20.51371 -0.08306 
BMPR2 28.33518 19.71322 28.94415 20.51371 -0.19153 
CER1 37.24395 19.71322 37.24757 20.51371 -0.79687 
CHRD 37.01204 19.71322 undetermined 20.51371 #VALUE! 
ENG 36.30861 19.71322 37.03303 20.51371 -0.07607 
FST 31.81458 19.71322 32.73969 20.51371 0.12461 
GDF11 27.29718 19.71322 27.84155 20.51371 -0.25611 
GDF1;LASS1 35.20585 19.71322 35.94738 20.51371 -0.05896 
GDF2 undetermined 19.71322 undetermined 20.51371 #VALUE! 
GDF3 undetermined 19.71322 undetermined 20.51371 #VALUE! 
GDF6 undetermined 19.71322 undetermined 20.51371 #VALUE! 
GDF7 undetermined 19.71322 37.05927 20.51371 #VALUE! 
GDF9 35.23329 19.71322 35.75269 20.51371 -0.28108 
GREM1 undetermined 19.71322 undetermined 20.51371 #VALUE! 
INHA 34.25590 19.71322 34.67130 20.51371 -0.38508 
INHBA 31.53516 19.71322 32.60780 20.51371 0.27215 
INHBB 36.78977 19.71322 37.59675 20.51371 0.00649 
INHBC 35.37048 19.71322 35.62355 20.51371 -0.54742 
INHBE 32.47049 19.71322 33.93227 20.51371 0.66129 
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Gene Name 
PC3RFP 
(exponential) 
Mean  
ct Value 
GAPDH 
Mean  
ct Value 
PC3RFP 
(confluent)  
Mean 
 ct Value 
GAPDH 
Mean  
ct Value 
Δ dct 
LEFTY2 38.16286 19.71322 37.92624 20.51371 -1.03710 
LTBP1 26.31649 19.71322 27.29221 20.51371 0.17523 
NBL1 26.88291 19.71322 27.63373 20.51371 -0.04967 
NOG 26.88119 19.71322 27.32347 20.51371 -0.35821 
SOST undetermined 19.71322 undetermined 20.51371 #VALUE! 
TGFB1 26.55849 19.71322 27.31067 20.51371 -0.04831 
TGFB2 31.15269 19.71322 31.91540 20.51371 -0.03777 
TGFB3 28.83040 19.71322 29.63135 20.51371 0.00046 
TGFBR1 27.90963 19.71322 28.60142 20.51371 -0.10869 
TGFBR2 28.34935 19.71322 28.88057 20.51371 -0.26927 
TGFBR3 29.51358 19.71322 30.19828 20.51371 -0.11579 
This Table shows the ct values and the differences in Δdct value between PC3RFP cells during 
exponential growth and PC3RFP cells during Confluent Phase. The dct was calculated by subtracting 
the gene of interest from the house keeping gene GAPDH for each cell type. The Δdct value was 
calculated by subtracting dct value of PC3RFP exponential from the dct value of the PC3RFP 
confluent cells. Data expressed as mean of 3 independent experiments.   
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Table 3A Express plate gene expression in confluent PC3RFP and SaOS2 cells. 
Gene Name SaOS2 
(Confluent) 
Mean ct Value 
GADH 
Mean 
ct Value 
PC3RFP 
(Confluent) 
Mean 
ct Value 
GADH 
Mean 
ct Value 
Δ dct 
ACVR1 29.27659 20.79617 29.61977 20.51371 0.62564 
ACVR1B 31.86756 20.79617 31.23541 20.51371 -0.34968 
ACVR2A 30.89819 20.79617 30.92702 20.51371 0.31130 
ACVR2A 30.70808 20.79617 30.73866 20.51371 0.31304 
ACVR2B 31.12031 20.79617 32.49391 20.51371 1.65607 
BMP10 36.63376 20.79617 undetermined 20.51371 #VALUE! 
BMP2 31.26523 20.79617 30.93080 20.51371 -0.05197 
BMP3 35.26695 20.79617 28.39143 20.51371 -6.59305 
BMP4 24.28215 20.79617 31.89929 20.51371 7.89961 
BMP5 35.69939 20.79617 37.14349 20.51371 1.72656 
BMP6 31.77471 20.79617 30.11338 20.51371 -1.37887 
BMP7 34.62957 20.79617 36.89372 20.51371 2.54661 
BMP8B;BMP8A 32.31136 20.79617 31.34903 20.51371 -0.67987 
BMPR1A 29.27017 20.79617 30.30324 20.51371 1.31553 
BMPR1B 30.79368 20.79617 30.65239 20.51371 0.14118 
BMPR2 27.14548 20.79617 28.94415 20.51371 2.08113 
CER1 undetermined 20.79617 37.24757 20.51371 #VALUE! 
CHRD 36.04893 20.79617 undetermined 20.51371 #VALUE! 
ENG 28.04512 20.79617 37.03303 20.51371 9.27038 
FST 31.18040 20.79617 32.73969 20.51371 1.84175 
GDF11 30.27658 20.79617 27.84155 20.51371 -2.15256 
GDF1;LASS1 32.21234 20.79617 35.94738 20.51371 4.01750 
GDF2 undetermined 20.79617 undetermined 20.51371 #VALUE! 
GDF3 undetermined 20.79617 undetermined 20.51371 #VALUE! 
GDF6 33.42246 20.79617 undetermined 20.51371 #VALUE! 
GDF7 36.16139 20.79617 37.05927 20.51371 1.18034 
GDF9 35.30662 20.79617 35.75269 20.51371 0.72854 
GREM1 26.31441 20.79617 undetermined 20.51371 #VALUE! 
INHA 36.58117 20.79617 34.67130 20.51371 -1.62740 
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This Table shows the ct values and the differences in Δdct value between PC3RFP cells compared to 
the SaOS2 cells during the Confluent Phase. The dct was calculated by subtracting the gene of 
interest from the house keeping gene GAPDH for each cell type. The Δdct value was calculated by 
subtracting dct value of PC3RFP confluent from the dct value of the saOs2 cells. Highlighted value 
represents more than 10 fold change in gene expression. Data expressed as mean of 3 independent 
experiments.   
 
  
Gene Name SaOS2 
(Confluent) 
Mean ct Value 
GADH 
Mean 
ct Value 
PC3RFP 
(Confluent) 
Mean 
ct Value 
GADH 
Mean 
ct Value 
Δ dct 
INHBA 27.27427 20.79617 32.60780 20.51371 5.61599 
INHBB 30.29594 20.79617 37.59675 20.51371 7.58327 
INHBC 36.23087 20.79617 35.62355 20.51371 -0.32487 
INHBE 32.29367 20.79617 33.93227 20.51371 1.92106 
LEFTY2 35.69972 20.79617 37.92624 20.51371 2.50898 
LTBP1 28.28688 20.79617 27.29221 20.51371 -0.71221 
NBL1 27.53839 20.79617 27.63373 20.51371 0.37781 
NOG 34.09049 20.79617 27.32347 20.51371 -6.48456 
SOST 36.60133 20.79617 undetermined 20.51371 #VALUE! 
TGFB1 24.28961 20.79617 27.31067 20.51371 3.30353 
TGFB2 28.49725 20.79617 31.91540 20.51371 3.70062 
TGFB3 29.29044 20.79617 29.63135 20.51371 0.62337 
TGFBR1 28.23259 20.79617 28.60142 20.51371 0.65130 
TGFBR2 27.90661 20.79617 28.88057 20.51371 1.25641 
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Table 4A  Express plate gene expression in confluent PC3RFP and MG63 cells. 
Gene Name 
PC3RFP 
(Confluent) 
Mean ct Value 
GAPDH 
Mean 
ct Value 
MG63 
(Confluent) 
Mean ct Value 
GAPDH 
Mean 
ct Value 
Δ dct 
ACVR1 29.61976751 20.51370811 27.45970345 22.97153473 -4.617890676 
ACVR1B 31.2354126 20.51370811 31.9857645 22.97153473 -1.707474709 
ACVR2A 30.92702103 20.51370811 30.46175385 22.97153473 -2.923093796 
ACVR2A 30.73865573 20.51370811 30.46175385 22.97153473 -2.734728495 
ACVR2B 32.49391492 20.51370811 34.45285702 22.97153473 -0.498884519 
BMP10 #DIV/0! 20.51370811 #DIV/0! 22.97153473 #DIV/0! 
BMP2 30.93079694 20.51370811 33.9507122 22.97153473 0.562088648 
BMP3 28.39143181 20.51370811 37.18087006 22.97153473 6.331611633 
BMP4 31.8992939 20.51370811 29.96717453 22.97153473 -4.389945984 
BMP5 37.14348984 20.51370811 31.46509647 22.97153473 -8.136219978 
BMP6 30.11337789 20.51370811 35.45298004 22.97153473 2.881775538 
BMP7 36.89372444 20.51370811 29.96841526 22.97153473 -9.383135796 
BMP8B;BMP8A 31.34903208 20.51370811 31.95696354 22.97153473 -1.849895159 
BMPR1A 30.30324173 20.51370811 31.45823956 22.97153473 -1.302828789 
BMPR1B 30.65238698 20.51370811 #DIV/0! 22.97153473 #DIV/0! 
BMPR2 28.94414584 20.51370811 27.97273445 22.97153473 -3.429238002 
CER1 37.24756622 20.51370811 36.50650787 22.97153473 -3.198884964 
CHRD #DIV/0! 20.51370811 33.97208977 22.97153473 #DIV/0! 
ENG 37.03303146 20.51370811 24.9516983 22.97153473 -14.53915977 
FST 32.73968506 20.51370811 32.96305561 22.97153473 -2.234456062 
GDF11 27.84155464 20.51370811 30.45579052 22.97153473 0.156409264 
GDF1;LASS1 35.94737625 20.51370811 26.95148277 22.97153473 -11.45372009 
GDF2 #DIV/0! 20.51370811 #DIV/0! 22.97153473 #DIV/0! 
GDF3 #DIV/0! 20.51370811 37.08481598 22.97153473 #DIV/0! 
GDF6 #DIV/0! 20.51370811 31.43332863 22.97153473 #DIV/0! 
GDF7 37.05926704 20.51370811 34.47594261 22.97153473 -5.041151047 
GDF9 35.75269318 20.51370811 33.96159649 22.97153473 -4.248923302 
GREM1 #DIV/0! 20.51370811 34.4677639 22.97153473 #DIV/0! 
INHA 34.67130407 20.51370811 33.45564842 22.97153473 -3.673482259 
INHBA 32.60780017 20.51370811 32.9467535 22.97153473 -2.118873278 
INHBB 37.59674581 20.51370811 36.96137238 22.97153473 -3.093200048 
INHBC 35.62354533 20.51370811 37.00120544 22.97153473 -1.080166499 
INHBE 33.93226624 20.51370811 31.45604229 22.97153473 -4.93405056 
LEFTY2 37.92624474 20.51370811 36.50269127 22.97153473 -3.881380081 
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Gene Name 
PC3RFP 
(Confluent) 
Mean ct Value 
GAPDH 
Mean 
ct Value 
MG63 
(Confluent) 
Mean ct Value 
GAPDH 
Mean 
ct Value 
Δ dct 
LTBP1 27.29220645 20.51370811 27.45436859 22.97153473 -2.295664469 
NBL1 27.63373184 20.51370811 26.47146511 22.97153473 -3.620093346 
NOG 27.32346916 20.51370811 34.46164322 22.97153473 4.680347443 
SOST #DIV/0! 20.51370811 #DIV/0! 22.97153473 #DIV/0! 
TGFB1 27.31066958 20.51370811 26.46272373 22.97153473 -3.305772463 
TGFB2 31.91540209 20.51370811 34.45627117 22.97153473 0.083042463 
TGFB3 29.63134766 20.51370811 32.96736717 22.97153473 0.878192902 
TGFBR1 28.6014239 20.51370811 28.43787479 22.97153473 -2.62137572 
TGFBR2 28.88056501 20.51370811 26.45248508 22.97153473 -4.885906537 
TGFBR3 30.19827906 20.51370811 28.95666027 22.97153473 -3.699445407 
 
This Table shows the ct values and the differences in Δdct value between MG63 cells and PC3-RFP 
cells during the Confluent Phase. The dct was calculated by subtracting the gene of interest from the 
house keeping gene GAPDH for each cell type. The Δdct value was calculated by subtracting dct 
value of PC3RFP confluent from the dct value of the MG63 cells. Highlighted value represents more 
than 10 fold change in gene expression. Data expressed as mean of 3 independent experiments.   
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Table 5A  TGFβ superfamily gene expression in co-culture SaOS2 compared to control SaOS2 
cells. 
Gene Name 
SaOS2 
(Control) 
ct Value 
GAPDH 
ct Value 
SaOS2 
(Co-cultured)  
ct value 
GAPDH 
ct Value 
Δ dct 
ACVR1 29.27659035 20.79617182 28.9532299 20.9656105 -0.492799123 
ACVR1B 31.86755816 20.79617182 31.980299 20.9656105 -0.056697845 
ACVR2A 30.89818891 20.79617182 29.95549583 20.9656105 -1.112131755 
ACVR2A 30.70807838 20.79617182 29.95549583 20.9656105 -0.92202123 
ACVR2B 31.12030538 20.79617182 29.97760201 20.9656105 -1.312142054 
BMP10 36.63376427 20.79617182 Undetermined 20.9656105 #VALUE! 
BMP2 31.26523209 20.79617182 31.93518066 20.9656105 0.500509898 
BMP3 35.26694616 20.79617182 30.94885635 20.9656105 -4.487528483 
BMP4 24.28214836 20.79617182 24.94000626 20.9656105 0.488419215 
BMP5 35.69938914 20.79617182 35.94908905 20.9656105 0.08026123 
BMP6 31.77471161 20.79617182 28.93636894 20.9656105 -3.007781347 
BMP7 34.62957382 20.79617182 33.95807648 20.9656105 -0.840936025 
BMP8B;BMP8A 32.31136322 20.79617182 30.97959328 20.9656105 -1.501208623 
BMPR1A 29.27017148 20.79617182 29.9485302 20.9656105 0.508920034 
BMPR1B 30.7936751 20.79617182 33.9930954 20.9656105 3.029981613 
BMPR2 27.14547729 20.79617182 26.96865082 20.9656105 -0.346265157 
CER1 #DIV/0! 20.79617182 Undetermined 20.9656105 #DIV/0! 
CHRD 36.04893112 20.79617182 36.98843765 20.9656105 0.770067851 
ENG 28.04511897 20.79617182 28.95251274 20.9656105 0.737955093 
FST 31.18039767 20.79617182 30.96162796 20.9656105 -0.388208389 
GDF11 30.27658081 20.79617182 28.94433784 20.9656105 -1.501681646 
GDF1;LASS1 32.21234194 20.79617182 31.95088196 20.9656105 -0.430898666 
GDF2 #DIV/0! 20.79617182 Undetermined 20.9656105 #DIV/0! 
GDF3 #DIV/0! 20.79617182 Undetermined 20.9656105 #DIV/0! 
GDF6 33.42245674 20.79617182 34.91986084 20.9656105 1.327965418 
GDF7 36.16138713 20.79617182 35.96345139 20.9656105 -0.36737442 
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Gene Name 
SaOS2 
(Control) 
ct Value 
GAPDH 
ct Value 
SaOS2 
(Co-cultured)  
ct value 
GAPDH 
ct Value 
Δ dct!
GDF9 35.30661774 20.79617182 35.95517349 20.9656105 0.479117076 
GREM1 26.31441498 20.79617182 30.96870232 20.9656105 4.484848658 
INHA 36.58116913 20.79617182 34.96567917 20.9656105 -1.78492864 
INHBA 27.27426974 20.79617182 26.95631599 20.9656105 -0.487392426 
INHBB 30.29593849 20.79617182 30.96619797 20.9656105 0.500820796 
INHBC 36.23087438 20.79617182 35.9522934 20.9656105 -0.448019663 
INHBE 32.29367383 20.79617182 31.95554733 20.9656105 -0.50756518 
LEFTY2 35.69972356 20.79617182 36.97317886 20.9656105 1.104016622 
LTBP1 28.28687859 20.79617182 26.94904137 20.9656105 -1.507275899 
NBL1 27.53838603 20.79617182 27.96681404 20.9656105 0.258989334 
NOG 34.09048971 20.79617182 27.94402695 20.9656105 -6.315901438 
SOST 36.6013298 20.79617182 35.99904633 20.9656105 -0.771722158 
TGFB1 24.289608 20.79617182 23.96656036 20.9656105 -0.492486318 
TGFB2 28.49724706 20.79617182 29.95263672 20.9656105 1.285950979 
TGFB3 29.29043706 20.79617182 29.96563911 20.9656105 0.505763372 
TGFBR1 28.23258909 20.79617182 28.93655777 20.9656105 0.534530004 
TGFBR2 27.9066143 20.79617182 27.95667267 20.9656105 -0.119380315 
TGFBR3 31.18359121 20.79617182 30.95687294 20.9656105 -0.396156947 
This Table shows the ct values and the differences in Δdct value between co-cultured SaOS2 cells 
and control SaOS2 cells during the Confluent Phase. The dct was calculated by subtracting the gene 
of interest from the house keeping gene GAPDH for each cell type. The Δdct value was calculated by 
subtracting dct value of control from the dct value of the co-cultured SaOS2 cells. Highlighted value 
represents more than 10 fold change in gene expression. Data expressed as mean of 3 independent 
experiments.   
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Table 6A  TGFβ superfamily gene expression in co-cultured PC3RFP with SaOS2 compared to 
control PC3RFP cells. 
Gene Name 
PC3 
(control) 
ct value 
GADH 
ct value 
PC3/SaOS2 
(co-cultured) 
Ct value 
GADH 
ct value Δ dct 
ACVR1 29.61976751 20.51371 27.96547699 19.95773315 -0.99360466 
ACVR1B 31.2354126 20.51371 30.9859333 19.95773315 1.01010704 
ACVR2A 30.92702103 20.51371 30.95611763 19.95773315 1.021625519 
ACVR2A 30.73865573 20.51371 30.95611763 19.95773315 1.120658875 
ACVR2B 32.49391492 20.51371 31.98219109 19.95773315 0.157283783 
BMP10 #DIV/0! 20.51371 Undetermined 19.95773315 #VALUE! 
BMP2 30.93079694 20.51371 30.95896149 19.95773315 1.035814285 
BMP3 28.39143181 20.51371 29.9454174 19.95773315 2.211952209 
BMP4 31.8992939 20.51371 30.95910645 19.95773315 0.010868073 
BMP5 37.14348984 20.51371 37.07818604 19.95773315 0.950033188 
BMP6 30.11337789 20.51371 28.97106934 19.95773315 0.051765442 
BMP7 36.89372444 20.51371 37.01209259 19.95773315 1.203203201 
BMP8B;BMP8A 31.34903208 20.51371 30.97738266 19.95773315 0.736444473 
BMPR1A 30.30324173 20.51371 31.94968796 19.95773315 2.65476799 
BMPR1B 30.65238698 20.51371 33.00383759 19.95773315 3.037137985 
BMPR2 28.94414584 20.51371 27.96653938 19.95773315 0.007659912 
CER1 37.24756622 20.51371 Undetermined 19.95773315 #VALUE! 
CHRD #DIV/0! 20.51371 Undetermined 19.95773315 #VALUE! 
ENG 37.03303146 20.51371 36.94768524 19.95773315 0.83490181 
FST 32.73968506 20.51371 29.96795845 19.95773315 -1.975879669 
GDF11 27.84155464 20.51371 26.95577049 19.95773315 -0.00038147 
GDF1;LASS1 35.94737625 20.51371 34.95160294 19.95773315 0.020875931 
GDF2 #DIV/0! 20.51371 Undetermined 19.95773315 #VALUE! 
GDF3 #DIV/0! 20.51371 Undetermined 19.95773315 #VALUE! 
GDF6 #DIV/0! 20.51371 Undetermined 19.95773315 #VALUE! 
GDF7 37.05926704 20.51371 Undetermined 19.95773315 #VALUE! 
GDF9 35.75269318 20.51371 35.97348022 19.95773315 1.016462326 
GREM1 #DIV/0! 20.51371 Undetermined 19.95773315 #VALUE! 
INHA 34.67130407 20.51371 32.95661545 19.95773315 -0.998556137 
INHBA 32.60780017 20.51371 30.9564724 19.95773315 -0.993232727 
INHBB 37.59674581 20.51371 37.01879883 19.95773315 -0.601884842 
INHBC 35.62354533 20.51371 35.96622086 19.95773315 1.01067543 
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Gene Name 
PC3 
(control) 
ct value 
GADH 
ct value 
PC3/SaOS2 
(co-cultured) 
Ct value 
GADH 
ct value Δ dct 
INHBE 33.93226624 20.51371 31.95113182 19.95773315 -1.012889862 
LEFTY2 37.92624474 20.51371 37.06781387 19.95773315 #VALUE! 
LTBP1 27.29220645 20.51371 26.95423508 19.95773315 1.011125565 
NBL1 27.63373184 20.51371 28.97649002 19.95773315 2.018360138 
NOG 27.32346916 20.51371 25.96490479 19.95773315 -0.420198441 
SOST #DIV/0! 20.51371 37.05952454 19.95773315 #VALUE! 
TGFB1 27.31066958 20.51371 26.9741497 19.95773315 1.012626648 
TGFB2 31.91540209 20.51371 32.96443558 19.95773315 2.149311066 
TGFB3 29.63134766 20.51371 31.96960831 19.95773315 3.00856781 
TGFBR1 28.6014239 20.51371 28.93507767 19.95773315 1.006612778 
TGFBR2 28.88056501 20.51371 27.94732666 19.95773315 -0.011320114 
TGFBR3 30.19827906 20.51371 29.94961548 19.95773315 1.013208389 
This Table shows the ct values and the differences in Δdct value the estimated fold change between 
co-cultured PC3RFP/with SaOS2 cells and control PC3RFP cells during the Confluent Phase. The 
Δdct was calculated by subtracting the gene of interest from the house keeping gene GAPDH for each 
cell type. The ddct value was calculated by subtracting Δdct value of control from the dct value of the 
co-cultured PC3RFP/with SaOS2 cells. Data expressed as mean of 3 independent experiments.   
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Table 7A TGFβ superfamily gene expression in co-culture MG63 compared to control MG63 
cells. 
Gene Name 
MG63 
(control) 
ct Value 
GAPDH 
ct Value 
MG63 
(Co-cultured) 
ct Value 
GAPDH 
ct Value Δ dct 
ACVR1 27.45970345 22.97153473 27.55764008 22.96488571 0.104585648 
ACVR1B 31.9857645 22.97153473 31.67817497 22.96488571 -0.300940514 
ACVR2A 30.46175385 22.97153473 36.96150589 22.96488571 6.506401062 
ACVR2B 34.45285702 22.97153473 30.74513245 22.96488571 -3.701075554 
BMP10 #DIV/0! 22.97153473 Undetermined 22.96488571 #DIV/0! 
BMP2 33.9507122 22.97153473 33.95262527 22.96488571 0.008562088 
BMP3 37.18087006 22.97153473 34.94942856 22.96488571 -2.22479248 
BMP4 29.96717453 22.97153473 29.96358109 22.96488571 0.003055573 
BMP5 31.46509647 22.97153473 31.99669647 22.96488571 0.538249016 
BMP6 35.45298004 22.97153473 34.03453827 22.96488571 -1.411792755 
BMP7 29.96841526 22.97153473 30.89259148 22.96488571 0.930825233 
BMP8B;BMP8A 31.95696354 22.97153473 32.98453522 22.96488571 1.034220695 
BMPR1A 31.45823956 22.97153473 30.94623184 22.96488571 -0.505358696 
BMPR1B #DIV/0! 22.97153473 Undetermined 22.96488571 #DIV/0! 
BMPR2 27.97273445 22.97153473 27.83947182 22.96488571 -0.126613617 
CER1 36.50650787 22.97153473 36.98629379 22.96488571 0.486434937 
CHRD 33.97208977 22.97153473 30.43661118 22.96488571 -3.528829575 
ENG 24.9516983 22.97153473 24.95506859 22.96488571 0.010019302 
FST 32.96305561 22.97153473 31.77300835 22.96488571 -1.183398247 
GDF11 30.45579052 22.97153473 29.44002342 22.96488571 -1.00911808 
GDF1;LASS1 26.95148277 22.97153473 27.34437943 22.96488571 0.39954567 
GDF2 #DIV/0! 22.97153473 Undetermined 22.96488571 #DIV/0! 
GDF3 37.08481598 22.97153473 Undetermined 22.96488571 #VALUE! 
GDF6 31.43332863 22.97153473 29.7163887 22.96488571 -1.710290909 
GDF7 34.47594261 22.97153473 35.96851349 22.96488571 1.499219894 
GDF9 33.96159649 22.97153473 33.49467468 22.96488571 -0.460272789 
GREM1 34.4677639 22.97153473 30.62531471 22.96488571 -3.835800171 
INHA 33.45564842 22.97153473 31.95536613 22.96488571 -1.49363327 
INHBA 32.9467535 22.97153473 32.61723328 22.96488571 -0.322871208 
INHBB 36.96137238 22.97153473 37.03042984 22.96488571 0.075706482 
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Gene Name 
MG63 
(control) 
ct Value 
GAPDH 
ct Value 
MG63 
(Co-cultured) 
ct Value 
GAPDH 
ct Value Δ dct 
INHBC 37.00120544 22.97153473 36.96479797 22.96488571 -0.029758453 
INHBE 31.45604229 22.97153473 31.71233749 22.96488571 0.262944221 
LEFTY2 36.50269127 22.97153473 Undetermined 22.96488571 #VALUE! 
LTBP1 27.45436859 22.97153473 26.56694794 22.96488571 -0.880771637 
NBL1 26.47146511 22.97153473 25.97489738 22.96488571 -0.489918709 
NOG 34.46164322 22.97153473 31.98920059 22.96488571 -2.46579361 
SOST #REF! 22.97153473 Undetermined 22.96488571 #REF! 
TGFB1 26.46272373 22.97153473 26.31716919 22.96488571 -0.138905525 
TGFB2 34.45627117 22.97153473 34.63266373 22.96488571 0.183041573 
TGFB3 32.96736717 22.97153473 31.81608772 22.96488571 -1.144630432 
TGFBR1 28.43787479 22.97153473 28.2257843 22.96488571 -0.205441475 
TGFBR2 26.45248508 22.97153473 26.95654869 22.96488571 0.510712624 
TGFBR3 28.95666027 22.97153473 29.66415405 22.96488571 0.714142799 
 
This Table shows the ct values and the differences in Δdct between the co-cultured MG63 cells and 
the control MG63 cells during the Confluent Phase. The dct was calculated by subtracting the gene of 
interest from the house keeping gene GAPDH for each cell type. The Δdct value was calculated by 
subtracting dct value of control from the dct value of the co-cultured MG63 cells. Highlighted value 
represents approximant 10 fold change in gene expression. Data expressed as mean of 3 
independent experiments. 
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Table 8A  TGFβ superfamily gene expression in co-cultured PC3RFP with MG63 compared to 
control PC3RFP cells. 
Gene Name 
PC3 
(Control) 
ct value 
GADH 
ct value 
PC3/MG63 
(Co-cultured) 
Ct value 
GADH 
ct value Δ dct 
ACVR1 29.61976751 20.51370811 28.97067451 22.26200676 -2.397391637!
ACVR1B 31.2354126 20.51370811 30.99282837 22.26200676 -1.990882874!
ACVR2A 30.92702103 20.51370811 Undetermined 22.26200676 #VALUE!!
ACVR2A 30.73865573 20.51370811 Undetermined 22.26200676 #VALUE!!
ACVR2B 32.49391492 20.51370811 31.97089386 22.26200676 -2.271319707!
BMP10 #DIV/0! 20.51370811 Undetermined 22.26200676 #DIV/0!!
BMP2 30.93079694 20.51370811 32.17337799 22.26200676 -0.505717595!
BMP3 28.39143181 20.51370811 31.51320839 22.26200676 1.373477936!
BMP4 31.8992939 20.51370811 32.49723053 22.26200676 -1.150362015!
BMP5 37.14348984 20.51370811 36.97239685 22.26200676 -1.919391632!
BMP6 30.11337789 20.51370811 31.93276978 22.26200676 0.071093241!
BMP7 36.89372444 20.51370811 35.96075439 22.26200676 -2.681268692!
BMP8B;BMP8A 31.34903208 20.51370811 32.85150909 22.26200676 -0.245821635!
BMPR1A 30.30324173 20.51370811 32.5143013 22.26200676 0.462760925!
BMPR1B 30.65238698 20.51370811 33.99121857 22.26200676 1.590532939!
BMPR2 28.94414584 20.51370811 28.98261261 22.26200676 -1.709831874!
CER1 37.24756622 20.51370811 Undetermined 22.26200676 #VALUE!!
CHRD #DIV/0! 20.51370811 37.004776 22.26200676 #DIV/0!!
ENG 37.03303146 20.51370811 30.94250298 22.26200676 -7.838827133!
FST 32.73968506 20.51370811 32.9630661 22.26200676 -1.524917603!
GDF11 27.84155464 20.51370811 27.95772743 22.26200676 -1.632125854!
GDF1;LASS1 35.94737625 20.51370811 32.95769882 22.26200676 -4.737976074!
GDF2 #DIV/0! 20.51370811 Undetermined 22.26200676 #DIV/0!!
GDF3 #DIV/0! 20.51370811 Undetermined 22.26200676 #DIV/0!!
GDF6 #DIV/0! 20.51370811 35.94604111 22.26200676 #DIV/0!!
GDF7 37.05926704 20.51370811 Undetermined 22.26200676 #VALUE!!
GDF9 35.75269318 20.51370811 36.96233368 22.26200676 -0.538658142!
GREM1 #DIV/0! 20.51370811 37.06842041 22.26200676 #DIV/0!!
INHA 34.67130407 20.51370811 34.91033554 22.26200676 -1.509267171!
INHBA 32.60780017 20.51370811 30.95749855 22.26200676 -3.39860026!
INHBB 37.59674581 20.51370811 39.07902908 22.26200676 -0.266015371!
INHBC 35.62354533 20.51370811 35.305233 22.26200676 -2.066610972!
INHBE 33.93226624 20.51370811 30.96523857 22.26200676 -4.715326309!
     !
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This Table represents the ct value and the differences in Δdct between co-cultured PC3RFP/with 
MG63 cells and control PC3RFP cells during the Confluent Phase. The dct was calculated by 
subtracting the gene of interest from the house keeping gene GAPDH for each cell type. The Δdct 
value was calculated by subtracting dct value of control from the dct value of the co-cultured 
PC3RFP/with MG63 cells. Highlighted value represents more than 10 fold change in gene expression. 
Data expressed as mean of 3 independent experiments.   
 
  
Gene Name 
PC3 
(Control) 
ct value 
GADH 
ct value 
PC3/MG63 
(Co-cultured) 
Ct value 
GADH 
ct value Δ dct 
LEFTY2 37.92624474 20.51370811 Undetermined 22.26200676 #VALUE!!
LTBP1 27.29220645 20.51370811 27.95863914 22.26200676 -1.081865946!
NBL1 27.63373184 20.51370811 28.77157402 22.26200676 -0.610456467!
NOG 27.32346916 20.51370811 28.9696579 22.26200676 -0.102109909!
SOST #DIV/0! 20.51370811 Undetermined 22.26200676 #DIV/0!!
TGFB1 27.31066958 20.51370811 26.9671917 22.26200676 -2.09177653!
TGFB2 31.91540209 20.51370811 34.96070862 22.26200676 1.297007879!
TGFB3 29.63134766 20.51370811 29.97441864 22.26200676 -1.405227661!
TGFBR1 28.6014239 20.51370811 32.97459793 22.26200676 2.624875387!
TGFBR2 28.88056501 20.51370811 27.96858025 22.26200676 -2.660283407!
TGFBR3 30.19827906 20.51370811 31.95786476 22.26200676 0.011287053!
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Table 9A  Expressed plate gene expression in confluent SaOS2 compared to SaOS2 treated 
with PC3RFP-CM. 
Gene Name 
SaOS2 in 
2%DMEM 
ct value 
GAPDH 
 ct value 
SaOS2 
treated with 
CM ct value 
GAPDH 
 ct value 
Δ dct 
ACVR1 29.9361897 21.9097481 29.7593397 22.6219705 -0.88907241 
ACVR1B 32.9362526 21.9097481 35.0935148 22.6219705 1.44503975 
ACVR2A 31.8985271 21.9097481 32.0458132 22.6219705 -0.56493632 
ACVR2B 31.7777367 21.9097481 32.6348483 22.6219705 0.1448892 
BMP10 36.3345566 21.9097481 undetermined  22.6219705 #VALUE! 
BMP2 31.9093113 21.9097481 33.7084211 22.6219705 1.08688736 
BMP3 35.96268845 21.90974808 36.7482605 22.6219705 0.07334964 
BMP4 24.9498692 21.9097481 26.0465806 22.6219705 0.38448906 
BMP5 36.6571846 21.9097481 36.9717407 22.6219705 -0.39766629 
BMP6 32.7582245 21.9097481 34.4436061 22.6219705 0.97315916 
BMP7 35.3900375 21.9097481 34.8728905 22.6219705 -1.22936948 
BMP8B;BMP8A 32.7899208 21.9097481 35.0839691 22.6219705 1.5818259 
BMPR1A 29.9286213 21.9097481 32.8083452 22.6219705 2.16750146 
BMPR1B 30.9656487 21.9097481 undetermined  22.6219705 #VALUE! 
BMPR2 27.6560421 21.9097481 28.9718819 22.6219705 0.60361736 
CER1 Undetermined 21.9097481 undeterrmined  22.6219705 #VALUE! 
CHRD 37.0776863 21.9097481  undetermined  22.6219705 #VALUE! 
ENG 28.6491699 21.9097481 28.6326841 22.6219705 -0.72870826 
FST 31.8238277 21.9097481 33.6058566 22.6219705 1.06980642 
GDF11 30.9474697 21.9097481 31.2135086 22.6219705 -0.44618351 
GDF1;LASS1 32.846386 21.9097481 32.9003754 22.6219705 -0.658233 
GDF2 Undetermined 21.9097481 undetermined  22.6219705 #VALUE! 
GDF3 Undetermined 21.9097481 undetrmiend  22.6219705 #VALUE! 
GDF6 33.9198875 21.9097481 34.9344215 22.6219705 0.30231158 
GDF7 37.1187057 21.9097481 undetermined  22.6219705 #VALUE! 
GDF9 35.9574242 21.9097481 35.0351753 22.6219705 -1.63447126 
GREM1 26.9796486 21.9097481 28.3748976 22.6219705 0.68302664 
INHA 36.9917336 21.9097481 35.9733238 22.6219705 -1.73063214 
INHBA 27.9405727 21.9097481 28.2518749 22.6219705 -0.40092023 
INHBB 30.9800072 21.9097481 31.9825058 22.6219705 0.29027622 
INHBC 36.9617653 21.9097481 35.9407425 22.6219705 -1.73324521 
INHBE 32.964592 21.9097481 32.2814961 22.6219705 -1.39531834 
LEFTY2 37.0844574 21.9097481 undetermined  22.6219705 #VALUE! 
LTBP1 28.9520969 21.9097481 30.9648317 22.6219705 1.30051232 
NBL1 27.9620457 21.9097481 28.3815346 22.6219705 -0.2927335 
NOG 34.96133041 21.90974808 32.1427184 22.62197049 -3.530834426 
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Gene Name 
SaOS2 in 
2%DMEM 
ct value 
GAPDH 
ct value 
SaOS2 
treated with 
CM ct value 
GAPDH 
ct value 
Δ dct 
SOST 36.9237061 21.9097481 35.9734052 22.6219705 -1.66252327 
TGFB1 24.9865398 21.9097481 24.093015 22.6219705 -1.60574722 
TGFB2 29.5937691 21.9097481 31.7834988 22.6219705 1.47750727 
TGFB3 29.9523315 21.9097481 31.3046659 22.6219705 0.64011192 
TGFBR1 28.8648186 21.9097481 30.9559104 22.6219705 1.37886937 
TGFBR2 28.7812004 21.9097481 29.4020443 22.6219705 -0.09137852 
TGFBR3 31.6579971 21.9097481 31.8710289 22.6219705 -0.49919064 
This Table shows the ct values and the differences in Δdct between confluent SaOS2 cells and 
SaOS2 treated with PC3RFP-CM. The dct was calculated by subtracting the gene of interest from the 
house keeping gene GAPDH for each cell type. The Δdct value was calculated by subtracting dct 
value of confluent SaOS2 from the dct value of the treated SaOS2 cells. Highlighted value represents 
more than 10 fold change in gene expression. Data expressed as mean of 3 independent 
experiments.   
 
  
The activity of the TGF beta superfamily in prostate cancer and the formation of bone metastases !
217!!
Table 10A  TGFβ superfamily gene expression in confluent MG63 compared to MG63 treated 
with PC3RFP-CM. 
Gene Name 
MG63 in 
4%DMEM 
ct value 
GADH  
ct value 
MG63 treated 
with CM ct 
value 
GADH  
ct value 
Δ dct 
ACVR1 27.45970345 22.97153473 29.36 21.3249569 3.54687439 
ACVR1B 31.9857645 22.97153473 32.2369 21.3249569 1.89771334 
ACVR2A 30.46175385 22.97153473 29.18759 21.3249569 0.37241399 
ACVR2B 34.45285702 22.97153473 33.1367 21.3249569 0.33042082 
BMP10 #DIV/0! 22.97153473 undetermined 21.3249569 #DIV/0! 
BMP2 33.9507122 22.97153473 35.2566 21.3249569 2.95246564 
BMP3 37.18087006 22.97153473 38.5057 21.3249569 2.97140778 
BMP4 29.96717453 22.97153473 30.5732 21.3249569 2.25260331 
BMP5 31.46509647 22.97153473 33.58139 21.3249569 3.76287137 
BMP6 35.45298004 22.97153473 35.77146 21.3249569 1.9650578 
BMP7 29.96841526 22.97153473 32.2354 21.3249569 3.91356258 
BMP8B;BMP8A 31.95696354 22.97153473 32.63694 21.3249569 2.3265543 
BMPR1A 31.45823956 22.97153473 30.1761888 21.3249569 0.36452707 
BMPR1B #DIV/0! 22.97153473 undetermined 21.3249569 #DIV/0! 
BMPR2 27.97273445 22.97153473 27.2886569 21.3249569 0.96250026 
CER1 36.50650787 22.97153473 37.09848 21.3249569 2.23854997 
CHRD 33.97208977 22.97153473 35.6306597 21.3249569 3.30514781 
ENG 24.9516983 22.97153473 28.6288312 21.3249569 5.32371077 
FST 32.96305561 22.97153473 34.4833489 21.3249569 3.16687108 
GDF11 30.45579052 22.97153473 32.7764193 21.3249569 3.96720664 
GDF1;LASS1 26.95148277 22.97153473 28.0790685 21.3249569 2.77416357 
GDF2 #DIV/0! 22.97153473 undetermined 21.3249569 #DIV/0! 
GDF3 37.08481598 22.97153473 undetermined 21.3249569 #VALUE! 
GDF6 31.43332863 22.97153473 33.523049 21.3249569 3.73629825 
GDF7 34.47594261 22.97153473 35.9563777 21.3249569 3.1270129 
GDF9 33.96159649 22.97153473 35.682586 21.3249569 3.36756738 
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Gene Name 
MG63 in 
4%DMEM 
ct value 
GADH 
ct value 
MG63 treated 
with CM ct 
value 
GADH 
ct value 
Δ dct 
GREM1 34.4677639 22.97153473 34.9466026 21.3249569 2.12541652 
INHA 33.45564842 22.97153473 34.4658814 21.3249569 2.65681077 
INHBA 32.9467535 22.97153473 32.4657466 21.3249569 1.1655709 
INHBB 36.96137238 22.97153473 37.0014827 21.3249569 1.68668811 
INHBC 37.00120544 22.97153473 34.6946348 21.3249569 -0.65999285 
INHBE 31.45604229 22.97153473 29.0104961 21.3249569 -0.79896831 
LEFTY2 36.50269127 22.97153473 36.6241201 21.3249569 1.76800665 
LTBP1 27.45436859 22.97153473 26.37953 21.3249569 0.5717392 
NBL1 26.47146511 22.97153473 28.5694281 21.3249569 3.74454086 
NOG 34.46164322 22.97153473 34.0599168 21.3249569 1.24485143 
SOST undetermined 22.97153473 undetermined 21.3249569 undetermined 
TGFB1 26.46272373 22.97153473 26.1342055 21.3249569 1.31805961 
TGFB2 34.45627117 22.97153473 31.5706183 21.3249569 -1.23907502 
TGFB3 32.96736717 22.97153473 31.7616317 21.3249569 0.44084232 
TGFBR1 28.43787479 22.97153473 31.9628773 21.3249569 5.17158031 
TGFBR2 26.45248508 22.97153473 29.1504873 21.3249569 4.34458001 
TGFBR3 28.95666027 22.97153473 31.8689219 21.3249569 4.55883949 
 
This Table shows the ct values and the differences in Δdct between confluent MG63 and MG63 
treated with PC3RFP-CM. The dct was calculated by subtracting the gene of interest from the house 
keeping gene GAPDH for each cell type. The Δdct value was calculated by subtracting dct value of 
control from the dct value of the co-cultured PC3RFP/with MG63 cells. Highlighted value represents 
more than 10 fold change in gene expression. Data expressed as mean of 3 independent 
experiments.   
 
